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Abstract
The transforming growth factor beta (TGFβ) signalling pathway is an essential
regulator of many cellular processes including epithelial growth control, epithelial to
mesenchymal transition (EMT), apoptosis, and the establishment of developmental fate.
Alterations in TGF signalling patterns are associated with various pathological disorders
such as fibrosis and cancer. In recent years it has become clear that regulation of TGF
signalling is dependent on the trafficking and endocytosis of the TGF receptors, however,
the factors that control these processes are still under investigation.
In this thesis, I examined the role of Protein Kinase C (PKC) in the regulation of
TGF signalling pathways and found that the Atypical PKC isoforms (aPKC; a subgroup of
the PKC family) indeed can alter TGF receptor signalling. My work has shown that the
modulation of aPKC expression or activity using inhibitors and/or small interfering RNA
(siRNA) prolongs the temporal phosphorylation of the downstream transcription factor
Smad2 through altered receptor membrane trafficking. Furthermore, I showed that aPKC
activity and expression alters the phosphorylation and degradation of Par6, which in turn
affects TGF induced EMT and migration. Finally, I examined global gene expression
changes in aPKC silenced cells - and related these effects to altered Smad nuclear
accumulation. Notably, we also found that these cells demonstrate enhanced p38 MAPK
signalling, which sensitizes them to TGF induced apoptotic response.
In conclusion, I found that aPKC isoform activity and expression is intricately linked
to the regulation of various TGF receptor signalling pathways that control gene
expression, EMT, and apoptosis.
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Chapter 1

INTRODUCTION

Components of this chapter have been published in Cell Adh Migr. (2013) 7(4):357-61
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1

Introduction

1.1 Introduction to the TGFpathway
The transforming growth factor beta (TGF) signalling pathway represents a class
of molecules that are essential regulators of embryonic development and tissue
homeostasis. TGF regulates diverse cellular processes including cell differentiation,
proliferation, migration, apoptosis, and cell plasticity.
Given the importance of TGF signalling in tissue homeostasis, aberrant
signalling leads to various pathologies and disorders including diseases of immunity and
inflammation, cancer, and fibrosis. Paradoxically, TGF can both inhibit, and promote
cancer, as it acts as a tumour suppressor in the early stages of cancer development, but a
tumour promoter in late stage cancers.
It has been over 30 years since TGF was first discovered as a multifunctional
cytokine[1], and although the general pathways surrounding TGF have been identified,
it has long been known that the contextual nature of TGF hints at a pathway more
complicated than the sum of its seemingly simple parts. Since its discovery, researchers
have uncovered that the pleiotropic nature of TGF is controlled by a network of
regulators along various points in the pathway that control the activity and outcome of
TGF signalling; In turn, how this pathway and its various components are regulated, can
dictate how cells respond to TGF signals.
Thus, knowledge of the mechanisms that govern the regulation and the signalling
of this incredibly powerful system are important to increase our understanding of animal
embryo development, tissue homeostasis, and diseases such as cancer.
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1.1.1 TGFligands
The TGFβ superfamily, which includes over 30 cytokine members, are involved
with the binding and the activation of ser/thr kinase receptors to mediate signalling
cascades and transcriptional events that control cellular homeostasis and metazoan
development (reviewed in [2-7]). These structurally related cytokines are characterized
by 6 conserved cysteine residues and the genes are encoded by 42 open reading frames in
the human genome [8]. The superfamily is further divided into 2 major subfamilies based
on sequence similarities and the downstream pathways they activate: specifically the
TGFActivin/Nodal subfamily and the BMP/GDF/MIS (Bone morphogenetic protein,
growth and differentiation factor, Muellerian inhibiting substance) subfamily [9].
TGF was the first discovered member of the superfamily, and is often
considered the prototype. There are three TGF isoforms in mammals: TGF1, TGF2
and TGF3. Each isoform is encoded from a different gene, although all activate the
same receptor system [6]. TGF1 is the major isoform in adults, as its expression is the
most predominant and ubiquitous, although all three isoforms are expressed during
development [10, 11]. Of the three ligands TGF1 is also the most frequently upregulated
in tumor cells and is often the focus of TGF studies in tumorigenesis [3, 12, 13].
TGF ligands are homo-dimeric proteins with each monomer forming several
extended -strands that interlock through three intrachain disulfide bonds. These
disulfide bridges form a tight structure common to TGF ligands known as the “cysteine
knot” [14]. The dimer is stabilized through hydrophobic interactions and also by an
inter-subunit disulfide bond [14].
TGF ligand is secreted as an inactive latent complex with two pro-segment
peptides [15]. The pro-peptide is called the latency-associated protein (LAP) and TGF
bound to LAP is not recognized by the TGF receptors. LAP also links TGF
homodimers to latent TGF-binding proteins (LTBPs) through direct disulfide bonds to
LAP. LTBPs can target the TGF-LAP complex to the cell surface for activation or to the
extracellular matrix for storage [16-18]. This latency complex mechanism safeguards
against inadvertent activation and allows for sequestration in the extracellular matrix
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(ECM) [3, 6, 7]. Importantly, sequestration of ligand in the ECM allows for a reservoir of
readily available ligand without the need for synthesis [17, 18].
The regulated activation process of TGF involves preferential cleavage and
degradation of the TGF prosegments by activating molecules and proteases. Latent
TGF can be activated by proteases and ECM proteins such as matrix metalloprotease 2
(MMP2), matrix metalloprotease 9 (MMP9), plasmin and thrombospondin [19-22]. It is
important to note that these proteases are often expressed in malignant cells and are
highly active at sites of cell migration and invasion – giving indication that the activation
of TGF plays a role in these processes [21, 22].
Once TGF ligand is activated, it mediates downstream transcriptional events
through the binding and activation of the TGF receptors.

1.1.2 TGFreceptors
TGF ligands bind and activate a family of transmembrane proteins known as the
TGF receptors. There are two major TGF receptor kinase subtypes in the superfamily
categorized by their structural and functional properties: type I receptors and type II
receptors. Type I and type II receptors are structurally related glycoproteins consisting of
a N-terminal extracellular ligand binding domain, a transmembrane domain, and a ser/thr
kinase domain near the C-terminus [6, 23, 24]. Together, these receptors mediate
intracellular signals upon activation and are crucial to the mediation of TGF stimulated
responses.
There are seven type I and five type II receptors in the human genome, all of
which mediate TGF signalling [25] (Figure 1.1). The type II receptors consist of:
ActRII, ActRIIB, TRII, BMPRII and AMHRII [6]. The seven type I receptors were
originally systematically classified as the activin receptor-like kinases (ALK), thus
named ALK1-7. As the physiological ligands of the ALK receptors became known, more
descriptive names were introduced [6]. For example, the Type I TGF receptor (TRI) in
the prototypical TGF pathway is also known as ALK5 [26, 27].
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At the cell surface, type II receptors form dimers that bind TGF ligand. Ligand
binding promotes the binding of type I receptor dimers, thus forming an activated
ligand/heterotetrameric receptor signalling complex [6, 7]. Classical TGF signalling
involves type II receptors (TRII) phosphorylating TRI, thereby activating it. Active
TRI in turn phosphorylates intracellular signalling mediators such as Smads, which
regulate the transcription of TGF target genes to mediate cellular response (Figure 1.2)
[23].
TRII is a constitutively active ser/thr protein kinase which is found on the cell
surface as a homodimer in the presence or absence of ligand. TGF ligand enhances the
formation of heteromeric complexes of TRII homodimers and TRI homodimers
(reviewed in [2, 28]). Interestingly, overexpression of TRI and TRII can also promote
the formation of the heteromeric complex without the addition of ligand [29]. Once TRI
and TRII are in a heteromeric complex, the constitutively active TRII
transphosphorylates TRI on a unique glycine-serine sequence termed the “GS domain”.
The GS domain is a thirty amino acid region adjacent to the kinase domain of TRI
containing a characteristic SGSGSG sequence, and is critical for proper TGF signalling
[23]. In the basal state, the GS domain of TRI presses against the catalytic center of the
kinase domain – thereby holding TRI inactive [30]. TRII phosphorylation of the GS
domain triggers the activation of TRI [30]. The phosphorylated GS domain also acts as
a docking site for “Smads” the canonical intracellular mediators of TGF signals and
mutations of serine and or glycine residues in the TRI GS domain can impair TGF
signalling potential [31]. In addition to the unique GS domain, TRI and TRII have
several other key differences. TRI has a shorter extracellular domain than TRII and
does not bind ligand independently [2, 32].

TRII also possesses a ser/thr rich

intracellular tail, which is not found in TRI [28]. Furthermore, unlike TRII, TRI
kinase activity is not constitutively active. However, mutational studies have discovered
that mutation of threonine 204 to aspartic acid locks the kinase in an active state and can
transduce TGF signals in the absence of ligand [31].
A third receptor type, termed the type III receptor, assists in TGF signalling by
facilitating the presentation of ligand to the type II receptor [33, 34]. There are two type

6

III receptors, known as endoglin, and betaglycan (also referred to as TRIII). These
membrane anchored receptors do not have enzymatic activity and are considered
accessory receptors as TGF signals can still be propagated in their absence [6].
Betaglycan can bind all three TGF ligand isoforms with high affinity [35, 36], but is
most evidently important with TGF2 ligand, which has a low intrinsic affinity for
binding TRII in the absence of betaglycan [36]. Unlike betaglycan, which shows a
greater range of expression, endoglin is primarily expressed in endothelial cells, and
interestingly, does not bind TGF2 [37-39]. Although, thought of as accessory receptors
that can aid in signalling, type III receptors can also inhibit TGF signalling potential.
For example, betaglycan’s extracellular domain can be released from the membrane; this
soluble betaglycan can thereby sequester TGF ligand and inhibit TGF signalling [40].
Thus, the exact role of type III receptors is complicated as they can both enhance and
reduce the signalling potential of TGF isoforms in varying contexts.
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Figure 1.1. TGF superfamily signalling components
The core components of various TGF pathways (vertebrate) are shown in this diagram.
TGF ligands bind type II receptors, which bind and phosphorylate type I receptors.
Type I receptors phosphorylate corresponding R-Smads, which bind the common Smad
(Smad 4) to form a transcriptional complex. I-Smads can inhibit R-Smad signalling by
competitively binding to type I receptors thereby excluding R-Smads from
phosphorylation. Shown in bold is the TGF pathway studied in this thesis.
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1.1.3 Smads
The Smad family of proteins are the originally identified substrates of the type I
receptor family and are essential in the co-ordination and regulation of the TGF signal
transduction process. The Smads were first identified as the gene products of the
Drosophila MAD gene (Mothers against Decaplentaplegic [DPP]) and the C. elegans
Sma gene [41-43]. Smads are ubiquitously expressed during development and in all adult
tissues [44, 45] and the deregulation of Smads are associated with numerous cancers
(reviewed in [12, 46]). Smads have two highly conserved “Mad Homology” (MH)
domains: an N-terminal MH1 domain and a C-terminal MH2 domain, which are attached
by a proline rich “linker” region [6, 23].
There are eight mammalian Smads divided into three functional groups: the
receptor regulated Smads (R-Smad), the common-Smad and the inhibitory Smads (ISmad) (Figure 1.1). Upon receptor activation, the type I receptor binds and
phosphorylates R-Smads, which then oligomerize with the co-Smad to regulate
transcriptional events at the nucleus. Alternatively, I-Smads can bind the activated
receptor, thereby blocking R-Smad binding, and subsequently recruiting ubiquitin ligases
to target the receptor complex for degradation.
The receptor regulated Smads (R-Smads) consists of Smad1, Smad2, Smad3,
Smad5 and Smad8. Smad2 and Smad3 are involved in the TGF/Activin pathways,
whereas Smad1, Smad5 and Smad8 participate in the BMP signalling pathway (Figure
1.1) [2, 23].
The specificity of the various R-Smad and type I receptor interactions is mediated
by the “L45 loop” in the kinase region of type I receptor and the L3 loop in the MH2
domains of R-Smads [47]. In the classical TGF pathway, the type I receptor is TRI,
the primary R-Smad is Smad2, and the I-Smad is Smad7. The phosphorylated GS region
of activated TRI acts as a docking site for Smad2. This interaction occurs via a
positively charged surface patch present in the Smad2 MH2 domain [48, 49] and
mutations in this basic patch of Smad2 limit its binding and activation by TRI [50].
R-Smads are directly activated by type I receptors through phosphorylation. RSmads contain an evolutionarily conserved SSXS motif in their MH2 domain, and the
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two most C-terminal serine (S) residues become directly phosphorylated by type I
receptors [6, 23, 51]. Phosphorylated Smad2 dissociates from TRI, and the
phosphorylated SXS region of Smad2 binds to a positively charged surface pocket on the
MH2 domain of the co-Smad, Smad4 [23]. The R-Smad-Smad4 heteromeric complex
then translocates to the nucleus where it binds to promoters of TGF target genes, or
interacts with various co-activators or co-repressors that ultimately control TGF specific
transcriptional programs [6, 7].
Unlike the R-Smads and co-Smads, which carry TGF signals to the nucleus, ISmads (Smad 6 and Smad7) act antagonistically to reduce TGF signal transduction [6,
7]. Smad7 primarily functions in the TGF/Activin and BMP pathways, whereas Smad6
preferentially functions in the BMP pathway. The MH1 domains of I-Smads show little
similarity to the MH1 domains of the R-Smads, but the MH2 domains of R-Smads, coSmad and I-Smads are homologous. However, unlike the R-Smads, the I-Smads do not
contain the characteristic C-terminal SSXS phosphorylation sequence. Lacking the ability
to be phosphorylated, this allows for I-Smads to stably interact with an activated receptor,
thereby antagonizing signalling by competing with R-Smads for activated receptor
binding [6, 7]. Furthermore, I-Smads mediate the interaction between the receptors and
Smurf 1 and Smurf2 (Smad ubiquitination regulatory factors), which are E3 ubiquitin
ligases that ubiquitinate and target the receptors for degradation, thereby suppressing
further TGF signalling [52, 53].
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Figure 1.2. Classical TGF receptor activation and signalling
TGF signalling is initiatied at the cell surface when the TGF type II receptor (TRII)
binds TGF ligand. Ligand binding promotes the binding of the TGF type I receptor
(TRI), leading to the formation of an activated ligand/heterotetrameric receptor
signalling complex. TRII activates TRI by phosphorylating it on its GS domain. The
active type I receptor in turn phosphorylates intracellular signalling mediators such as
Smad2, which stimulates the binding of Smad4 to the R-Smad. Smad2-Smad4
association creates a transcriptional unit that accumulates in the nucleus to regulate the
transcription of TGF target genes. The activated TGF receptors can also activate
various Non-Smad signalling pathways.
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1.1.4 Pleiotropic effects of TGF
The effects exerted by TGF signalling have long been known to be cell and
context dependent (reviewed in [5, 12, 54]. In mature tissues, TGF has multiple roles
that ultimately lead to homeostasis. For example, TGF stimulates fibroblasts of the
stroma to grow and deposit extra cellular matrix proteins; TGF inhibits the growth of
endothelial cells and controls their morphogenesis; TGF can inhibit cells of the immune
system by inhibiting T-cell proliferation and natural killer cell function; and in the
epithelium, TGF controls cell growth through stimulating cell cycle arrest, apoptosis,
and adhesion (Figure 1.3) (reviewed in [12]). Given the important homeostatic role for
TGF signalling, its deregulation leads to various pathologies. For example, aberrant
TGF signalling is a hallmark of many epithelial derived cancers [3, 55], and drives
tumour progression. Normally, TGF acts as a tumour suppressor by controlling the
growth of the epithelium, but in many tumours TGF undergoes a role switch and
becomes a cancer promoting metastatic agent [3, 4, 55-58]. The growth suppressive
function of TGF was originally described to be through the phosphorylation of RB
(retinoblastoma protein) [59]. RB functions as a cell cycle gatekeeper, and in its
underphosphorylated state, prevents cells from entering into mitosis from the G1
checkpoint of the cell cycle [60]. Interestingly, TGF arrests cells in the G1 phase of the
cell cycle through the prevention of RB phosphorylation thereby leading to growth
suppression [59]. Phosphorylation of RB occurs through cyclin dependent kinases CDK4
and CDK6 [60]. TGF stimulation leads to the upregulation of the CDK inhibitors p15
and p21, which prevent the actions of CDK4 and CDK6 thereby preventing RB
phosphorylation and the ultimately stimulating growth arrest [5, 12]. Other mechanisms
of growth arrest include the TGF induced repression of growth stimulatory transcription
factors including Myc, and members of the ID family [5, 12, 54]. Thus, although the
mechanisms can differ among various cell types, TGF normally causes growth arrest in
mature epithelium, maintaining it in a homeostatic state.
In addition to controlling epithelial cells through a cytostatic program, TGF can
also stimulate apoptosis to maintain homeostasis. Apoptosis is a form of programmed cell
death and is important for normal cell turnover; however, deregulation of apoptosis is
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also involved in various pathological disorders (reviewed in [61]). Apoptotic signalling
can be classified into extrinsic (via death receptor), and the intrinsic (mitochondrial)
pathways, however, each pathway can influence the other. Activation of either pathway
leads to the cleavage of a group of cysteine proteases called caspases, which execute the
apoptotic program to result in DNA fragmentation, chromatin condensation, protein
degradation, and membrane blebbing, which leads to the formation of cell fragments
called apoptotic bodies. These apoptotic bodies are subsequently engulfed by phagocytic
cells such as macrophages [61]. Because apoptotic bodies do not release the cellular
contents into the surrounding interstitial tissue, an inflammatory response is not triggered
[61]. The extrinsic pathways that trigger apoptosis utilize transmembrane death receptors
which most often include members of the tumor necrosis factor (TNF) receptor gene
superfamily [62]. The best characterized of these are the Fas ligand/Fas receptor complex
and the TNF-/TNFR1 models. Activation of these receptors by their ligands leads to the
recruitment of cytoplasmic adaptor proteins to form a death-inducing signalling complex
(DISC) [63]. DISC ultimately triggers the activation of caspases through cleavage [61].
The intrinsic apoptosis pathway involves non-receptor mediated signals that cause
changes in the inner mitochondrial membrane that disrupt membrane potential resulting
in the release of normally sequestered pro-apoptotic proteins into the cytosol [61].
TGF has been reported to operate in both apoptotic pathways. For example,
TRII can interact directly with the pro-apoptotic adapter protein DAXX, a member of
the Fas pathway, which leads to the activation of JNK and the induction of apoptosis of
epithelial cells [64]. Furthermore, TGF can also operate in the intrinsic pathway through
its transcriptional induction of DAPK (death associated protein kinase) [65]. DAPK can
regulate cytochrome C release from mitochondria, and ultimately apoptotic response
[65].
Thus, the cytostatic and apoptotic actions of TGF signalling make it a clear
regulator of cellular and tissue homeostasis. Deregulation of various components of the
TGF pathway often lead to diseases of hyperproliferation, such as cancer.
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Figure 1.3. The multi-functional nature of TGF.
TGF signalling has cell type and context-specific effects. TGF has an important role in
controlling the growth homeostasis of the epithelium by regulating cell-cycle arrest and
apoptosis. Whereas in fibroblasts, TGF stimulates ECM production and proliferation,
important aspects of tissue repair. However, as tumours progress, the growth inhibitory
aspects of TGF are lost, and then TGF signalling can stimulate EMT, migration, and
invasion, thereby facilitating tumour progression.
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1.2 Regulation of TGF signal transduction
It has become clear that the complex nature of TGF responses is partly
related to the regulation of TGF receptor signalling. The importance of this regulation is
highlighted by the complex roles of TGF in development, and the detrimental
consequences of aberrant TGF signalling in various diseases such as cancer and fibrosis.
Much work has been devoted to understanding the mechanisms that govern the regulation
of TGF receptor signalling, however, many questions still remain to be addressed.

1.2.1 Endocytosis and membrane trafficking
Endocytosis of cell surface receptors has been shown to be an important
regulatory event. Endocytosis refers to the process by which membrane associated
molecules are taken into the cellular environment through internal membrane
compartments (reviewed in [66]). This process involves the invagination of the plasma
membrane to encapsulate the cargo, followed by budding from the membrane, and the
formation of an intracellular vesicle containing the internalized molecules. Importantly,
endocytosis of cell surface receptors can modulate signalling processes by spatially
removing receptors from accessing extracellular ligand, but also opens complex avenues
of signalling or down-regulation pathways depending on the intracellular itinerary of the
cargo. Thus, how receptors are trafficked in the cell, can determine whether receptors are
down-regulated or whether they can continue signalling.
Interestingly, modulation of TGF receptor activity is controlled by the
endocytosis and trafficking of the TGF receptors. Cell surface TGF receptors are
dynamic and are constitutively being internalized via “clathrin dependent” and
“membrane raft- dependent” endocytosis. Furthermore, clathrin-dependent endocytosis
positively influences signalling and propagates TGF Smad signalling, whereas
membrane raft-dependent endocytosis results in receptor degradation and signal
termination [67, 68].
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1.2.2 Classical clathrin-dependent endocytosis
Clathrin-dependent endocytosis is a conserved mechanism which is responsible
for the cellular internalization of pathogens, antigens, nutrients, growth factors and many
receptor types (reviewed in: [66, 67, 69]). The defining feature of this endocytic pathway
involves the recruitment of soluble clathrin from the cytoplasm to the plasma membrane.
The clathrin triskelia aggregate at the membrane and create a polygonal lattice to form an
invagination referred to as a “clathrin-coated pit”. Clathrin binding adaptor proteins,
such as adaptor protein 2 (AP-2), promote the clathrin polymerization as well as bind
other cargo proteins to facilitate their endocytosis. AP-2 as well as Eps15 (epidermal
growth factor substrate 15) facilitates the formation of the clathrin lattice, leading to an
increase in the plasma membrane curvature and creating the pit. The clathrin-coated pit
pinches off from the plasma membrane to form a “clathrin-coated vesicle”. This process
is dependent on Dynamin, a GTPase that promotes the scission of the clathrin coated pit
into a newly formed intracellular vesicle. Following endocytosis, the newly formed
vesicles are uncoated, and then become ‘early endosomes’. The early endosome is an
important intracellular compartment that acts as a key sorting facility for the proteins it
contains. The vesicular cargo can be sorted into recycling endosomes, which return to the
cell surface, or can be trafficked to late endosomes where they are furthered targeted to
the lysosome for degradation. Interestingly, these sorting and trafficking events can be
directed by post-translational modifications of the cargo, such as ubiquitination,
phosphorylation, or the interaction with specific proteins [69]. Furthermore, these
directed trafficking events are controlled by a large family of small GTPases called the
Rab GTPases. Rab GTPases are Ras-like small G-proteins that are tightly associated with
membranes, molecular motors, and vesicular coat components and their activity controls
endocytosis, trafficking, and exocytosis by regulating the processes of docking, fusion,
and tethering between vesicular compartments [66, 67]. The different endosomal
compartments are associated with distinct Rab GTPase function, and specific Rabs are
often experimentally used as markers of specific compartments. For example, Rab4 and
Rab5 are localized and enriched in the early endosome, Rab 4 and Rab 11 are enriched in
recycling endosomes, and Rab7 and Rab 9 are enriched in late endosomes [66].

16

As with specific Rabs, the early endosome is also characterized by specific early
endosome proteins containing a unique “FYVE” domain (Fab1, YOTB, Vac1, EEA1).
The FYVE domain binds these proteins to the membrane lipid phosphatidylinositol-3phosphate (PtdIns3P), which is highly enriched in the early endosome. FYVE domain
proteins are thought to facilitate endosomal trafficking dynamics. For example, the early
endosome marker EEA1 (early endosome antigen-1), is a FYVE domain containing
effector of Rab5 that helps control early endosomal fusion [66, 67]. Thus, protein-protein
interactions, as well as various protein-lipid interactions within endosomal compartments
are important in guiding the sorting of intracellular cargo following clathrin-mediated
endocytosis.

1.2.3 Non-classical endocytosis: Membrane-rafts
Clathrin-independent endocytosis is also a common mode of internalization for a
number of molecules from the extracellular environment. Clathrin-independent
endocytosis routes are sensitive to cholesterol depletion, pointing to the importance of
membrane rafts (sometimes also called lipid rafts). Membrane rafts are liquid ordered
membrane microdomains that are discrete from clathrin-coated pits. They are
characterized by portions of the plasma membrane that have a very distinct lipid
composition:

they

are

rich

in

cholesterol,

glycosphingolipids,

and

glycosylphosphatidylinositol-anchored (GPI) proteins [67, 70]. This unique composition
makes membrane rafts less fluid and more rigid than non-raft areas of the plasma
membrane [71]. Interestingly, these properties allow membrane rafts to create platforms
that recruit and/or exclude specific lipids and proteins and thus can segregate cell surface
components from the rest of the plasma membrane, allowing for another mechanism of
endocytosis and protein trafficking [67, 71].

Interestingly, membrane raft-mediated

endocytosis seems to be especially important for proteins that contain a GPI anchor [72,
73]. The spingholipids and cholesterol in membrane rafts tether GPI-anchored proteins by
binding to the acyl chain on the GPI-anchor [74]. Another mechanism linking cell surface
molecules to membrane rafts are through interactions with raft resident proteins such as
caveolin, flotillin and annexin [67, 70, 73, 74].
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Membrane rafts important to the regulation of the TGF pathway are “caveolae”.
Caveolae are a subset of membrane rafts that are morphologically identifiable as flasklike invaginations of the plasma membrane approximately 60-80 nm in diameter [66, 70,
72, 75]. Caveolae, like membrane rafts, are rich in cholesterol and sphingolipids, but they
are also highly enriched in a type of protein called the caveolins [76]. There are three
types of caveolins: caveolin-1, caveolin-2, and caveolin-3. Caveolin-2 is only found
expressed in muscle cells, whereas caveolin-1 and 2 show widespread cellular
expression. However, caveolin-1 (cav-1) is the most important for the formation of
caveolae in most cells and cav-1 knockout mice lack caveolar structures [77, 78].
Caveolae form through the oligomerization of cav-1 proteins and their association with
cholesterol molecules [67, 79]. Similar to clathrin-mediated endocytosis, protein-protein
interactions with constituents of membrane rafts, such as cav-1, can regulate entry into
caveolae and control the endocytosis of molecules into these intracellular compartments.
Caveolae-dependent endocytosis has been shown to be important for the internalization
of various nutrients, viruses and cell surface receptors, including various GPCRs, RTKs
and TGF receptors [67-70, 79, 80].

1.2.4

Endocytic trafficking regulates TGF receptor activity
Interestingly, TGF induced signalling events are intricately linked to the

trafficking of TGF receptors (Figure 1.4) [68, 81-86]. TGF receptors are constitutively
internalized via both membrane raft-dependent and clathrin-dependent endocytosis, and
the

specific trafficking of the TGF receptors, was determined to dictate whether the

TGF signal would be propagated or degraded [68]. In this study, Di Guglielmo et al.
report that the inhibition of clathrin-dependent endocytosis using Eps15 or Dynamin
dominant negative mutants blocked the ability of TGF receptors to access the early
endosome, and increased their propensity to access caveolae. Similarly, using a
cholesterol depletion technique, which inhibits membrane-raft dependent endocytosis,
receptors were less likely to access caveolae and found more in the early endosome. This
interesting finding indicated that TGF receptors could internalize from the cell surface
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at least two ways: via clathrin coated pits into the early endosome or via membrane rafts
into caveolae – and these processes could be manipulated by altering trafficking
machinery. It is interesting to note that because the TGF receptors are constitutively
being internalized, ligands in this system do not regulate trafficking events, but instead,
stabilize heterotetrameric interactions between the Type I and II TGF receptors [68].
Internalization of activated receptor complexes into distinct endocytic compartments,
such as the early endosome or caveolae, serves to bring the receptors to distinct Smads
and Smad associated proteins associated with each particular compartment. Moreover,
the fate of the receptors and ultimately the TGF signal, was related to the subcellular
compartment that the receptors accessed. Receptors accessing the early endosome were
more likely to phosphorylate Smad2 and propagate TGF signalling, whereas receptors
accessing caveolae were more likely to be targeted for degradation (Figure 1.4) [68]. This
finding was particularly interesting, as classically the internalization of various
membrane receptors into the early endosome was thought to solely be a mechanism by
which signalling is reduced or for the down regulation of receptors. However, it is now
known that endosomes can be highly specific signalling platforms for various receptors
(reviewed in [69]) and this was true of the TGF receptors.
Di Guglielmo et al. found that TGF receptors that internalized into the early
endosome via clathrin promoted TGF signalling through the enhanced activation of
Smad2 [68]. TGF receptors are pulled into the early endosome through clathrinmediated endocytosis due to a direct protein-protein interaction of a dileucine motif in
TRII with the clathrin adaptor protein AP-2 [82]. The early endosome, is enriched in an
anchoring protein called SARA (Smad Anchor for Receptor Activation), which functions
to spatially facilitiate the phosphorylation of R-Smads by activated TGF receptors [87].
Like many other early endosome proteins, SARA contains a FYVE domain, which binds
to PtdIns3P, a membrane lipid enriched in early endosomes [7, 87]. SARA binds the RSmads (Smad2 and Smad3) via their MH2 domain, and the carboxy terminal domain of
SARA binds to the activated TGF receptor complex, effectively bridging the receptor
and R-Smads [87]. SARA preferentially binds non-phosphorylated forms of Smad2, and
it is thought that the activated receptor complex, which is formed at the plasma
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membrane, is captured by SARA in the early endosome, and then presents the bound RSmad to the receptor for phosphorylation [7].

Once Smad2 is phosphorylated, it

dissociates from SARA, and then binds Smad4, leading to nuclear translocation and the
initiation of transcription [87, 88]. This idea that TGF receptors access R-Smads at the
early endosome greatly implicates trafficking events in controlling the intensity and
duration of Smad phosphorylation. Indeed, maximal signal transduction is dependent on
TGF receptors reaching the early endosome [89]. More specifically, in this study the
authors show that although TGF receptors can still phosphorylate Smad2 when clathrinmediated endocytosis is inhibited, endocytosis was required for Smad2 to fully
translocate to the nucleus and mediate transcription [89]. Furthermore, over expression of
SARA mutants that lack the FYVE domain mislocalizes Smad2 and inhibits Smad2
phosphorylation and gene transcription [87]. These interesting finding suggests that there
is an important spatial regulation of the R-Smad activation and translocation process.
Furthermore, these reports identify an important regulatory role for trafficking and the
spatial organization of TGF receptors and Smads in executing TGF dependent
transcription. Indeed ongoing work seeks to uncover the pathways, and proteins that
control these regulatory endocytic processes and ultimately the TGF signal.
In addition to being internalized by clathrin-mediated endocytosis, TGF
receptors can undergo membrane-raft mediated endocytosis, which targets them to a
caveolin positive vesicle [67, 68]. The cytoplasmic tail of TRI contains a caveolinbinding motif, which facilitates its interaction with the scaffolding domain of caveolin-1,
and this interaction ultimately targets receptors to caveolae [85]. In contrast to the early
endosome, the cav-1 positive endosome facilitates the interaction of Smad7 instead of
Smad2 with the activated receptors [68]. As mentioned, Smad7 is an inhibitory Smad,
and has an antagonistic role in TGF signalling. More specifically, it sterically prevents
the interaction of Smad2 with TRI through competitive binding thereby preventing its
activation and subsequent binding to Smad4 [90, 91]. Furthermore, it acts as an adaptor
protein for the ubiquitin ligase Smurf2 that targets the activated receptor complex for
degradation through ubiquitination [92]. Ubiquitin is a small 76 amino acid protein that is
covalently added to lysine residues of proteins by ubiquitin ligases, which catalyze this
post-translational modification. Poly-ubiquitin chains can target proteins for degradation

20

by the proteasome and can also regulate trafficking events to the lysosome [93].
Ubiquitin mediated protein degradation controls the turnover and stability of various
proteins including many cell surface receptors [93]. Interestingly, ubiquitin itself has
seven lysine residues to which further ubiquitin molecules can be attached. Monoubiquitination and Lys-63 linked polyubiquitination are known to be important regulators
of the localization and/or function of proteins, whereas Lys-48 linked polyubiquitination
of proteins is a signal for proteasomal degradation [93, 94]. Ubiquitination is facilitated
by a multi-enzyme cascade consisting of E1, E2, and E3 ligases (reviewed in [93]). E1
enzymes activate ubiquitin for conjugation, E2 enzymes are ubiquitin conjugating
enzymes, and E3 are ubiquitin protein ligases which transfer the ubiquitin chain to the
target lysine residue [93]. Smurf2 is a HECT-domain (Homologous to the E6-AP
Carboxyl Terminus) E3 ubiquitin ligase, which like other protein members of this class,
can directly target ubiquitin to specific substrates. Smurf2 is normally nuclear, but its
binding to Smad7 induces export and stable interaction with the activated TGF receptor
complex [92]. Smurf2 then ubiquitinates the TGF receptor-Smad7 complex which leads
to their targeted degradation through proteasomal and lysosomal pathways [92]. Thus,
TGF receptor internalization via membrane rafts into cav-1 positive compartments
seems to be an important negative regulator of TGF induced Smad signalling. Indeed,
receptor trafficking and ubiquitination acts as a tight control mechanism for TGF
receptor degradation, and subsequently the availability of active receptor complexes.
It has become clear that the method of receptor internalization influences the
magnitude, duration and efficiency of TGF signal transduction. More specifically,
trafficking of the TGF receptors into SARA enriched early endosomes facilitates
signalling whereas trafficking into cav-1 positive vesicles targets the receptor complex
for degradation through the interactions of Smad7 and Smurf2 (Figure 1.4). Thus, the
early endosome acts as a signalling platform for the TGF receptors that effectively
sequesters the receptor away from cav-1 and raft mediated endocytosis and also promotes
the access of the substrate Smad2 through its enriched levels of SARA.
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Figure 1.4. Endocytosis and trafficking control TGF receptor activity
Activated TGF receptors internalize via clathrin coated pits into the early endosome to
facilitate downstream signalling. In the early endosome, SARA presents Smad2 to the
activated receptor complex. TRI phosphorylates Smad2 , which stimulates the
dissocation from SARA and the subsequent interaction with Smad4. This Smad complex
translocates to the nucleus to activate TGF target genes. Alternatively, receptors
internalize into caveolin-positive vesicles and interact with the inhibitory Smad7 leading
to subsequent Smurf dependent ubuiqitination and degradation of the receptors. Thus, the
function of these internalization pathways is dictated by the resident proteins associated
with each compartment, and altered trafficking and internalization of TGF receptors can
alter TGF signalling outcomes.

22

1.2.5 Regulation of Smads
As mentioned above, R-Smads are direct targets of ligand bound TGF receptors,
and are the key regulators of TGF transcriptional response. Generally, in quiescent
cells, Smad2 localizes primarily in the cytoplasm, I-Smads are primarily nuclear, and
Smad4 resides in both the nucleus and cytoplasm [6]. Upon phosphorylation, Smad2
forms a heteromeric complex with Smad4 and this complex accumulates in the nucleus
where it regulates transcription. Once TGF signalling is terminated, R-Smads are
rapidly dephosphorylated by PPM1A in the nucleus and exported back to the cytoplasm
[95, 96]. Although, classically Smads accumulate in the nucleus following TRI
mediated phosphorylation, it is also clear that R-Smads undergo dynamic shuttling to and
from the nucleus allowing for a mechanism to constantly “sense” activated TGF
receptors (reviewed in [23, 97, 98]). Subsequently, the subcellular localization of Smads
is also controlled by various mechanisms, partly owing to the presence of distinct nuclear
localization sequences (NLS) and nuclear export sequences (NES) [97].
Although small molecules can passively diffuse into the nucleus, proteins larger
than 40 kDa (such as Smads) must be actively transported across the nuclear membrane
through the nuclear pore complex (NPC) (reviewed in [99, 100]). The classical nuclear
import pathway across the NPC involves the aid of a complex of two receptor transporter
proteins, importin- and importin-. Importin- acts as an adaptor that recognizes and
binds the characteristic basic residues (arginine and lysine) in the NLS of target proteins.
Importin- binds importin--tethered cargo and the entire complex can enter the nucleus
through its interactions with nucleoporins, which are proteins that constitute the nuclear
pore complex (reviewed in [101]). Target proteins can also bind directly to importin-, or
directly to nucleoporins to permit their nuclear entry. Similarly, nuclear export is largely
dependent on the export transporter CRM1 (chromosome region maintenance 1) also
sometimes referred to as exportin-1 [100, 101]. CRM1 binds to the leucine rich NES, and
then interacts with nucleoporins to permit transport back into the cytosol [100]. However,
cargo can also bind nucleoporins directly to permit their export.
The MH1 domain of all Smads contains a conserved NLS, however, the nuclear
import of Smad2 occurs independently of Importin-[102]. Instead, nuclear shuttling of
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Smad2 is dependent on a direct interaction of the MH2 domain of Smad2 with
nucleoporin proteins. Smad2 directly interacts with CAN/Nup214, a nucleoporin protein
that resides on the cytosolic side of the NPC, which facilitates the entry of Smad2 into the
nucleus [102]. On the nuclear side of the NPC, Smad2 can bind the nucleoporin Nup153,
which facilitates its export from the nucleus [102]. Interestingly, the residency of Smad2
in the nucleus or the cytosol is dependent on cytosolic or nuclear interacting proteins that
can act as retention factors. For example, SARA (an endosomal protein) competes with
CAN/Nup214 for binding to hydrophobic patches in the MH2 domain of Smad2 [103].
Because receptor mediated phosphorylation of Smad2 decreases its affinity for SARA
[88], this may enhance the ability of Smad2 to bind CAN/Nup214 and thus nuclear
transport. Once in the nucleus, Smad2 then interacts with transcriptional co-factors,
which retain it in the nucleus. Consistent with this idea, expression of the Smad binding
domain of SARA, reduces nuclear accumulation of the Smad MH2 domain [88], whereas
Smad2 nuclear accumulation is promoted through the expression of the Smad binding
nuclear transcription factor FoxH1 [102, 104]. Phosphorylated forms of Smad2 are
retained in the nucleus more efficiently than unphosphorylated forms, indicating that
phosphorylation increases the association of transcription co-factors and Smad4 binding
[23]. Moreover, although the MH1 domain of R-Smads can bind DNA, this intrinsic
DNA binding affinity is relatively low and Smad mediated transcription requires other
DNA binding transcription factors in a complex with Smads [98]. Thus, the idea that
Smad2 can constantly shuttle to and from the nucleus emerges as a mechanism by which
the Smads can constantly monitor the activity status of the TGF receptors – where
regulatory factors such as SARA retain it in the cytoplasm, and nuclear partners retain it
in the nucleus for TGF mediated transcription.
Interestingly, the nuclear import of Smad4 follows a more classical nature. Smad4
contains a NLS in its MH1 domain, which unlike Smad2, does interact with importin. Smad4 has two NESs, one is located in its MH1 domain and the other in its
linker region, and nuclear export is mediated by CRM1 [97, 105-107].

Smad4

accumulates in the nucleus through its association with R-Smads, however, evidence for
Smad4 shuttling independent of ligand was provided when it was discovered that
mutations in the NLS reduces nuclear entry, whereas mutations of the NES promote
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nuclear accumulation [105-107]. Upon ligand stimulation, the Smad4 NES is masked by
the interaction of Smad4 with the phosphorylated R-Smad, which allows Smad4 to
accumulate in the nucleus [95, 106]. Smad4 dissociates from R-Smads once R-Smads are
dephosphorylated, and both are exported from the nucleus to the cytoplasm [95]. If TGF
receptors are still active, R-Smads are phosphorylated, bind Smad4, and return to the
nucleus.
Thus, constant nucleo-cytoplasmic shuttling of Smads is a key feature of TGF
signalling. The continuous cycles of receptor mediated phosphorylation in the cytoplasm,
and rapid nuclear dephosphorylation allows for a constant sensing mechanism that
detects the activation status of the receptors, and allows for proper termination in the
absence of ligand or receptor termination.
Interestingly, other signalling pathways can also converge on Smad signalling to
regulate its activities. As mentioned, Smads consist of an MH1 domain and an MH2
domain separated by a “linker” region. As mentioned above, the MH1 domain is involved
in DNA binding, and the MH2 domain is involved in binding other protein partners, such
as activated receptors, cytoplasmic retention factors, nucleoporins, and nuclear proteins
involved in transcription such as co-factors. The linker region in between the MH1 and
MH2 domains is variable among the Smads, and has been shown to have various
regulatory functions (reviewed in [108]). Interestingly, several ser/thr kinases have been
discovered to phosphorylate the Smad linker region. For example, all three members of
the mitogen activated protein kinase pathways (MAPK), including extracellular-signal
related kinase (ERK), Jun N-terminal kinase (JNK) and p38 kinase have all been shown
to phosphorylate Smads in the linker [108]. Initially, ERK was found to phosphorylate
the R-Smads 1, 2 and 3 on multiple residues in the linker region and this effectively
reduced the ability of R-Smads to accumulate in the nucleus in response to TGF [109,
110]. This became an interesting topic, as a properly timed nuclear exclusion of R-Smads
through linker phosphorylation was shown to be quite important for early embryonic
developmental processes (reviewed in [111]). More specifically, R-Smad linker
phosphorylation by MAPK, and subsequent attenuation of TGF-Smad signalling,
deprives the ability of the ectoderm to become mesoderm, and was also shown to be
important to promote the neural differentiation and dorsalization of the mesoderm in
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Xenopus frog embryos [112, 113].

Smad linker phosphorylation has also been shown to

play a role in oncogenic progression. Many cancer cells are often transformed by
oncogenic Ras, which activates mitogenic signalling by ERK, and thus enhances
proliferation. Normally, TGF signalling can override the proliferative effects of
mitogenic Ras signalling in epithelial cells – however, it was discovered that oncogenic
Ras signalling to ERK can antagonize TGF tumour suppressive effects through Smad
linker phosphorylation and nuclear exclusion [110]. However, although these initial
reports describe Smad linker phosphorylation by ERK leading to nuclear exclusion, since
then multiple studies have also reported that linker phosphorylation (by various kinases)
can also enhance TGF-dependent transcription [114-117] – seemingly two completely
opposite effects. Furthermore, in addition to MAPK members, multiple other kinases
such as GSK-3, CDKs, CAMK, and ROCK, have been shown to phosphorylate the Smad
linker region regulating various processes in various cell types, indicating that the role of
Smad linker phosphorylation is significantly more complicated than initially anticipated
[108]. Clearly, linker region phosphorylation does have the ability to modify TGF
signalling, but the exact mechanisms and outcomes in varying contexts are still unclear
and are currently still being investigated.

1.3 Protein Kinase C
1.3.1 The Protein Kinase C Family
Protein kinase C (PKC) consists of a family of ser/thr kinases involved in diverse
cellular processes, including cell proliferation, migration, differentiation, apoptosis,
neurotransmission, signal transduction and cell polarity (reviewed in [118-124]). The
PKC family consists of at least 10 members divided into three subgroups based on their
structure and their requirements for activation: the classical PKCs (cPKC), the novel
PKCs (nPKC) and the atypical PKCs (aPKC) (Please see Figure 1.5) [118-124].
Classical PKCs () require calcium and diacylglycerol (DAG) for
activation, novel PKCs () require DAG, and atypical PKCs (and) are
independent of DAG or calcium [119-123, 125]. All PKCs also utilize phosphatidylserine
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as a co-factor for activation [126, 127]. PKC isoforms contain an N-terminal regulatory
region, and a C-terminal kinase domain. Within the regulatory region lies an N-terminal
psuedosubstrate domain which binds and autoinhibits the kinase domain of the enzyme
by mimicking PKC substrate sequences and occupying the substrate binding site [124].
The cPKCs contain two cysteine rich domains. One is termed the C1 domain,
which binds DAG and other phospholipids, the other is termed the C2 domain which
binds calcium. The nPKCs have a C1 domain but no functional C2 domain, resulting in
their calcium insensitivity. These two groups can also be activated by phorbol myristate
acetate PMA, which mimics endogenous DAG [128]. The aPKCs lack a C2 domain and
their C1 domain is truncated and does not bind DAG (or PMA) – thus rendering them
insensitive to calcium or DAG [129, 130]. Instead, aPKCs can be activated by other lipid
components such as phosphatidylinositols, phosphatidic acid, arachidonic acid and
ceramide or by kinases such as PI3K (phosphatidylinositol 3 kinase) or PDK1 (3’PIdependent kinase 1) [131-136].
Numerous extracellular signals control the activity status of the various PKC
isoforms, which in turn affect the activity of transcription factors, enzymes, cytoskeletal
proteins, and cellular receptors. Classically, PKCs are activated through cell surface
receptors that trigger intracellular signalling pathways. G-protein coupled receptors
(GPCRs) and receptor tyrosine kinases (RTKs) activate PKC through signalling pathways
that produce second messenger molecules such as calcium and DAG [124]. For example,
the activation of GPCRs by their extracellular ligands regulates the activity of
intracellular G-proteins, some of which can lead to the activation of phospholipase C 
(PLC). PLC triggers the production of inositol 1,4,5 triphosphate (IP3) and DAG. IP3
triggers increases in the intracellular levels of calcium, whereas DAG activates both
cPKCs and nPKCs. In addition to GPCRs and RTKs, more recently TGF ser/thr kinase
receptor activity has also been shown to lead to PKC activation [137]. Additionally,
other proteins and lipids can influence the regulation of PKCs. For example, arachidonic
acid and similar fatty acids are also known to activate PKC [138]. Furthermore, the
localization of several PKC isoforms to specific subcellular destinations can be altered
through their interactions with RACK proteins (receptors for activated C kinase) which
act as escorts to specific areas of the cell [118].
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In the basal state, PKCs localize mainly to the cytoplasm in a folded inactive
structure. The N-terminal pseudosubstrate domain folds over to bind to the C-terminal
catalytic domain of the PKC thereby holding PKC inactive. When intracellular levels of
calcium and DAG increase, PKC translocates to the plasma membrane where it can bind
these second messengers, which ultimately cause the pseudosubtrate domain to dissociate
from the kinase domain. This allows PKC to interact with and phosphorylate its
substrates, thereby triggering downstream signalling cascades[124].
Various studies have shown that many PKC isoforms are expressed in virtually all
tissue and cell types, and that expression is developmentally regulated and is related to
the differentiation status of a tissue (reviewed in [139-141]). Originally it was difficult to
attribute specific functions to specific PKC isoforms, due to the similar activator
requirements and substrate specificities of the various PKCs in vitro. However, genetic
manipulations of specific isoforms have identified PKC isoform specific functions,
making it clear that PKCs can execute unique and non-redundant functions within the
cell. Consistent with this, PKC isoforms show different subcellular localization, tissue
distribution, and binding partner specificity, which all contribute to their differential
activations and specified functions [121, 142, 143].
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Figure 1.5. Schematic representation of the PKC family
Most of the PKC isoforms have 4 conserved domains (C1-4) that form the diacylglycerol
(DAG), calcium, ATP and substrate binding sites. All PKCs also have a pseudosubstrate
region (PS) which autoinhibits kinase activity by binding to the substrate binding region
of the inactive enzyme. Both novel and atypical PKCs lack amino acids in the C2 region
to bind calcium. Atypical PKCs have only 1 cysteine-rich motif, and no detectable DAG
binding sites. aPKCs also contain a Phox-Bem 1 (PB1) motifs that are protein-protein
interaction domains and will bind to proteins such as Par6.
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1.3.2

Protein Kinase C and Membrane Trafficking/Endocytosis
Upon activation, PKCs regulate signalling pathways that control various cellular

functions. In particular, PKCs can regulate the endocytosis, membrane trafficking, and
desensitization of various receptors. Although the mechanisms are still being uncovered,
PKC isoforms may be central in controlling the vesicular trafficking of various
transporters, receptors and other plasma membrane proteins (reviewed in [118]). For
example, the activation of various GPCRs can lead to the activation of PKCs which
initiate downstream signalling events, however, PKCs can also phosphorylate the GPCRs
themselves. PKCs can phosphorylate residues within the cytoplasmic loops and Cterminal domains of many GPCRs initiating their desensitization, endocytosis and
sometimes degradation [118, 144-147]. Furthermore, it is well known that endocytosis of
GPCRs can be further facilitated by the binding of the signal terminator adaptor proteins
beta-arrestins to these phosphorylated residues [147, 148]. Internalized receptors can be
recycled back to the plasma membrane through either a fast recycling pathway, or they
may reside in endosomes for an extended period of time before undergoing a slow
recyclying, or degradation [148]. Interestingly, roles have emerged for PKCs in both of
these pathways thereby implicating PKCs as important mediators of intracellular receptor
traffic [146, 149, 150]. The intracellular itinerary of proteins following PKC-activated
internalization of receptors can vary. For example, H+/K+ ATPase ion pumps exhibit
decreased recycling and activity, whereas -integrin receptors exhibit increased recycling
to the cell surface and enhanced activity [151, 152]. Interestingly, the atypical PKCs
(aPKCs) can stimulate the translocation of EGF receptors to late endosomes through the
association of aPKC to the late endosome sequestering protein p62 [153]. The atypical
PKC isoforms constitute a unique class of PKCs, and interestingly one member (PKC)
has been implicated in TGF processes previously [154, 155].

1.3.3 Atypical Protein Kinase C
The atypical PKCs (aPKC), which consists of PKCis the mouse homolog)
and PKC are a unique set of PKCs that do not require DAG, phosphatidylserine, or
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calcium for their activation [156]. This distinctive characteristic is largely due to a unique
regulatory domain [125, 157] at the NH2 terminus, which lacks a DAG or calcium
binding motif [121, 158]. aPKC plays a critical role in establishing both front-rear and
apical-basal cell polarity through its interaction with the polarity complex Par6, Par3,
cdc42 and Rac1 [155, 159-161]. PKC and PKC share a 72% sequence homology at the
amino acid level [162], however, they may have some diverging functions. The most
striking example of this is that PKC knockout is embryonic lethal, whereas PKC
knockout mice develop normally, although with immunological deficits [130, 158, 163].
It still remains unclear whether the critical role of PKC/ in mouse development is
related to the establishment of cell polarity, or to some other critical embryonic function.
Interestingly, a third atypical isoform of aPKC, termed PKM, was discovered to be
expressed in the brain and is known to be important in long term potentiation (LTP)
maintenance and memory [164-167]. This brain specific isoform was originally thought
to be a cleavage product of full length PKC, as PKM is essentially the kinase domain
of PKC and thus lacks an autoinhibitory regulatory domain. However, this constitutively
active kinase was later shown to be an alternatively transcribed mRNA in the brain
through an internal promoter within the PKC gene and not a proteolytic product [168].
Classical mechanisms of activation of aPKCs consist of two main events: release
of pseudosubstrate inhibition and phosphorylation of the aPKC kinase domain on Thr410 by PDK1 and Thr-560 by other unknown kinases or possibly autophosphorylation
(reviewed in [130]). As mentioned, unlike the other PKCs, which are released from
pseudosubtrate inhibition by DAG, the aPKCs are activated by other lipid components
such as phosphatidylinositols, phosphatidic acid, arachidonic acid and ceramide. PIP3
appears to be a major activator of aPKC as its formation contributes to the direct
modulation of aPKC pseudosubstrate inhibition and also by activating PDK1 which then
phosphorylates the aPKC kinase domain [130]. Furthermore, direct interacting proteins
can regulate aPKC function. For example, prostate apoptosis response-4 (Par-4) can
interact with regulatory domain of aPKCs and inhibits their activities [169]. Furthermore,
the polarity complex protein Par3 (also known as ASIP; aPKC-specific interacting
protein) interacts with the kinase domain of aPKCs and inhibits their activity [170].
Another polarity protein, Par6, interacts with aPKC along with Par3 to form the polarity
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complex. In this complex, aPKC is held inactive until an active form of Cdc42 binds
Par6, thereby leading to activation of aPKC, and phosphorylation of target proteins that
drive the establishment of cell polarity [171, 172]. aPKCs have been implicated in
functioning in numerous other intracellular signalling pathways including MAPK, NFB,
TGF, and Rac1 (reviewed in [130, 163, 172]) and are becoming increasingly important
targets in human pathologies.

1.3.4

aPKC in cancer
Early in the 1980s, PKCs were discovered to be the major intracellular receptor of

the tumour-promoting phorbol esters, which stimulated a massive effort to define roles of
PKCs in oncogenesis [121, 173]. Although variations in PKC localization, activity,
phosphorylation, and/or expression have been documented in virtually all tumour types,
aPKCs have garnered considerable attention in cancer biology, as the atypical PKC is
considered to be a human oncogene (reviewed in [158, 174].
Interestingly, it is possible that aPKC isoforms have cell and tissue specific roles
in cancer. For example, increased PKC expression has been documented in bladder,
hepatocellular, and head and neck carcinomas [175-177]. Similarly, PKC overexpression
has been reported in breast, ovarian, and liver cancers [178-180] and has been implicated
in glioma proliferation and invasion [181-184]. Furthermore, PKC is reported to be
oncogenic in non-small cell lung cancer (NSCLC) and elevated expression is correlated
with poor prognosis in NSCLC patients [157, 158, 160, 185-187]. Between the two
isoforms, PKC has garnered the most attention with respect to cancer as ithas been
implicated in the promotion of carcinogenesis in vivo and in vitro and is accepted by
some as the first PKC to be a human oncogene [158]. For example, six non-small cell
lung cancer cell (NSCLC) lines (A549, H1299, H292, ChaGoK1, Sk-Mes1 and H520)
have elevated expression of PKC compared to non-transformed lung epithelial cells
(HBE4). In NSCLC immunohistochemistry studies show that overexpression of PKCis
confined to lung tumour cells with little to no expression present in adjacent stroma
[160]. The elevation of PKCexpression in NSCLC patients is predictive of poor
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outcome: patients with early stage lung cancer and high PKCexpression are more than
10 times likely to die from the disease than those with low PKC. A similar trend is
evident in patients with increased PKC DNA copy number and ovarian cancer [178].
Increased PKCexpression is also correlated with increased cyclin E expression in
ovarian cancers, and is implicated with increased proliferation, defects in cell polarity,
and overall decreased survival [178].

Expression of a kinase deficient mutant

(kdPKCin human A549 lung adenocarcinoma cells results in a loss of anchorage
independent growth, but does not affect adherent cell growth, which suggests that
PKCis essential to driving transformed growth [186]. This effect is also apparent in
vivo, as nude mice challenged with NSCLC cells expressing kdPKC displayed a
reduction in tumourigenicity as compared to mice challenged with wild-type NSCLC
tumours [186]. Aurothiomalate (ATM), a gold compound that has been used in the past to
treat rheumatoid arthritis, has been found to be a potent inhibitor of the PB1 interaction
between PKCand Par6 [187]; Inhibiting this interaction is thought to inhibit transformed
growth of tumours by targeting the PKC-Par 6 interaction and at the time of writing, has
currently passed phase 1 clinical evaluation for use in non-small cell lung cancer [188].
An earlier study highlighted the pro-apoptotic effects of ATM on aggressive prostate
cancer cells by the activation of ERK and p38 MAP kinases [189] indicating that the
interaction of aPKC with Par6 may be important for survival of aggressive tumour cells.
aPKCs are also considered survival genes, and several studies have highlighted the
oncogenic characteristics of PKC in NSCLC, ovarian, colon, breast, and pancreatic
cancers [157, 160, 185-187, 190, 191], and thus aPKCs may be a viable therapeutic target
for various human cancers. Interestingly, aPKC is linked to various TGF pathways
through direct interactions of TRI binding partners such as the polarity complex protein
Par6, and the E3 ubiquitin ligase TRAF6 (Figure 1.6) [5, 192, 193]. Although connected,
whether aPKCs alter TGF receptor functions and their corresponding signalling
pathways remains to be elucidated.
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Figure 1.6. Potential roles for aPKC in TGF pathways
The aPKC has been shown to associate with the TGF receptors through the scaffolding
polarity protein Par6. This interaction occurs via PB1 domains contained on both aPKC
and Par6. Importantly, PKC and Par6 can also bind Smurf1, an ubiquitin ligase that can
target proteins for degradation. aPKC can also directly bind TRAF6, a component of the
TGF-p38MAPK pathway, and p62, another PB1 domain containing scaffold protein.
Although, aPKC has been linked to the TGF receptors, its role in TGF signalling is not
understood.
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1.4 Par6 and the polarity complex
1.4.1 Cell Polarity
Higher order organisms consist of various specialized cell types that can execute
specific functions. For example, neurons have long axons and make hundreds of
connections with other cells to create a complex signalling network that can transmit
information to peripheral regions of the body. Alternatively, one function of epithelial
cells is to regulate and limit the transport of molecules to inner tissues, thereby creating a
physiological and mechanical barrier from the outside environment. This asymmetry of
cellular function is called ‘cell polarity’ and is created by conserved signalling pathways
that create asymmetric distribution of constituents within the cell. Cell polarity can refer
to the antero-posterior polarity critical for asymmetric cell division during development,
apical-basal polarity of epithelial cells, front-rear polarity seen in polarized migrating
cells, or axon formation from naïve neurites seen in neurons (reviewed in [172]).
Interestingly, these seemingly very different cell polarity processes are controlled by a set
of evolutionarily conserved proteins involving Par6 and aPKC. There are 6 Par genes,
Par1 and Par4 are ser/thr kinases, Par2 is a RING-finger protein, Par3 and Par6 are PDZdomain-containing scaffold proteins, and Par5 is a member of the 14-3-3 family of
proteins [172]. These proteins are critical for asymmetrical cell division of the early
worm embryo, and regulate fundamental mechanisms regarding cell polarization
(reviewed in [194]). Importantly, Par6, aPKC and Par3 form part of the polarity complex
in diverse cell types, and this functional unit acts dynamically to regulate cell polarization
processes in various contexts in diverse organisms.

1.4.2 Par6 and the polarity complex
Par6 was originally discovered as one of six Par (partitioning-defective) proteins
required for the asymmetrical division of the C. elegans embryo [195-197]. Since then,
Par6 has been found in metazoans ranging from worms to mammals (reviewed in ref.
[194]) and has been established as a mediator in many cellular processes including
apical-basal cell polarity, directional cell polarization, cell migration, cell proliferation
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and axonal specification. Par6 is an adaptor molecule for the polarity complex, a highly
conserved group of interacting protein partners including aPKC, Par3 and several small
GTPases that work in a spatiotemporally co-ordinated effort to generate asymmetry
within a cell [161, 170, 171, 198-200]. This scaffolding ability is made possible by
various important domains on Par6 including a PB1 domain which binds aPKC, a
GTPase binding domain which has a semi-CRIB motif that binds Cdc42 and Rac1, and a
PDZ domain which binds Par3 (reviewed in [201, 202]). Many studies have documented
the role for the polarity complex as fundamental players in normal cell functions, tissue
maintenance and development. For example, the polarity complex controls the formation
of tight junctions between epithelial cells, and contributes to apical-basal polarity [170,
203-205]. The plasma membrane of epithelial cells is divided into an apical (facing the
extracellular space), and a basolateral domain (the portion of the membrane that forms
the base and side surfaces), and these membranes contain different lipid and protein
compositions. The membrane domains of epithelial cells are separated by junctional
complexes, such as tight junctions, adherens junctions, and desmosomes, which act to
physically attach cells to each other and also provide a diffusion barrier to prevent the
free movement of solutes through the extracellular space [206]. aPKC and Par6 bind
through a PB1-PB1 domain heterodimerization, and this complex becomes activated
through the binding of activated Cdc42 or Rac1 to the CRIB domain of Par6 [170, 203,
205]. The active aPKC-Par6 complex then binds Par3 by directly interacting with aPKC
kinase domain, and also through a PDZ domain interaction with Par6 [207, 208]. This
tertiary complex is linked to junctional complex proteins such as JAM1 (junction
adhesion molecule 1) through Par3 and promotes the formation of sub-apical junction
formation (reviewed in [209]). Furthermore, active aPKC-Par6 complexes lead to the
phosphorylation of LGL (lethal giant larvae), and this aPKC induced phosphorylation
cause translocation of LGL to basolateral regions of the cell, and constricts them from
being at the apical membrane [204, 210, 211]. This physical restriction of LGL to the
basolateral region further potentiates cell polarity by interacting with the basolateral
membrane bound proteins discs large 1 (DLG1) and Scribble [212, 213]. Thus, aPKC and
Par6 are part of intricate signalling networks that regulate cell polarity through the basis
of mutual exclusion and spatial restriction.
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Similarly, Par6 and aPKC have been shown to be essential regulators of the
polarized migration through the localized activation of Par6-aPKC at the leading edge
through binding of the small GTPase Cdc42 [214]. In this model, scratching a monolayer
of primary astrocytes leads to a reorganization of the microtubule network and
repositioning of the Golgi apparatus, mediated by the integrin stimulated activation of
Cdc42 at the leading edge of the migrating cells. Furthermore, the activation of aPKCPar6 at the leading edge of migrating cells, inhibits the activity of GSK-3, which
promotes the localized association of adenomatous polyposis coli (APC) with the plus
ends of microtubules and the formation of DLG1 positive puncta in the plasma
membrane [199, 215]. DLG1 interacts with APC directly, and this interaction is required
for the microtubule dynamics that regulate cytoskeleton polarization [199]. Thus, the
activation of the aPKC-Par6 complex at the leading edge by Cdc42, drives the
microtubule dynamics associated with elongation at the leading edge, which is crucial for
cell polarization and directional migration [198, 199, 214, 216, 217].
Interestingly, some of these polarity proteins may also play a role in membrane
trafficking and endocytosis. Recently, a genome wide screen deciphered that several
polarity proteins are critical in regulating membrane trafficking [218, 219]. These include
aPKC, Par6, Par3, and the small GTPase, cdc42 [218, 219]. Knockdown of these proteins
using small interfering RNA (siRNA) effected changes in clathrin dependent endocytosis,
and endosomal recycling [218, 219]. Interestingly, these polarity proteins, once thought
to be strictly involved in controlling cell polarity and migration, may also be important
players in regulating endocytic traffic.
Although polarity proteins regulate normal cell and tissue polarity, they are often
deregulated in tumour cells (reviewed in ref. [220]) indicating that loss in tissue
architecture and oncogenesis may go hand in hand. The loss in organization associated
with oncogenic transformation is likely to involve changes in the expression, localization
and activation patterns of key polarity proteins such as Par6 and aPKC [221]. Indeed
Par6 has recently been reported to be overexpressed in breast cancer and enhances the
progression of breast cancer through disruption of cellular organization and enhancing
proliferation [222, 223] and roles for aPKC in oncogenesis are emerging as described
above.
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1.4.3 The TGF-Par6 axis
The alterations in the normal function of polarity proteins such as Par6 and aPKC
may contribute to tumour progression. It is likely that the switch from controlling normal
cell polarity to the disruption of tissue architecture may also depend on extrinsic cues in a
context dependent manner. One such cue was discovered when a novel screen identified
Par6 as a binding partner of the type I receptor of the TGF pathway [224]. This
interaction proved to be important, as TGF activation induced the phosphorylation of
Par6 by TRII on a conserved serine residue (S345) resulting in altered cytoskeletal
plasticity and EMT (Figure 1.7) [155]. This phosphorylation stimulated the recruitment
of the ubiquitin ligase Smurf1 to target RhoA for degradation at tight junctions. The
localized degradation of RhoA was shown to be required for the dissolution of junctional
complexes, rearrangement of the actin cytoskeleton, and EMT (Figure 1.7) [155].
Importantly, this pathway is parallel but independent of the classical TGF-Smad
pathway known to regulate the genetic programme associated with EMT. Furthermore,
phosphorylation of Par6 was found to be important in the invasion and metastatic
progression of breast cancer cells and consequently has also been correlated with reduced
survival in breast cancer patients [223]. Thus, the phosphorylation of Par6 is important in
EMT, tumour cell invasion, tissue disruption, and ultimately tumour progression – and
until recently, this phosphorylation has only been documented to occur through the TGF
receptors. Uncovering the details around the TGF-Par6 axis with respect to normal cell
polarization, and tissue disrupting processes such as EMT is an ongoing area of study.
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Figure 1.7. TGF receptors phosphorylate Par6 to trigger EMT
TGF receptors participate in accessory non-Smad pathways to regulate responses. One
such non-Smad pathway is the TGF-Par6 axis. The polarity proteins Par6 and PKC
form a complex with the TGF type I receptor at junctional complexes of polarized
epithelial cells. Upon TGF stimulation, the TGF type II receptor is recruited to the
complex and phosphorylates Par6 on S345. This induces the recruitment of Smurf1
which ubuiqitinates RhoA, a small GTPase critically involved in regulating the actin
cytoskeleton, and targets it for degradation. This results in actin cytoskeleton remodeling,
dissolution of tight junctions, and the onset of epithelial to mesenchymal transition
(EMT) and tumour progression [155, 223].
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1.5 The Epithelial to Mesenchymal Transition (EMT)
Normal epithelial cells have several defining characteristics. Firstly, they form
organized layers of cells that are closely adjoined and held together by special junctional
complexes such as tight junctions, adherens junctions, and desmosomes [225, 226]. Also,
epithelial cells have apical-basolateral polarity, are attached to a basement membrane,
and maintain complete cell-cell adhesion with their neighbours. Under normal conditions
these cells do not detach and move away from the epithelial layer [225, 226].
Mesenchymal cells on the other hand, do not have apical-basal organization, have
fibroblast morphology and are highly motile and migratory [225, 226]. Epithelial cells
under certain environmental pressures can undergo a shift into a mesenchymal
phenotype: a process known as epithelial to mesenchymal transition (EMT) and involves
dissolution of junctional complexes, reorganization of the actin cytoskeleton, loss in
polarity, and independent motile behavior (Figure 1.8) [155, 225]. EMT is characterized
by a shift in cells from an epithelial phenotype expressing epithelial markers such as Ecadherin, Occludins, and Desmosplakin to cells that are more motile expressing
fibroblastic markers such as N-cadherin and Fibronectin [225, 226]. EMT, although a
critically important process in development [159, 225, 227], marks a major pathological
event in cancer biology whereby tumour cells attain an invasive and migratory phenotype
and is a prelude to advanced metastatic disease [228, 229]. TGF signalling emerged as
an important regulator of EMT through its promotion of invasion and metastasis [9, 12,
57] and understanding the mechanisms by which TGF causes highly polarized and
adjoined epithelial cells to transform into randomly migrating cells is critical to our
understanding of tumour development.

1.5.1 Types of EMT
EMT is an evolutionarily conserved mechanism by which polarized epithelial
cells, which are normally attached to a basement membrane, acquire a mesenchymal
phenotype. This occurs through various biochemical changes leading to a cell phenotype
that is characterized by enhanced invasive potential, increased resistance to apoptosis,
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and increased deposition of extracellular matrix. The resulting transition yields cells that
can degrade the basement membrane and escape the original epithelial layer from which
they originated.
Interestingly, EMT has been observed in three distinct biological settings. More
specifically, EMT is observed during development, during wound healing, and during
tumour progression. Although the exact interplay of cellular signals that dictate the EMTs
in these various functional scenarios is not yet clear, it has been proposed that EMTs
should be subcategorized into these three distinct types (reviewed in [230]).
Type 1 EMT is the differentiation processes observed during development. For
example, EMT is critical for the generation of the embryonic three layered body plan
consisting of the endoderm, mesoderm, and ectoderm, which arise through gastrulation
[225]. Thus, type 1 EMT is associated with implantation and embryonic gastrulation to
generate the mesoderm, endoderm, and mobile neural crest cells. Furthermore, the
primitive epithelium during development, and more specifically the epiblast, undergoes
an EMT to become the primitive mesenchyme [230]. Importantly, type 1 EMTs neither
cause systemic spread via the circulation, nor do they cause fibrosis. Principally, the
purpose of type 1 EMT is to generate mesenchymal cells important during development.
While EMT is critical for body patterning and organogenesis during development,
the process can also be recapitulated in the adult. A second type of EMT is involved in
tissue regeneration, wound healing, and organ fibrosis; this type has been termed type 2
EMT. Type 2 EMTs are part of a repair-associated event that would normally create
fibroblasts in order to reconstruct a damaged tissue after trauma or inflammatory injury
[230]. Under normal conditions, this EMT is associated with inflammation and should
desist once the inflammation has attenuated, as is the case for wound healing. However,
persistent inflammation without attentuation can lead to a persistent EMT response
leading to tissue fibrosis and eventual organ destruction through excessive ECM
deposition and scarring [230]. Essentially, fibrosis can be considered the result of
aberrant EMT and wound healing due to persistent inflammation, and this process is
known to be involved in the fibrotic disorders of the kidney, liver, and lung [230].
The third type, type 3 EMT, centers on the transition of neoplastic cells. In order
for tumour cells to metastasize, they must detach from the primary tumour, invade into
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the surrounding tissue or basement membrane, intravasate into the lymphatic or blood
system, and extravasate at a distant site [231, 232]. During tumour progression, the
ability of stationary epithelial cells to gain mesenchymal phenotype is essential to the
metastatic process. Thus, the EMT program involved in the acquisition of invasiveness
and metastatic potential of a growing primary tumour constitute type 3 EMTs.
Interestingly, type 3 EMTs can occur in cancer cells to a different extent, with some cells
retaining certain epithelial traits, while shedding others, whereas some cells can become
fully mesenchymal [230]. This gradient in EMT potential is likely related to the
biochemical and epigenetic heterogeneity of tumour cells, and although shares some
common features with developmental EMT programmes, type 3 EMTs are different than
the rigid execution of EMT seen during development.

1.5.2 TGF in EMT
Importantly, EMT is stimulated by extracellular activators that lead to complex
genetic and intracellular signalling programmes that regulate this process. TGF
signalling is a well-known activator of EMT and metastasis [233]. TGF was first shown
to induce EMT in 1994, where the authors show that the stimulation of mammary
epithelial cells with TGF induced a mesenchymal phenotype through a signal
transmitted by the type I TGF receptor [234]. Since then, the process of EMT has been
studied extensively in vitro, and TGF can stimulate the progressive loss of epithelial
markers such as E-cadherin, ZO-1, Occludins, and cytokeratin, and the subsequent gain
of mesenchymal markers such as N-cadherin, fibronectin, vimentin, and rearrangement of
the cell cytoskeleton through various pathways [3, 4, 225, 230, 232, 233, 235]. Although
multiple TGF pathways can regulate EMT, the downregulation the major adhesion
molecule of epithelial cells, E-cadherin, is central to the EMT process. E-cadherin is a
transmembrane cellular adhesion receptor, and constitutes the main type of adhesion
system in epithelial cells [232]. E-cadherin based junctional complexes stabilize the
multicellular architecture of the epithelium, providing a physical link between adjacent
cells to maintain the structural integrity and polarized phenotype of epithelia [225, 232].
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TGF signalling can potently induce the downregulation of E-cadherin through
transcriptional repression, but also by destabilizing cellular polarity. More specifically,
the TGF Smad depedendent transcriptional programme induces the expression of the
transcription factors SNAI1 (snail) and SNAI2 (slug), which transcriptionally repress the
expression of E-cadherin [236-238]. Importantly, TGF stimulation can also lead to the
destruction of E-cadherin based junctions through the phosphorylation of Par6 (the
TGF-par6 pathway) as described above [155]. Thus, both Smad dependent, and Smad
independent pathways are involved in the stimulation of EMT.
TGF is a critical player in EMT during development, and TGF isoforms
regulate EMTs in the atrioventricular canal of the heart, and are important for the fusion
of the palate [225, 233]. Furthermore, upon pathological examination of human cancers,
stromal TGF is often found at the invasion front, whose cells are characteristic of those
that have undergone EMT [233]. Interestingly, TGF has also been discovered to
promote cancer cells to acquire a stem cell-like phenotype, through the expression of
stem cell markers and the acquisition of self-renewal [233, 239-241]. Importantly, TGF
induced EMT can stimulate metastasis, but also may be important in generating cancer
cells with the ability to self-renew (also referred to as cancer stem cells), thereby creating
a tumour promoting phenotype [233]. Thus, characterizing the intricate mechanisms and
interplay with other pathways by which TGF regulates EMT is an important area of
research.
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Figure 1.8. Features of EMT
Epithelial to mesenchymal transition (EMT) is an important process during development,
but marks an important event during tumour progression where cells are becoming more
invasive and metastatic. The essential components of EMT include the disruption of cellcell junctional complexes, (e.g. tight junctions [TJs], adherens junctions [AJs], and
desmosomes), the loss of apical basal polarity, and a restructuring of the actin
cytoskeleton.

Importantly, EMT also involves a shift in epithelial cell expression

markers such as E-cadherin, Occludins, and cytokeratins to cells that express
mesenchymal markers such as N-cadherin and Fibronectin. Cells that have undergone
EMT show an enhanced migratory capacity, increased invasive potential, and an
increased resistance to apoptosis. A reverse process, the mesenchymal to epithelial
transition (MET), can also occur, allowing for environmentally regulated cell plasticity.
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1.6 Non-canonical TGF signalling to MAPK
The activation of the Smad signalling cascade by TGF is considered the
canonical pathway, however, TGF receptors can also activate multiple other
intracellular signalling cascades. Other pathways and effectors downstream of the TGF
receptors have been shown to act independently, synergize, or even antagonize classical
Smad signalling. TGF is known to activate a variety of signalling networks including,
the PI3 kinase-Akt pathway, Wnt pathways, Notch pathways, and MAPK pathways
(reviewed in [32, 235, 242]. For this thesis, I will focus on MAPK pathways.
Mitogen-activated protein kinases (MAPKs) are signalling components that
transduce extracellular stimuli into a range of intracellular responses. There are 3
principle MAPK pathways: ERK, JNK, and p38 - each of which has a complex but
apparent role in the development and progression of cancer [243]. In response to various
stimuli (including TGF) MAPK members become activated through phosphorylation.
This phosphorylation occurs through upstream MAP kinase kinases (MAP2Ks), which
are activated by MAP kinase kinase kinases (MAP3Ks) [244]. ERKs are classically
involved in mitogenic signalling, and often exhibit high expression and activation
patterns in various tumours. Furthermore, they are the downstream targets of oncogenic
Ras signalling [244]. The JNK and p38 MAPKs are SAPKs (stress associated protein
kinases) that have more complicated roles in cancer as they can both inhibit, and/or
stimulate tumour progression, depending on cellular context [243, 244].
MAPK pathways generally have various mechanisms by which they respond to
TGF induction [242]. MAPK signalling may modify the Smads (e.g. by
phosphorylation) thereby mediating the activity of Smads as transcription factors by
either stimulating or reducing nuclear translocation [235]. TGF receptors can activate
non-Smad proteins to initiate signalling cascades that run parallel to Smad signalling to
regulate a complex gene response [242]. New lines of research are uncovering networks
of complex signalling patterns and crosstalk between multiple pathways that converge to
elicit a specific physiological TGF response.
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1.6.1 TGF and MAPK activation
TGF can activate all three MAPK pathways (Figure 1.9). TGF stimulation can
activate ERKs through the type I receptor. Briefly, upon TGF stimulation, TRI recruits
and directly phosphorylates ShcA, which then associates with the adaptor protein Grb2
and a nucleotide exchange factor Sos, and this complex activates Ras, which then
initiates ERK signalling through Raf and Mek. [245]. This pathway is Smad independent,
and it is important to mention that the activation occurs at a much lower level than does
stimulation with classical ERK activators such as tyrosine kinase activity [245].
TGF also activates the other two MAPK pathways, but by reportedly different
mechanisms. Both p38 and JNK activation rely on the type I TGF receptor and also a
MAP3K, TAK1 (TGF associated kinase 1). Briefly, upon TGF activation TRI
directly associates with an E3 ubiquitin ligase called TRAF6 [192, 193]. TRAF6 becomes
lys-63 poly-ubiquitinated, which promotes the association and activation of TAK1 [192].
This process was shown to be important in p38 and JNK activation, as knockdown of
TRAF6 using siRNA (small interfering RNA) abrogated this effect [192]. Interestingly,
this activation occurred independent of the kinase activity of TRI, but the E3 ligase
activity of TRAF6 and TGF stimulation were required for TRAF6 auto-ubiquitination
and TAK1 activation [193]. Importantly, the TGF-p38 MAPK pathway described has
been reported to be important for p38-stimulated apoptosis. Inhibition of the TGFTraf6- p38 axis using pharmacological inhibition or siRNA knockdown blocks the TGF
induced apoptosis of various epithelial cells [192, 193, 235, 246, 247]. However,
signalling through p38 is complex, as in some instances p38 can also stimulate cell
growth and survival indicating possible complex interplay of multiple pathways [243].
Interestingly, aPKCs have been shown to play a role in p38 induced apoptosis, as
inhibition or knockdown of aPKC sensitizes glioblastoma cells to chemotherapeutic
agents via a p38 dependent mechanism [183]. Interestingly, aPKC is a known direct
binding partner of TRAF6 and links it to other signalling pathways (such as NFB)
through binding the late endosome marker and PB1 adaptor protein p62 (Figure 1.6)
[153, 248]. Whether atypical PKC plays a role in TGF induced p38 MAPK signalling is
still not clear.
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Figure 1.9. TGF can activate MAPK pathways independently of Smads.
Activated TGF receptors have been reported to activate all three MAPK pathways in a
cell-type and context specific manner. TGF receptors can activate ERK MAPK through
cascade starting with the direct phosphorylation of Shc. ERK signalling is typically
mitogenic in epithelial cells. TRI can also bind the ubiquitin ligase TRAF6 to stimulate
its autoubiquitination, which ultimately triggers a cascade that culminates in the
phosphorylation and activation of p38 MAPK and JNK. Both p38 MAPK and JNK are
generally pro-apoptotic in epithelial cells.
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1.7 Purpose of Study, Hypothesis, Aims
1.7.1 Purpose of Study
TGF signalling controls a diverse set of cellular processes including cell
polarity, wound healing, differentiation, migration and proliferation [6, 7, 23, 24].
Aberrant TGF signalling is a hallmark of many epithelial derived cancers [3, 55], and
understanding the mechanisms by which TGF signalling is impaired would aid our
understanding of tumour progression. Normally, TGF acts as a tumour suppressor by
controlling the growth of the epithelium, but in many tumours TGF undergoes a role
switch and becomes a metastatic agent through its induction of the mesenchymal
transition and the promotion of invasion [3, 4, 55-58]. This loss of TGF growth control,
followed by TGF induced cancer progression is exhibited in lung cancer [56-58]. Nonsmall cell lung cancer (NSCLC) is the major form of lung cancer, and accounts for the
majority of lung cancer related mortalities [249].
Although, TGF should normally play an anti-proliferative role in lung tumours,
in NSCLC, the growth inhibitory effects of TGF are lost, despite these cells producing
functional ligands and receptors [250]. Moreover, TGF induces NSCLC cell migration
and invasion, which are hallmarks of metastatic tumours [56-58].

Therefore,

understanding the mechanisms for TGF dysfunction is critical to furthering our
understanding of lung cancer progression, and ultimately to developing therapies to
circumvent altered TGF signalling patterns.
Because TGF signal propagation is linked to the membrane trafficking of TGF
receptors [68, 83, 89, 251, 252], elucidating the factors that contribute to altered
membrane trafficking is an important area of research. Furthermore, characterizing the
mechanisms that drive TGF signalling responses in cancer will require the examination
of both Smad and Non-Smad signalling pathways.

1.7.2 Rationale
TGF tumour suppression is lost in NSCLC, and TGF signalling regulates lung
tumour metastasis. The mechanisms by which TGF signalling is deregulated to become
a tumour promoter are unknown. We believe that the deregulated TGF signalling
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pathway seen in many NSCLC tumours may be related to altered TGF receptor
trafficking, as well as alterations to both Smad-dependent and Smad-independent
pathways (including Par6 and p38 MAPK). Several lines of evidence suggest that
polarity proteins such as aPKC and Par6 have aberrant actions in NSCLC, with aPKC
being considered an oncogene [157, 158, 160, 185-187, 253]. Furthermore, polarity
proteins have recently been described as important regulators of vesicular trafficking
[218]. Finally, aPKC is known effector and binding partner of multiple proteins in TGF
pathways, including Par6 and TRAF6, although its exact role has not been defined. Thus,
aberrant aPKC activity and a crosstalk with TGF components may contribute to how
cells respond to TGF signalling (Figure 1.10).

1.7.3 Hypothesis and Aims
My Hypothesis is that aPKC regulates TGF receptor signalling pathways
by:
1) Altering TGF receptor internalization to alter Smad-dependent and Smadindependent signalling
2) Altering Par6 phosphorylation leading to increased migration and EMT of
lung cancer cells.
This hypothesis was tested through the following 3 major aims:
AIM 1: Examine the role of PKC in TGF receptor trafficking and signalling.
AIM 2: Elucidate the role of the aPKC in the TGF-Par6 pathway.
AIM 3: Characterize TGF and aPKC knockdown dependent gene changes and
examine other non-canonical TGF pathways such as p38 MAPK.
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1.7.4 Overview of Cell Models
This work primarily used A549s and H1299 lung adenocarcinoma cell lines as
these are two readily used, and well established NSCLC cell models. These cell lines
have been used for in vitro studies of cell migration [254-256], EMT [57, 257-260], as
well as in in vivo metastasis mouse models [261, 262]. Furthermore, both of these cell
lines have functional and intact TGF signalling pathways [263-265]. In addition to the
above mentioned NSCLC cell lines, we also used HEK293T (human embryonic kidney)
cells and Rat2 fibroblast cells, both of which are reliably used in our lab [266]. HEK293T
cells were used for overexpression and interaction studies, as they are highly
transfectable and are a key cell line in helping us dissect the molecular mechanisms
surrounding the polarity proteins and TGF pathway. Rat2 cells are a highly migratory,
mesenchymal, fibroblast cell type, and are used here as proof of concept, as they readily
migrate, and respond to TGF. HEK293T and Rat2 cells are indispensable tools in
helping us understand the molecular mechanisms surrounding TGF biology. Finally,
we also use Mink lung (Mv1Lu) cells which have been used extensively in the past to
dissect the molecular mechanisms underlying the biology and signal transduction of the
TGF receptors. These cells express TGFreceptors, their associated Smads, and are
especially sensitive to TGFinduced gene induction and phenotypic response. However,
the detection of the endogenous expression of TGFreceptors using immunofluorescence
microscopy has been limited by a lack of good quality receptor antibodies. Therefore, we
use Mv1Lu cells stably expressing HA-tagged TGFtype II receptor (HAT cells). These
cells express near-endogenous levels of receptors but the HA tag on TRII allows us to
readily study the trafficking of TGFreceptors from the cell surface into intracellular
vesicles using HA antibodies [68, 267, 268].
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Figure 1.10. Exploring a role for aPKC in Smad-dependent and Smad-independent
pathways
Activated TGF receptors can activate Smads, phosphorylate Par6, and trigger the
phosphorylation of p38 MAPK. aPKCs have known roles in endocytic trafficking, and
are known binding partners of Par6 and TRAF6 and thus have rational connections to the
TGF pathway. Whether aPKC plays a role in TGF signalling processes is investigated
in this thesis.
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Chapter 2

2.1 Chapter Summary
TGFβ signalling is linked to the membrane trafficking of TGFβ receptors. The
Protein Kinase C (PKC) family of ser/thr kinases have been implicated in modulating the
endocytic processes of various receptors. The present study investigated whether PKC
activity plays a role in the trafficking, and signalling of TGFβ receptors, and further
explored which PKC isoforms may be responsible for altered TGFβ signalling patterns.
Using immunofluorescence microscopy and

125

I-TGFβ internalization assays, we show

that the pharmacological inhibition of PKC activity alters TGFβ receptor trafficking and
delays TGFβ receptor degradation. Consistent with these findings, I demonstrate that
PKC inhibition extends TGFβ-dependent Smad2 phosphorylation. Previous studies have
shown that PKC associates with TGFβ receptors to modulate cell plasticity. I therefore
used siRNA directed at the atypical PKC isoforms to investigate if reducing PKC and
PKC protein levels would delay TGFβ receptor degradation and extend TGFβ
signalling. Our findings suggest that atypical PKC isoforms regulate TGFβ signalling by
altering cell surface TGFβ receptor trafficking and degradation.
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2.2 Introduction
The TGFβ signalling pathway is an essential regulator of many cellular processes
including epithelial growth control, apoptosis, and the establishment of developmental
fate. Alterations in the TGFβ pathway, such as changes in expression, mutations, or
altered signalling patterns, have all been linked to pathological disorders of cell growth,
such as fibrosis and cancer [1-5]
Although TGFβ signalling is cell type and context dependent, in most normal
epithelium, TGFβ typically controls cell growth and division [1, 6-8]. However, in many
pathologies, TGFβ signalling is deregulated and can induce gene changes that are
associated with an invasive or fibrotic phenotype. Elucidating the factors that contribute
to the alteration of the TGFβ signal can shed light on how TGFβ signalling is deregulated
in various disease states. One major factor in the progression of the TGFβ signal involves
receptor trafficking and endocytosis [9-13].
The classical TGFβ signalling cascade involves the formation of a cell surface
receptor complex that is composed of the TGFβ type I and type II receptors (TβRI and
TβRII). TβRII is a constitutively active serine/threonine kinase, and phosphorylates TβRI
upon ligand binding.

Once activated, TβRI further transduces the signal by

phosphorylating Smad2 [14, 15].
Ligand binding to cell surface TGFβ receptors induces their internalization from
the cell membrane. The activated receptor complex internalizes one of two ways;
Receptor endocytosis via a clathrin-dependent mechanism into the early endosome
promotes TGFβ-dependent signal transduction, whereas partitioning into membrane rafts
facilitates receptor degradation and signal termination [9].
Trafficking of TGFβ receptors into the early endosome, results in phosphorylation
and activation of a TGFβ effector, Smad2. Phosphorylated Smad2 complexes with
Smad4, and this unit translocates to the nucleus to mediate TGFβ gene response.
Alternatively, trafficking of receptors into caveolin positive membrane rafts leads to the
recruitment of the inhibitory Smad7 and the binding of the E3 ubiquitin ligase Smurf2,
which target the receptors for proteasomal degradation [9]. Thus, the membrane
trafficking of TGFβ receptors plays an important role in the regulation of the TGFβ
pathway and altered receptor trafficking may be linked to aberrant TGFβ signal
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propagation. One family of proteins that is becoming increasingly important in endocytic
trafficking is Protein Kinase C (PKC).
The PKC family consists of at least 10 members divided into three subgroups
based on their structure and their requirements for activation. Conventional PKCs (cPKC)
require calcium and diacylglycerol (DAG) for activation, novel PKCs (nPKC) depend
only on DAG, and atypical PKCs (aPKC) are independent of DAG or calcium. The PKC
serine/threonine kinases are involved in diverse cellular processes and signal transduction
pathways that control cell proliferation, migration, differentiation and apoptosis [16-20].
Several lines of evidence suggest that PKC carries important roles in controlling
the vesicular pathways of various plasma membrane proteins, transporters and receptors
([16, 21-24] reviewed in [25]). Furthermore changes in PKC expression, localization, or
activity can lead to changes in receptor phosphorylation, endocytosis, desensitization, and
receptor degradation. For example, PKC has been shown to regulate the endocytosis and
desensitization of various G protein coupled receptors (GPCRs) through direct
phosphorylation [26]. PKC can also alter other membrane proteins, for example, PKC
phosphorylation of the epidermal growth factor receptor (EGFR) regulates its
intracellular trafficking, shifting it into recycling endosomes instead of a degradative
pathway [27]. Similarly, the trafficking of the Dopamine transporter (DAT) has also
been shown to be dependent on PKC activation [28], as DAT seems to be targeted for
degradation through a PKC-dependent ubiquitination [29, 30]. Given the increasing
evidence emerging that PKC is an important regulator of receptor trafficking, we have
explored the role of PKC in regulating TGFβ signalling.
It is unknown whether one or more PKC isoforms plays a role in the regulation of
TGFβ receptor trafficking. Interestingly, the atypical PKCs (aPKC) PKCι and PKCζ have
recently been given considerable interest with respect to cancer, and others have
classified PKCι to be an oncogene [31-35]. Notably, PKCζ has already been shown to be
a factor in TGFβ induced epithelial to mesenchymal transitions through its involvement
in the recruitment of ubiquitin ligases that drive degradation of the small GTPase RhoA,
and ultimately epithelial cell plasticity [36, 37]. Thus, the aPKCs are likely candidates for
regulating the endocytic trafficking of TGFβ receptors.
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In the present study, we show that PKC kinase activity alters TGFβ receptor
trafficking, degradation, and ultimately TGFβ signalling. More specifically, we have
shown that the inhibition of aPKC isoforms delays receptor degradation and extends
TGFβ induced Smad2 phosphorylation.

2.3 Materials and Methods
2.3.1 Antibodies and Reagents
Commercially available antibodies were purchased from the following vendors:
primary monoclonal anti-GFP (Living Colors-JL8), anti-Flag (Sigma F3165), anti-HA
(Santa Cruz-Y11-SC-805), anti-β-Actin (Sigma-A2668), anti-PKCι (Santa CruzSC11399), anti-PKCζ (Cell Signalling Tech-9372), anti-Phospho-Smad2 (ChemiconAB3849), anti-Smad2/3 (BD Trans-610842), anti-Smad7 (Santa Cruz SC-7004), antiMyc (Santa Cruz SC-40), anti-EEA1 (BD Trans Labs-610457) and anti-caveolin-1 (BD
Trans Labs-610060) were used as per the manufacturers' suggestions. HRP conjugated
secondary goat anti-rabbit (Thermo Scientific-31460), goat anti-mouse (Thermo
Scientific-31430) and donkey anti-goat (Santa Cruz SC-2020) were used for western blot
analysis.

Fluorescently conjugated goat anti-mouse (Jackson ImmunoResearch-

715225150) and goat anti-rabbit (Jackson ImmunoResearch-711175152) were used for
immunofluorescence studies. Protein G-Sepharose was purchased from GE Healthcare.
Gö6976 and GF109203X were purchased from Calbiochem. siRNA to human PKCζ
(10620319) and PKCι (10620319) were purchased from Invitrogen.

The constructs

encoding Flag or HA-tagged TGFβ receptors, Myc-Smurf2, Smad7-HA and PKCζ-HA
were used as previously described [36, 38].The GFP-tagged PKCι was a kind gift from
Drs. A. Babwah (The Children's Health Research Institute, London ON, Canada) and S.
Ferguson (Robarts Research institute, London ON, Canada) [39].

The HA-tagged

Ubiquitin construct was a kind gift from Dr. L. Dagnino (University of Western Ontario,
London, ON, Canada) [40].
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2.3.2 Cell Culture
A549 non-small cell lung cancer (NSCLC), Rat2 fibroblast and HEK293T cell
lines were maintained in Dulbecco’s Modified Eagle Medium supplemented with 10%
fetal bovine serum. Mink Lung cells stably transfected with HA-tagged TβRII (HAT)
cells were maintained in Minimal Essential Medium supplemented with 1% Nonessential amino acids and 10% fetal bovine serum, and 0.3% hygromycin. Cells were
kept in a humidified tissue culture incubator at 37ºC in 5% CO2. Calcium phosphate
transfections were carried on cells at approximately 40% confluency, followed by a
change in media approximately 24 hours from time of transfection. Cells were serum
starved overnight in 0.2% FBS media prior to treatment with 250 pM TGFβ. siRNA
transfections were conducted using Lipofectamine RNAi max according to the
manufacturer’s protocol. For ubiquitination studies, transfected cells were pretreated with
vehicle or GFX for 1 hour followed by the addition of the proteasome inhibitor MG132
(2.5 M) for 6 hours prior to lysis.

2.3.3 Protein Concentration
Protein concentrations were determined using the Lowry method (Fisher).

2.3.4 Immunoblotting and Immunoprecipitation
Prior to cell lysis, cells were rinsed with phosphate buffered saline (PBS). Cells
were lysed in TNTE (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5%
Triton X-100, 1mM phenylmethylsulfonyl fluoride, and mixture of protease inhibitors
[pepstatin, PMSF, NaF and NaPPi]) and centrifuged at 14,000 rpm at 4 °C for 10 min.
Aliquots of supernatants were collected for analysis of total protein concentration. For
immunoprecipitation, cell lysates were incubated with the indicated primary antibody,
followed by incubation with protein-G-sepharose. The precipitates were washed three
times with lysis buffer, eluted with Laemmli sample buffer. Proteins were resolved using
SDS-PAGE. Proteins were transferred to nitrocellulose followed by blocking in 5% skim
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milk, and incubation with primary antibody overnight at 4ºC. Following incubation with
HRP conjugated secondary antibody, proteins were visualized using West Dura Super
Signal ECL (Fisher) and imaged on a VersaDoc Imaging system (BioRad).

2.3.5 Immunofluorescence Microscopy
Receptor internalization experiments were carried out using Mv1Lu cells stably
expressing extracellularly HA-tagged TβRII (HAT cells). HAT cells were incubated with
anti-HA Fab fragments followed by anti-rabbit-cy3 Fab fragments in the presence of
DMSO, Gö6976, or GF 109203X at 4°C. The cells were then incubated at 37°C for 1 hr
to allow receptor internalization, fixed with 4% paraformaldehyde, permeabilized with
0.25% Triton X-100, and incubated with rabbit anti-EEA1 and mouse anti-Cav1
antibodies at 4°C overnight. Following incubation with the appropriate Cy-conjugated
secondary antibodies, the early endosome and membrane rafts were visualized by
immunofluorescence microscopy using an inverted IX81 Microscope (Olympus,
Canada). Co-localization of receptors with EEA1 or Cav-1 were quantitated over 3
experiments using computer software designed and programmed at the Samuel Lunenfeld
Research Institute (SLRI) (Toronto, Ontario) and represented as the mean ±SD. At least
30 cells per experiment per treatment were quantified.

2.3.6 Affinity Labeling
Cells were pre-incubated in control media (containing DMSO) or media
containing 10 mM Gö6976, or GF 109203X for 1 hour at 37ºC, placed on ice and treated
with 250 pM
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I TGFβ in KRH plus 0.5% bovine serum albumin at 4ºC for 2h.

Following cross-linking with disuccinimidyl suberate, cells were lysed (time 0) or
incubated at 37ºC for 2, 4, or 8 hours prior to lysis. Receptors were visualized by SDSPAGE and quantified using phospho-imager analysis (Amersham Biosciences).
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2.3.7 Phospho-Smad Signalling Assays and TGF Treatment
Cells were pre-incubated in serum deprived media (0.2% FBS) containing
DMSO, Gö6976, or GF 109203X for 1 hr. They were then treated with 250 pM TGFβ for
30 minutes, washed and further incubated in the presence or absence of the PKC
inhibitors in serum deprived media for an additional 1 or 4 hours prior to lysis. Lysates
were then processed for SDS-PAGE, and immunoblotted for Phospho-Smad2 and total
Smad2 levels.
For the 24 hr TGFβ chase experiment, siRNA treated A549 cells were pretreated with DMSO (control) or SB431542 (10 mM) for 0.5 hours prior to TGFβ
treatment for 1 hour. Cells were then washed with PBS 3 times, followed by incubation
in low serum media containing DMSO or SB431542 for an additional 24 hours before
lysis. Lysates were processed for SDS-PAGE and immunoblotted as described above.

2.3.8 Statistical Analyses
One-way or Two-way ANOVA analyses followed by post-hoc Tukey’s Test were
used to evaluate the significance of the results. Statistical analyses were performed using
GraphPad Prism® Software and p values of <0.05 were considered statistically
significant.

2.4 Results
2.4.1 Inhibition of PKC alters TGF receptor trafficking
TGFβ signal transduction is highly regulated through receptor endocytosis and
membrane trafficking. To determine whether PKC had an effect on the internalization of
the TGFβ receptors, we pharmacologically inhibited PKC activity and assessed TGFβ
receptor endocytosis using Mv1Lu cells stably expressing extracellularly HA-tagged
TβRII receptors (HAT cells). Stable expression of HA tagged TRII in this cell line
allows for sensitive detection of the movement of TGF receptors into intracellular
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vesicles using immunofluorescence microscopy [9, 41]. The cells were cultured in
control media, or media containing a classical PKC inhibitor (Gö6976), or a pan PKC
kinase inhibitor, GF109203X (Figure 2.1). Cell surface TGFβ receptors were labelled at
4˚C and after incubation at 37°C for 1 hour, the cells were fixed, permeabilized and
counterstained with markers for the early endosome (using anti-EEA1) or membrane rafts
(anti-Cav-1) (Figure 2.1).
In untreated cells we observed that after 1 hr of internalization, TGFβ receptors
gained access to the interior of the cell. Approximately half of the receptors co-localized
with either the EEA1-positive or Cav-1-positive compartments in equal proportion
(Figure 2.1A, quantified in 2.1D). The cPKC inhibitor, Gö6976, did not alter the ratio of
receptors in the EEA1-positive or Cav-1-positive compartments (Figure 2.1B). We did
however notice a general accumulation of receptors and Cav-1 positive vesicles at the
peri-plasma region of the cell (Figure 2.1B). Interestingly, the pan PKC inhibitor, GF
109203X, did not perturb the position of the Cav-1 compartment but increased TGFβ
receptor co-localization with the EEA1 compartment (Figure 2.1C and 2.1D).
These results suggest that the inhibition of different PKC isoforms will alter
receptor trafficking. Indeed, pan PKC inhibition shifted the ratio of receptors into the
EEA1-positive signalling endosomes whereas targeting classical PKC isoforms did not
(Figure 2.1D). From these results we predicted that the rate of receptor degradation, and
possibly signal transduction, would be affected. We first assessed whether the alteration
in receptor internalization would lead to changes in the rate of TGFβ receptor
degradation.
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Figure 2.1
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Figure 2.1. PKC inhibition alters TGF receptor trafficking
Mv1Lu cells stably expressing extracellularly HA-tagged TRII were incubated with
anti-HA Fab fragments followed by anti-rabbit-cy3 Fab fragments in the presence of
DMSO (Control; A), 10 M Gö6976 (B), or 10 M GF109203X (C). The cells were then
incubated at 37°C for 1 hr (to allow receptor internalization), fixed, permeabilized and
incubated with mouse anti-EEA1 and rabbit anti-Cav1 antibodies. Following incubation
with the appropriate secondary antibodies, the receptors (red), the early endosomal
compartment (EEA1; blue) and membrane rafts (Cav-1; green) were visualized by
immunofluorescence microscopy. Co-localization of receptors with EEA1 or Cav-1 is
indicated with arrowheads or arrows, respectively. Note that Gö6976 induces an
accumulation of receptors and Cav-1-positive structures at the peri-plasma membrane
(grey arrowheads; B). Bar = 10 m.
(D) Receptors co-localizing with EEA1 or Cav-1 positive vesicles were quantitated from
three separate experiments and represented as the mean +/-SD. (n=3).
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2.4.2 Inhibition of PKC activity extends TGF receptor half-life
To determine whether PKC kinase activity had an effect on TGFβ receptor
degradation, we used

125

I-radiolabelled TGFβ to conduct receptor half-life studies.

Briefly, serum starved Mv1Lu cells were treated with

125

I-TGFβ at 4°C; a temperature

where TGFβ receptors halted at the cell surface. After cross-linking the 125I-TGFβ to cell
surface receptors, the cells were incubated in control media or media containing PKC
inhibitors (Gö6976 or GF109203X) at 37°C. Cells lysates were then processed for SDSPAGE, and receptor levels are analyzed using phospho-imaging (Figure 2.2).

We

observed that the inhibition of PKC kinase activity with either inhibitor decreased the rate
of TGFβ receptor degradation (Figure 2.2A). The receptor half-life in untreated cells was
2.4 ± 0.3 hours and extended to 4.4 ± 0.8 in Gö6976-treated and 6.6 ± 1.7 in GFX-treated
cells (Figure 2.2B). Interestingly, receptor degradation was reduced in the presence of
either classical or pan PKC inhibitors.
After observing that PKC inhibition could alter receptor degradation and receptor
trafficking, we next addressed if PKC inhibition would affect TGFβ dependent Smad2
phosphorylation.
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Figure 2.2. PKC inhibition extends TGF receptor half-life
(A) Mv1Lu cells incubated in the presence of DMSO (control), 10 M Gö6976 or 10 M
GF109203X were affinity labelled with

125

I-TGF, cross-linked and incubated at 37°C

for 0, 2, 4, or 8 hours. Cells were then lysed, and subjected to SDS-PAGE followed by
phospho-imaging. The relative mobilities of 125I-TGF-bound TRII (~90 kDa) and 125ITGF-bound TRI (~65 kDa) are indicated.
(B) Three separate experiments as described in Panel A were carried out and the amount
of the receptors was quantitated using QuantityOne software and plotted as a percentage
of receptors at time 0. The mean +/- SD is shown. (n=3).
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2.4.3 TGF dependent Smad phosphorylation is extended with PKC
inhibition
Smad2 phosphorylation is a key component in TGFβ signalling and is the central
mediator of TGFβ-dependent transcription. To assess whether PKC could alter TGFβ
dependent Smad signalling, we assessed Smad2 phosphorylation levels over a 4-hour
time course (Figure 2.3).

Briefly, HAT, Rat2 fibroblast or A549 human lung

adenocarcinoma cells were treated for 1 hr with DMSO (control), Gö6976 or
GF109203X, prior to TGFβ stimulation for 0.5 hr. After washing out the TGFβ, cells
were incubated in the respective serum-deprived media in the presence or absence of
inhibitors for an additional 1 or 4 hr before they were lysed (Figure 2.3A). Activated
TGF receptors will continuously signal until degraded once internalized, thus washout
of TGF allows for analysis of the duration of TGF signalling of internalized receptors.
Quantitation showed that HAT cells that were incubated in media containing PKC
inhibitors had prolonged levels of Smad2 phosphorylation compared to vehicle-treated
cells (Fig 2.3B). These results were not cell line or cell type specific as Rat2 fibroblasts
and A549 human NSCLC cells also showed increased and prolonged Smad2
phosphorylation in the presence of PKC inhibitors (Figure 2.3C and 2.3D). We next
sought to further determine which class of PKCs was responsible for this extension.

86

Figure 2.3
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Figure 2.3. PKC inhibition extends TGF induced Smad2 phosphorylation
(A) Schematic of the experimental procedure to assess phosphorylated Smad2 levels in
PKC inhibited cells. HAT (B) Rat2 (C) or A549 (D) cells were pre-incubated in media
containing 10 M Gö6976, 10 M GF109203X, or DMSO (vehicle). They were then
treated with 250 pM TGF for 0 or 30 minutes, washed and further incubated in the
presence or absence of the PKC inhibitors for an additional 1 or 4 hours prior to lysis.
Lysates were then processed for SDS-PAGE and immunoblotted with anti ()-phosphospecific Smad2 or Smad2/3 antibodies as indicated. Accompanying densitometrical
analyses of average P-Smad2 levels from at least 3 independent replicate experiments is
presented graphically for each representative immunoblot. The mean +/- SEM is shown,
Two-way ANOVA, *p <0.05.
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2.4.4 Targeting aPKC kinases extends Smad2 phosphorylation
Although we observed that both types of PKC inhibitors could extend Smad2
phosphorylation, the signalling pattern was much more prominent in cells inhibited with
the broad PKC inhibitor GF109203X compared to the classical PKC inhibitor. This
suggested that classical PKC isoforms may play a more subtle role in TGFβ signalling
compared to either the novel or aPKC isoforms. To test whether aPKC isoforms were the
likely candidates in dampening TGFβ signalling, we carried out similar signalling assays
as described above in A549 cells (Figure 2.4). For this assay we incubated cells with two
different concentrations of GF109203X: 1 M, which only effectively inhibits the
classical and novel PKC isoforms, and 10 M, which inhibits all classes of PKCs. Our
results demonstrated that signalling was more prominently extended in cells inhibited
with 10 M GF109203X, suggesting that aPKC kinase activity was important in
regulating TGFβ signalling.
To confirm our pharmacological observations, we next assessed the effects of
PKC

isoforms

on

TGFβ-dependent

overexpression and siRNA studies.

receptor

signalling

and

degradation

via
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Figure 2.4
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Figure 2.4. aPKC inhibition extends TGF induced Smad2 phosphorylation
A549 cells were incubated with 1 M (inhibits classical and novel PKCs) or 10 M
(inhibits all PKCs) GF109203X for 1 hour. They were then treated with 250 pM TGF
for 0 or 30 minutes, washed and further incubated in the presence or absence of the PKC
inhibitor for an additional 1 or 4 hours prior to lysis. Lysates were then processed for
SDS-PAGE and immunoblotted with anti phospho-specific Smad2 or Smad2/3 antibodies
as indicated. Accompanying densitometrical analysis of average P-Smad2 levels from 3
independent replicate experiments is presented graphically for each representative
immunoblot. The mean +/- SEM is shown, n=3, Two-way ANOVA, *p <0.05. The
asterisk (*) beside immunoblots indicates a second band underneath Smad2 in A549 cells
that may represent Smad3 in this cell line.
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2.4.5 aPKC over-expression reduces TGF receptor steady state
levels
TGFβ receptor degradation may be a key determinant in the extension of Smad2
signalling. Our data suggested that aPKCs may be primarily responsible for the negative
regulation of TGFβ receptors. To test this, we expressed TGFβ receptors and increasing
amounts of a representative member of the classical PKC family, PKC, or increasing
amounts of an aPKC, PKCι into HEK 293T cells (Figure 2.5A). Western blot analysis
indicated that PKCι decreased the levels of steady state TGFβ receptors. Of note, the
multiple bands that represent the core and glycosylated forms of TRII receptors as well
as TRI were reduced in the presence of increasing levels of PKCι. In contrast, no
apparent changes in receptor levels were noted with increasing expression of the classical
PKC, PKC. Quantitation confirmed that aPKC, but not the cPKC, reduced receptor
levels (Figure 2.5B).
To test if aPKC kinase activity was necessary for altering receptor levels, we
conducted similar experiments with increasing expression levels of wild-type (WT) or
kinase-deficient (KR) versions of PKCζ. Our results showed that increasing amounts of
PKCζ lead to decreased steady-state levels of TGFβ receptors. In contrast, increasing
amounts of the kinase-deficient PKCζ did not alter TRI or TRII expression (Figure
2.5C and 2.5D). We next assessed TGF receptor ubiquitination levels.
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Figure 2.5
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Figure 2.5. aPKC overexpression reduces steady state TGF receptor levels
(A) HEK 293T cells were transiently transfected with cDNA encoding the indicated
proteins. Equal amounts of TRI-FLAG and TRII-HA were co-transfected with
increasing amounts of either GFP tagged PKC, or PKC. 48 hours post-transfection,
cells were lysed and processed for SDS-PAGE and immunoblotting to assess receptor
levels. A representative immunoblot from three separate independent trials is shown.
(B) Average densitometrical quantitation of TGF receptors was carried out from 3
separate experiments using QuantityOne software and graphed (n=3).
(C) HEK 293T cells were transiently transfected with cDNA encoding the indicated
proteins. Equal amounts of TRI-FLAG and TRII-HA were co-transfected with
increasing amounts of either HA tagged PKC-WT or a kinase deficient version, PKCKR. 48 hours post-transfection, cells were lysed and processed for SDS-PAGE and
immunoblotting to assess receptor levels. A representative immunoblot from three
separate independent trials is shown.
(D) Average densitometrical quantitation of TGF receptors was carried out from 3
separate experiments using QuantityOne software and graphed (n=3).
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2.4.6 PKC inhibition alters TGF receptor ubiquitination levels
TGF receptors can be degraded through the conjugation of ubiquitin to activated
receptor complexes by the E3 ubiquitin ligase Smurf2 [38]. Therefeore, we next
addressed whether PKC inhibition could affect receptor ubiquitination levels (Figure 2.6).
HEK293T cells expressing receptors, ubiquitin, Smad7 and Smurf2 were incubated in the
presence or absence of GF109203X. Following co-expression of receptors with ubiquitin
and wild type Smurf2 and Smad7, the steady state levels of the TGF receptors, as well
as Smurf2 and Smad7 in the total cell lysates was reduced (Figure 2.6, lower panel lane
3).

This was paralleled with an increase in high molecular weight ubiquitinated

complexes in the receptor immunoprecipitations (Figure 2.6, top panel lane 3). In
contrast, receptors that were co-expressed with a catalytically inactive mutant of Smurf2
(Smurf2-CA) were protected. Interestingly, the levels of the higher molecular weight
ubiquitinated complexes increased in cells treated with PKC inhibitor (Figure 2.6, top
panel lane 5). Taken together these findings suggested that aPKC kinase activity might
be altering TGFβ receptor trafficking to enhance degradation, and inhibiting aPKC results
in an increase of ubiquitinated receptors. To test this hypothesis, we next used small
interfering RNA directed at the aPKCs and examined cell surface TGFβ receptor
degradation.
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Figure 2.6
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Figure 2.6. PKC inhibition reduces clearance of ubiquitinated TGF receptor
complexes
HEK 293T cells expressing combinations of TRII, TRI-Flag, Ubiquitin-HA, Smad7HA, and the wild-type (WT) or catalytically inactive (CA) E3 ubiquitin ligase, MycSmurf2, were lysed, immunoprecipitated using anti-Flag monoclonal antibodies to isolate
TGF receptors. The immunoprecipitates were then subjected to SDS-PAGE, followed
by immunoblotting with the indicated antibodies. Anti-HA immunoblotting was used to
detect ubiquitinated receptors and/or associated proteins (denoted by the asterisk). Total
lysates are shown in the bottom panel. Cells were pre-treated with vehicle or GF109203X
for 1 hour followed by addition of the proteasome inhibitor MG132 for 6 hours prior to
lysis. A representative immunoblot from 3 independent replicate experiments is presented
(n=3).
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2.4.7 siRNA targeting aPKC reduces TGF receptor degradation
We next addressed whether endogenous aPKC, and which isoform, regulates the
degradation of endogenous TGFβ receptors. To ensure that we were able to detect each
aPKC specifically, we first tested our antibody specificity in HEK293T cells to test for
possible cross-reaction of isoforms (Figure 2.7A). By western blotting, we observed that
both the PKCι and PKCζ antibodies were specific. We next we next assessed our siRNA
targeting of the two aPKC isoforms was specific and effective. Our results showed that
the siRNA constructs are specific for their targets, however, we also noted that there is a
compensation effect for PKCζ, when we silence PKCι: In siPKCι knock down cells, there
was a small, yet consistent, increase in expression of PKCζ (Figure 2.7B). Having
ascertained that the siRNA to the different aPKC isoforms was specific and effective, we
assessed their influence on TGFβ receptor degradation (Figure 2.7C). Consistent with
our observations using pharmacological inhibitors, we observed that silencing aPKC
isoforms with siRNA resulted in a significant reduction in the degradation of cell surface
TGFβ receptors after 8 hours (Figure 2.7C and 2.7D).
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Figure 2.7. aPKC knockdown reduces TGF receptor degradation
(A) Lysates from HEK 293T cells expressing GFP tagged PKC or PKC were subjected
to SDS-PAGE followed by immunoblotting with antibodies directed at GFP, PKC,
PKC and Actin as a loading control.
(B) A549 cells were transfected with siRNA directed at PKC, PKC, both PKC and
PKC

(PKC/) or control siRNA. Cells were lysed and subjected to SDS-PAGE and

immunoblotting to assay for PKC or PKC protein expression. Note: Both PKC and
PKC siRNAs are effective in all 3 conditions.
(C) A549 cells transfected with the indicated siRNA were affinity labelled with

125

I-

TGF, cross-linked and incubated at 37°C for 0, 2, 4 or 8 hours. Cells were then lysed,
and subjected to SDS-PAGE followed by phospho-imaging analysis.
mobilities of

125

I-TGF-bound TRII (~90 kDa) and

125

The relative

I-TGF-bound TRI (~65 kDa)

are indicated.
(D) Three separate experiments as described in Panel C were carried out and the amount
of the receptors was quantitated using QuantityOne software and plotted as a percentage
of receptors at time 0. The mean +/- SD is shown, n=3, Two-way ANOVA, *p<0.05.
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2.4.8 Knockdown of aPKC extends Smad2 phosphorylation
Using PKC kinase inhibitors and PKC overexpression, we observed that aPKC
expression increases receptor degradation and aPKC activity also negatively regulates
TGFβ induced Smad2 signalling. Furthermore, knockdown of aPKC using siRNA results
in reduced TGFβ receptor degradation. Next we used siRNA to test whether knockdown
of specific aPKCs could extend TGFβ induced signalling. After transfecting A549 cells
with combinations of siRNA directed towards aPKC isoforms, we conducted Smad2
phosphorylation time courses (Figure 2.8). Our results indicate that in cells where both
aPKCs were knocked down (siPKCι/), there was an extension of phospho-Smad2 levels
compared to cells transfected with control siRNA. This extension was also seen in
siPKCζ cells, but less pronounced in siPKCι cells, indicating that silencing both aPKCs
had the greatest effect on phospho-Smad2 levels (Figure 2.8). We next tested to see
whether aPKC knockdown could cause longer phospho-Smad2 levels.

101

Figure 2.8. aPKC knockdown extends Smad2 phosphorylation
A549 cells transfected with the indicated siRNA were serum starved and treated with 250
pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours prior to lysis.
Lysates were then processed for SDS-PAGE and immunoblotted with anti phosphospecific Smad2 or Smad2/3 antibodies. Accompanying densitometrical analysis of PSmad2 levels from 3 independent replicate experiments is presented graphically for each
representative immunoblot. The mean +/- SEM is shown, n=3, Two-way ANOVA, *p
<0.05.
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2.4.9 Smad2 phosphorylation persists 24 hours in aPKC silenced
cells
To test if phospho-Smad2 levels could persist for an extended period of time, we
stimulated siRNA treated cells with TGFβ for 1 hour, followed by washout and further
incubation of cells for 24 hours (Figure 2.9). Interestingly, we found that in knock down
cells, phospho-Smad2 was maintained even after cells were washed of exogenously
added ligand. Finally, to test whether any extended Phospho-Smad2 levels were
specifically due to the activation of TGFβ receptors, we incubated cells with the TβRI
kinase inhibitor, SB431542. This inhibitor blocks TβRI from phosphorylating Smad2,
and thus should reduce TGFβ induced phospho-Smad2 signalling. As expected, the
extension in phospho-Smad2 levels was abrogated when cells were co-treated with
SB431542, indicating that any changes we observed in signalling were TGFβ receptor
dependent (Figure 2.9).
Taken together, our data suggest that aPKC isoforms regulate TGFβ signal
transduction by regulating receptor trafficking and degradation, summarized in Figure
2.10.
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Figure 2.9. aPKC knockdown extends TGF induced Smad2 phosphorylation even
after 24 hours
siRNA transfected A549 cells were serum starved and pre-treated with vehicle (DMSO)
or 1 M of the TRI kinase inhibitor, SB431542. Cells were then treated with 250 pM
TGF for 1 hour, washed and further incubated for 24 hours in control or SB431542
media prior to lysis. Lysates were then processed for SDS-PAGE and immunoblotted
with anti phospho-specific Smad2 or Smad2/3 antibodies. Accompanying densitometrical
analysis of P-Smad2 levels from 3 independent replicate experiments is presented
graphically for each representative immunoblot. The mean +/- SEM is shown, n=3, TwoWay ANOVA, *p <0.05.
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Figure 2.10. Regulation of TGF receptor trafficking and signalling by atypical
protein kinase C
Pharmacological inhibition of all PKC isoforms alters TGF receptor trafficking by
shifting receptors into the early endosome, reducing receptor degradation, and extending
TGF-induced Smad2 phosphorylation. siRNA knockdown of atypical PKC isoforms
also reduces TGF receptor degradation and extends TGF induced Smad2
phosphorylation.
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2.5 Discussion
The TGFβ signalling pathway controls many biological responses orchestrated
through the regulation of various genes and downstream effectors. Altered TGFβ
signalling patterns are often a hallmark in epithelial derived cancers. In certain tumours
the proteins involved in TGFβ signalling are still intact and functional, but the pathway is
deregulated by some other means. This seems to be the case in non-small cell lung cancer
(NSCLC) as many of these tumours are unresponsive to the tumour suppressive
properties of TGFβ, despite producing functional ligands and receptors [42, 43]. One
proposed mechanism is a change in TGFβ receptor signalling patterns due to altered
membrane trafficking of the TGFβ receptors upon internalization. PKCs, which are major
regulators of intracellular trafficking, may therefore regulate TGFβ signalling. In the
present study we propose that atypical PKC isoforms are involved in altering the
vesicular fate of TGFβ receptors to ultimately change TGFβ signalling patterns.
We have shown that PKC kinase activity plays a role in the membrane trafficking
and degradation of TGFβ receptors, as broad PKC inhibition with GF109203X caused a
shift of receptors into the early endosome and a reduction in TGFβ receptor degradation.
Interestingly, the classical PKC inhibitor, Gö6976, did not shift receptors into the early
endosome, but did however alter the trafficking of Cav-1 positive vesicles and reduced
TGFβ receptor degradation. This brings up the possibility that classical PKC isoforms
alter general membrane trafficking and we suspect that this would have an effect not only
on TGF receptor trafficking but other cell membrane proteins as well.
We observed that the overexpression of aPKC isoforms negatively regulate the
steady state levels of both the type I and type II TGFβ receptors. This is in contrast to
steady receptor levels when a classical PKC (PKC) or a kinase deficient aPKC are
overexpressed.
Furthermore, using siRNA targeted to aPKC isoforms, we observed that
knockdown of aPKC expression results in a reduction in TGFβ receptor degradation from
the cell surface. These data suggest that aPKC promotes TGFβ receptor degradation upon
endocytosis. Interestingly, the PKCζ knockdown and the double PKCι/ knockdown
seem to produce the greatest effect. However, it is important to note that in siRNA treated
cells where PKCι has been silenced, we observed a consistent increase in PKCζ
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expression, which may be responsible for the less prominent effects on Smad2
phosphorylation. We reason that both aPKC isoforms are capable of increasing TGFβ
receptor degradation as double knockdown of PKC produces the greatest effect on
temporal extension of TGF induced P-Smad2 levels.
Interestingly, although we observe reductions in TGF receptor cell surface
degradation with PKC inhibition, Smurf2 mediated ubiquitination of TGF receptors was
increased. This may be the result of an accumulation of ubiquitinated complexes due to
an increased residence time of receptors in intracellular compartment(s) and is consistent
with our observations that PKC inhibition can delay receptor degradation and extend the
duration of phosphorylated Smad2 levels.
This study addresses the idea that aPKC can alter TGFβ receptor trafficking and
also alter local TGFβ signalling patterns in A549 lung cancer cells after an initial short
TGFβ stimulus. It will be interesting to see whether aPKC knockdown can alter
phenotypic changes in cells that receive constant TGFβ stimulation; similar to tumour
cells growing in a microenvironment where autocrine and paracrine TGFβ
overproduction leads to higher and constant levels of TGFβ stimulation.
Aberrant aPKC expression and activity are becoming more apparent in various
cancers [32, 34, 44-46]. More specifically, in NSCLC where an increased expression of
aPKC is reported, it is plausible that the TGF receptor signalling pathway may be
altered by an interplay with aPKC. More specifically, our data suggest that enhanced
aPKC expression and activity may contribute to increases in TGF receptor degradation,
alterations in the TGF signal, and consequently a loss in some of the characteristic
TGF tumour suppressive properties. This is supported by the fact that aPKC localize
and can be anchored to late endosomes that are targeted for degradation [24].
Furthermore, since we have observed that aPKC kinase activity is important for changes
in TGF receptor trafficking, degradation, and signalling, there exists the possibility that
aPKC directs TGF receptor trafficking into specific compartments through the
phosphorylation of one or more of the TGF receptors, as is the case for the EGFR [27].
This is supported by the finding that PKCζ is a TGF receptor interacting partner in a
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complex which regulates cytoskeletal changes involved in epithelial to mesenchymal
transition [36, 37].

2.6 Footnotes
The work carried out in this study was supported by the Canadian Institutes of Health
Research (GMDG, grant: MOP-93625).
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3.1 Chapter Summary
EMT is controlled by cellular signalling pathways that trigger the loss of cell-cell
adhesion and lead to the restructuring of the cell cytoskeleton. TGF has been shown to
regulate cell plasticity through the phosphorylation of Par6 on a conserved serine residue
(S345) by the type II TGF receptor. Here we show that aPKC isoforms are an essential
component to this signalling pathway in non-small cell lung cancer (NSCLC) cells. We
show that the aPKC, PKC interacts with TGF receptors through Par6, and that these
proteins localize to the leading edge of migrating cells. Furthermore, Par6
phosphorylation on Ser 345 by TGF receptors is enhanced in the presence of aPKC.
aPKC kinase activity as well as association with Par6 were found to be important for
Par6 phosphorylation. In effect, siRNA-targeting aPKC reduces TGFinduced RhoA
and E-cadherin loss, cell morphology changes, stress fibre production and the migration
of NSCLC cells. Interestingly, re-introduction of a phospho-mimetic Par6 (Par6-S345E)
into aPKC-silenced cells rescues both RhoA and E-cadherin loss with TGF stimulation.
In conclusion, our results suggest that aPKCs co-operate with TGF receptors to regulate
phospho-Par6-dependent EMT and cell migration.
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3.2 Introduction
During tumour progression, EMT characterizes an event where the cohesive,
apico-basolaterally polarized cells of the epithelium detach from the basement membrane
and acquire the ability for independent movement as mesenchymal like cells [1-3]. EMT
is characterized by the loss of E-cadherin based adherens junctions allowing for
stationary carcinoma cells to escape the physical constraints of cell-cell adhesion leading
to invasion of the stromal compartment [3]. The process of EMT involves altering cell
genetic programs and inducing morphological changes that foster an invasive and
migratory phenotype [1, 2, 4-6]. TGF signalling is an important regulator of EMT
through its promotion of invasion and metastasis [7-9]. In conjunction to the canonical
TGF-Smad pathway that has been shown to alter transcriptional responses leading to
EMT, a second TGF pathway was defined, in which the conserved polarity protein Par6
was shown to be a binding partner and substrate of the TGF receptors [10, 11]. Indeed,
TGF-dependent phosphorylation of Par6 on Serine 345 leads to Smurf1 mediated
degradation of RhoA. This in turn leads to significant remodelling of the actin
cytoskeleton, and the dissolution of tight and adherens junctions leading to EMT and
metastasis [10, 12, 13].
Par6 is an adaptor molecule for the polarity complex [14-18]; a highly conserved
group of interacting protein partners, including aPKC, Par3, and several small GTPases
that work in concert to control apical-basal cell polarity, directional cell polarization,
migration, and cell proliferation [14, 17, 19-24]. Notably, aPKC was shown to be part of
the complex that regulates protrusion formation through the TGF receptors [10, 25, 26]
although its exact role has not been defined.
The aPKCs, which consist of PKC and PKC are a unique subset of PKCs that
do not require diacylglycerol (DAG), phosphatidylserine, or calcium for their activation
[27]. PKChas been implicated in carcinogenesis [28-34] and is considered to be the first
member of the PKC family to be a human oncogene [29]. Our recent work has shown
that PKC activity can regulate the trafficking and degradation of TGF receptors as well
as the duration of Phoshpho-Smad2 signalling [35].
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Here, we report that in addition to TGF receptors, aPKCs phosphorylate Par6 on
Ser 345, and aPKC expression increases Par6 steady state levels. Furthermore, reduction
in aPKC expression or the association of aPKC with Par6 reduces EMT and migration of
NSCLC cells.

3.3 Materials and Methods
3.3.1 Antibodies and Reagents
Primary monoclonal anti-GFP (Living Colors-JL8), anti-Flag (Sigma F3165),
anti-HA (Santa Cruz-Y11-SC-805), anti--Actin (Sigma-A2668), anti-PKC (Santa CruzSC11399)/ (BD Transduction-610175), anti-PKCand anti-PPKC (Cell Signalling
Tech-9372 and -9378), anti-Rac1 (BD Transduction-610650), and anti-E-cadherin (BD
Transduction-610182 and Cell Signalling Tech-3195) were used as per the
manufacturers' suggestions. Anti-P-Par6 (S345) was a gift from Dr. Jeff Wrana. HRP
conjugated secondary goat-anti-rabbit (Thermo Scientific -31460) and goat-anti-mouse
(Thermo Scientific -31430) were used for immunoblot analysis.

Fluorescently

conjugated goat -mouse (Jackson ImmunoResearch-715225150), goat -rabbit (Jackson
ImmunoResearch-711175152)

and

Cy3

conjugated

Streptavidin

(Jackson

ImmunoResearch-016160084) were used for immunofluorescence studies. A555
conjugated Phalloidin (Invitrogen-A34055) was used for F-actin staining.. Human siRNA
constructs were purchased from Invitrogen (Stealth) (siPKC, siPKC and siControl
catalogue

numbers:

(10620319-HSS183348,

10620319-HSS183318,

12935112)

respectively. The constructs encoding Flag or HA-tagged TGFβ receptors, Flag-Smurf1,
Flag-Par6 (WT and S345), PKCζ-HA were used as previously described [10, 36].The
GFP-tagged PKCι was a kind gift from Drs. A. Babwah (The Children's Health Research
Institute, London ON, Canada) and S. Ferguson (Robarts Research institute, London ON,
Canada) [37]. Transwell migration assays were conducted using Costar transwell
permeable support inserts with a pore size of 8 m (Costar-3422).
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3.3.2 Cell Culture and Transfections
Rat2 fibroblast, and HEK293T cell lines were maintained in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum. A549 and H1299
NSCLC cell lines were maintained in F12K and RPMI-1640 Medium (respectively)
supplemented with 10% fetal bovine serum. Cells were kept in a humidified tissue
culture incubator at 37ºC in 5% CO2. Calcium phosphate transfections were carried on
cells at approximately 40% confluency, followed by a change in media approximately 24
hours from time of transfection. siRNA transfections were conducted using
Lipofectamine RNAi max (Invitrogen) according to the manufacturer’s protocol. DNA
transfection of H1299 and A549 cells was conducted with Lipofectamine 2000
(Invitrogen) or Lipofectamine LTX (Invitrogen) respectively, according to the
manufacturer’s protocol.

3.3.3 Protein Concentrations
Protein concentrations were determined using the Lowry method (Fisher).

3.3.4 Immunoblotting and Immunoprecipitation
Cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and a mixture of protease inhibitors)
and centrifuged at 14,000 rpm at 4 °C for 10 min. Aliquots of supernatants were collected
for analysis of total protein concentration. For immunoprecipitation, equal amounts of
remaining cell lysates were incubated with primary antibody, followed by incubation
with protein G-Sepharose beads. The precipitates were washed three times with lysis
buffer, eluted with sample buffer, and subjected to SDS-PAGE. Proteins were transferred
to nitrocellulose followed by blocking in 5% skim milk, and incubation with primary
antibody in TBST overnight at 4ºC. Following incubation with HRP conjugated
secondary antibody, proteins were visualized using West Dura Super Signal ECL (Fisher)
and imaged on a VersaDoc Imaging system (BioRad).
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3.3.5 Scratch Assays and Polarization Assay
To assess cell migration, a confluent monolayer of cells was scratched with a
sterile pipette tip to create an opening, or “wound”. Following wounding, cells were
incubated in serum containing medium for 4 hours to allow for cell polarization and
leading edge formation. Cells were then fixed and processed for Immunofluorescence
microscopy. For the polarization assay, A549 cells were transfected with control or aPKC
directed siRNA. 24 hours post transfection, cells were seeded subconfluently onto
coverslips to allow cells to establish front-rear polarization. 24 hours following seeding,
cells were fixed and processed for immunofluorescence microscopy. For quantification of
polarization, immunofluorescence images were acquired and scored for polarization
phenotype. At least 100 cells were assessed per condition, per experiment. Graphs
represent the average of 3 independent experiments ±SD.

3.3.6 Immunofluorescence Microscopy
For immunofluorescence microscopy studies, cells were fixed with 4%
paraformaldehyde, permeabilized with 0.25% Triton X-100 and incubated for 1 hour in
blocking solution (10% FBS/PBS) then incubated with the indicated primary antibodies
in blocking solution. Following incubation with the appropriate Cy-conjugated secondary
antibodies (or streptavidin), and A555 Phalloidin, cells were visualized by
immunofluorescence microscopy using an inverted IX81 Microscope (Olympus,
Canada).

3.3.7 Transwell Migration Assays
H1299 cells were transfected with equal amounts of either empty vector (pIRES)
or one of the Par6 constructs in the pIRES vector. Cells were serum starved for 3 hours
prior to being seeded onto the top of a transwell chamber (Costar). 30 000 cells per
condition were seeded and were allowed to migrate towards medium containing 10%
serum. In parallel, 30 000 cells from each condition was seeded onto coverslips in
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medium containing 10% serum. After 18 hours, cells on the topside of the transwell
membrane were removed with a cotton swab, and the migrated cells (on the underside of
the transwell) were fixed with 4% paraformaldehyde. Cells on both transwell and the
coverslips were stained with DAPI and mounted onto glass slides. Images were acquired
using an IX81 inverted microscope (Olympus). Ten representative fields were acquired at
200x magnification and quantified. Graphs represent the average of 3 independent
experiments. Cells expressing GFP were counted for each transwell. Cells that were
plated simultaneously on coverslips were also quantified and were compared to DAPI
stained cells (total cells) to determine transfection efficiencies.

3.3.8 EMT and Migration
A549 cells were transfected with either control or aPKC directed siRNA. 24 hours
post transfection, cells were serum starved for 3 hours prior to treatment. Cells were then
incubated in serum free medium containing none, or 250 pM TGF for 0, 48, or 72 hours
to induce EMT. At each time point, cells were brightfield imaged using a IX71 inverted
microscope (Olympus), processed for immunofluorescence microscopy, or processed for
immunoblotting. For quantification of stress fibre formation, immunofluorescence images
(multiple fields) were acquired and assessed for F-Actin morphology over 3 independent
experiments. At least 100 cells were assessed per condition, per experiment (> 600 cells
total per experiment were assessed). “Cortical” was defined as cells showing F-actin
staining to the outer regions (membrane) with no F-Actin fibres through the middle of the
cell; “Intermediate” was defined as cells that still showed some cortical staining, but had
several F-actin fibres spanning through the middle of the cell (1-5); “Elongated” was
defined as cells that showed little cortical staining, and >5 stress fibres spanning through
the middle of the cell. Graphs represent the average of 3 independent experiments.
For cell migration analysis, transfected A549 cells were serum starved and treated
with TGF for 48 hours. After 48 hours, 30 000 cells were seeded into transwell
chambers. Cells were allowed to migrate towards serum free medium, or medium
containing 10% FBS. After 18 hours, transwell chambers were processed as described
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above. Cell nuclei on the underside of the membrane were visualized and counted using
DAPI staining. Ten representative fields were acquired at 200x magnification and
quantified. Graphs represent the average of 4 independent experiments normalized to the
serum free control. Cells that were plated simultaneously into a 6 well culture dish were
lysed after 18 hours and processed for SDS-PAGE to assess E-cadherin loss, and
subsequently whether EMT had occurred.

3.3.9 Reverse Transcription, Real time PCR and Statistical Analyses
Total RNA was isolated from A549 cells using the RNAeasy Mini kit (Qiagen)
according to the manufacturer’s protocol. For complementary DNA (cDNA) synthesis,
1000 ng of total RNA was reverse transcribed using the Superscript® VILO cDNA
synthesis kit according to manufacturer’s protocol. (Applied Biosystems). A cDNA
equivalent to 10 ng of total RNA was used for all PCR reactions in a total volume of 20
l. Each reaction was carried out in triplicate. Quantitative PCR (qPCR) reactions were
conducted using SsoFast EvaGreen® supermix (BioRad) using a Chromo4 Real-time
Thermal Cycler (Bio-Rad) according to the recommended protocol of the manufacturer.
Primer sequences (5'-3') are as follows: PKC (TACGGCCAGGAGATACAACC and
TCGGAGCTCCCAACAATATC), PKCATCATTCATGTTTTCCCGAGCA and
GTTGGCACGGTACAGCTTCSNAI-1

(AATCGGAAGCCTAACTACAGCG

andGTCCCAGATGAGCATTGGCA),SNAI-2 (ATACCACAACCAGAGATCCTCA
andGACTCACTCGCCCCAAAGATG),

Beta-Actin

(GGGAAATCGTGCGTGACATTAAG andTGTGTTGGCGTACAGGTCTTTG), and
POLR2A (GGATGACCTGACTCACAAACTG and CGCCCAGACTTCTGCATGG).
Primers were selected using Primer3 [38] as well as PrimerBank [39-41]. Baseline and
threshold for Ct calculation were set manually using the Opticon Monitor 3.1 Software
(Bio-Rad). PCR efficiencies (E) were calculated using cDNA dilution curves and were >
90% for all genes assessed. Calculated PCR efficiencies were used for gene expression
quantification using the Pfaffl formula[42], ratio = (Etarget)Ct target(control-treated)/ (Ereference)Ct
ref(control-treated)

, where control = siControl, no TGF. Final ratios were calculated using
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geometric averaging [43] from two reference genes: POLR2A, a gene which was found
to be a suitable reference gene in NSCLC models [44], and -Actin. Gene expression of
each treatment is expressed in relation to the control (siControl, no TGF) and is an
average of 3 independent experimental trials. One- way ANOVA analysis followed by
post-hoc Tukey’s Tests was used to evaluate the significance of the results. Statistical
analyses were performed using GraphPad Prism® Software 5.0 and p values of <0.05
were considered statistically significant.

3.3.10

Site Directed Mutagenesis

Lysine (K) 19 and Serine (S) 345 were mutated to alanine (A) and glutamic acid
(E) respectively using the Quikchange mutagenesis kit (Agilent Technologies) onto the
Par6-Flag-pCMV5b template according to manufacturer guidelines. Both mutants were
transformed into a XL1 Blue strain of Escherichia coli, amplified, purified by the Qiagen
Miniprep Kit (Qiagen), and sequenced at the London Regional Genomics Centre
(London, ON, Canada).

3.3.11

Statistical Analysis

One-way or Two-way ANOVA analysis followed by post-hoc Bonferroni’s Tests
were used to evaluate the significance of the results. Statistical analyses were performed
using GraphPad Prism® Software 5.0 and p values of < 0.05 were considered statistically
significant.

3.4 Results
3.4.1 TGF receptors and aPKC localize to the leading edge of
migrating cells
Migrating fibroblasts are polarized and show a clear leading edge as they migrate
towards a wound. The TGF receptors as well as the atypical PKC have been shown to
localize to the leading edge of migrating cells [45]. Furthermore, PKC, TGF and Par6
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have been shown to be involved in membrane protrusion dynamics through Smurf1 [12,
25]. Here we investigated whether PKC, the other member of the aPKC family, colocalizes with TGF receptors at the leading edge and membrane protrusions of
migrating

cells.

To

do

this

we

carried

out

scratch

assays

followed

by

immunofluorescence microscopy (Figure 3.1). Polarized Rat2 fibroblasts were
immunostained for PKC and Rac1, a leading edge marker, and TGF receptors, using
biotin-labelled TGF ligand. We observed that the TGF receptors and PKC colocalized with Rac1 at the leading edge of migrating fibroblasts (Figure 3.1A), whereas
GM130, a marker for the Golgi apparatus, was not detected at the leading edge with
PKC and the TGF receptors (Figure 3.1B). This co-localization was also observed in
polarized A549 adenocarcinoma cells (Figure 3.9B, please see below).

Having

ascertained that aPKC and TGFreceptors co-localized in migrating cells, we next
sought to determine whether there was an interaction between PKC and the TGF
receptors.
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Figure 3.1
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Figure 3.1. Atypical PKC co-localizes with TGF receptors at the leading edge of
migrating cells
Rat2 fibroblasts were scratched and incubated for 4 hours to establish cell polarity and
then fixed, permeabilized and immunostained with anti-PKC (PKC, blue), biotinlabelled TGF (biotin-TGF; red), anti-Rac1 (Rac1, green; A) or anti-GM130 (Golgi
apparatus marker, green; B). The direction of cell migration is indicated with the white
arrows and PKC, Rac1 and TGF receptors at the leading edge of migrating cells are
indicated by blue, green and red arrowheads, respectively.

The white arrowheads

indicate the co-localization of all three proteins. Shown are representative images from at
least 3 independent replicate experiments. Bar = 10 m.
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3.4.2 TGF receptors and PKC interact via Par6
Previous work has shown that PKC interacts with TGF receptors through an
association with Par6 [10]. Par6 and aPKC each contain a distinct PB1 (Phox-BEM1)
domain through which they interact [46]. Par6 is also known to be an adaptor protein
linking several kinases and small GTPases to facilitate cellular processes such as cell
polarization and migration [16, 17, 24, 26, 47]. To determine if PKC interacted with
TGFreceptors, we expressed TGF receptors in the presence of wild-type Par6 or a
mutant of Par6 that lacks the PB1 domain (Par6-PB1) and PKC in HEK293T cells.
Following immunoprecipitation of TRII and immunoblot analyses, we observed that
PKC interacted with TGF receptors. Furthermore, this association occurred in the
presence of wild-type Par6 but not in the presence of the mutant of Par6 that lacks the
PB1 domain (Figure 3.2, lanes 9 and 10). This result suggests that there is a complex
formation between the TGF receptors and aPKC via Par6.
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Figure 3.2. Atypical PKC associates with TGF receptors through Par6
HEK293T cells expressing the indicated combinations of GFP-tagged PKC, HA-tagged
TGF type II receptors (TRII), Flag-tagged TGF type I receptors (TRI), wild type
Par6 (Par6 WT) or a mutant of Par6 that does not associate with TGF receptor (Par6PB1) were lysed and immunoprecipitated (IP) with anti-HA antibodies.

The

immunoprecipitates were then subjected to SDS-PAGE, and immunoblotted with anti
()-GFP, -HA or -Flag antibodies as primary antibodies to visualize proteins that coprecipitated with TRII (top panel). The non-specific immunoglobulin heavy chain is
indicated (IgG) and cell lysates are shown in the bottom panel. Shown are representative
immunoblots from at least 3 independent replicate experiments.
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3.4.3 aPKC phosphorylates Par6
Phosphorylation of Par6 by TRII on S345 is an important step in TGFdependent epithelial to mesenchymal transition (EMT) [10, 12]. Given the oncogenic role
of aPKC in various cancers, and after seeing that aPKC and TGF receptors co-localized
and interacted through Par6, we assessed whether aPKC had an effect on phospho-Par6
levels (P-Par6). We used immunoblotting to determine the levels of S345 phosphorylated
Par6 in the presence of receptors and aPKC isoforms (Figure 3.3).
We first expressed TGF receptors and Par6 in HEK293T cells and assessed PPar6 levels in the presence of TGF receptors (Figure 3.3A). As expected, co-expression
of TGF receptors and Par6 resulted in Par6 phosphorylation. We next determined
whether co-expression of aPKC would alter P-Par6 levels by co-expressing TGF
receptors, wild type Par6, a Par6 mutant that does not bind aPKC (Par6 K19A), and/or
aPKC isoforms (Figure 3.3B). Expression of Par6 with TGF receptors resulted in an
increase in P-Par6 levels and this was greatly increased in the presence of either PKC or
PKC (Figure 3.3B, lanes 2, 4 and 7). Interestingly, when we co-expressed the receptors,
aPKC and a mutant of Par6 that does not interact with aPKC Par6 (K19A), we observed
Par6 phosphorylation levels seen with TGF receptors alone (Figure 3.3B, lanes 5 and 8).
This indicated that aPKC enhanced Par6 phosphorylation when co-expressed with
receptors, however, the possibility existed that aPKC could phosphorylate Par6
independent from the TGF receptor (diagrammed in Figure 3.3C). We explored this idea
next.

3.4.4 aPKC phosphorylates Par6 independent of TGF receptors
To further assess if aPKC could induce the phosphorylation of Par6 in the absence
of TGF receptors, we expressed Par6 in the presence or absence of wild-type or kinase
deficient aPKC, in the absence of exogenous TGF receptor expression (Figure 3.4A).
We observed that active aPKC phosphorylated Par6 but the kinase deficient aPKC did
not (Figure 3.4A). To assess if the physical interaction of aPKC and Par6 is necessary for
the phosphorylation of Par6, we conducted an immunoprecipitation experiment in cells
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expressing the indicated WT or mutant constructs (Figure 3.4B). We observed that both
the wild type and kinase deficient PKC associated with Par6, but only active PKC
increased P-Par6 levels (Figure 3.4B). In addition, we utilized a mutant of Par6 (Par6K19A) that does not interact with aPKC due to the mutation of a lysine residue in the
PB1 domain of Par6 [22, 48, 49]. Accordingly, we observed that both active and kinase
deficient PKC do not associate with Par6-K19A, and correspondingly, we observed very
little Par6 phosphorylation. Finally, when we co-expressed Flag-Par6 and each aPKC in
A549 NSCLC cells we also observed that both aPKCs increased phosphorylated Par6
levels indicating that the above results were not cell type specific (Figure 3.4C). These
results show that in addition to TGF receptors, Par6 can be phosphorylated by aPKC.
Furthermore, this phosphorylation is dependent on both aPKC-Par6 association and
aPKC kinase activity. These results are summarized in a diagram in Figure 3.4D.
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Figure 3.3
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Figure 3.3. aPKCs associate and phosphorylate Par6 on S345
(A) TGF Receptors phosphorylate Par6 on S345. HEK 293T cells expressing the
indicated combinations of HA-tagged TGF type II receptors (TRII), Flag-tagged TGF
type I receptors (TRI) or Par6 (Par6) were lysed and immunoblotted with anti ()-HA,
-Flag or -Phospho-specific S345 Par6 (-P-Par6) antibodies. The relative mobility of
each protein is indicated on the left. Shown are representative immunoblots from at least
3 independent replicate experiments.
(B) aPKC isoforms enhance TGF receptor phosphorylation of Par6. HEK293T cells
expressing the indicated combinations of GFP-tagged PKC, HA-tagged PKC or TGF
type II receptors (TRII), Flag-tagged TGF type I receptors (TRI), wild type Par6
(Par6 WT) or a mutant of Par6 that does not associate with aPKC (K19A) were lysed,
subjected to SDS-PAGE, and immunoblotted with anti () -GFP, -PKC, -Flag, Par6 or -P-Par6 antibodies. Shown are representative immunoblots from at least 3
independent replicate experiments.
(C) A summary of the data are diagrammed in C. (1): aPKC can increase Par6
phosphorylation alongside TGF receptors, but also, potentially independent of the TGF
receptors (2).
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Figure 3.4
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Figure 3.4. aPKC can phosphorylate Par6 independent of TGF receptors
(A) Par6 phosphorylation is dependent on aPKC activity. HEK293T cells expressing the
indicated combinations of HA-tagged wild type (WT) or kinase deficient (KR) PKC and
Flag-tagged Par6 (Par6) were lysed, subjected to SDS-PAGE and immunoblotted with
anti ()-PKC, -Par6 or -P-Par6 antibodies. Shown are representative immunoblots
from at least 3 independent replicate experiments.
(B) Par6 phosphorylation is dependent on aPKC association. HEK293T cells expressing
HA-tagged wild type (WT) or kinase deficient (KR) PKC and Flag-tagged Par6 (Par6)
or a mutant of Par6 that does not associate with aPKC (K19) were lysed and
immunoprecipitated (IP) with anti-Flag antibodies. The immunoprecipitates were then
subjected to SDS-PAGE and immunoblotted with anti ()-PKC, or -Par6 antibodies
(top panel).

Cell lysates were immunoblotted with the antibodies indicated to assess

protein expression and Par6 phosphorylation (bottom panel). Shown are representative
immunoblots from at least 3 independent replicate experiments.
(C) Par6 phosphorylation occurs in A549 cells. A549 cells transfected with the indicated
combinations of Flag-Par6, GFP-PKC, and HA-PKC were lysed, processed for SDSPAGE, and immunoblotted for anti()-GFP, -HA, -Flag, -Actin and -P-Par6 as
indicated. A non-specific band in the P-Par6 blot is indicated by an asterisk. Shown are
representative immunoblots from at least 3 independent replicate experiments.
(D) A summary of the data are diagrammed in D. aPKC can phosphorylate Par6 in the
absence of TGF receptors. The kinase activity of aPKC and aPKC binding ability to
Par6 are important for this phosphorylation.
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3.4.5 Par6 acts as a scaffold between aPKC and TGF receptors
We next set out to determine whether increased expression of aPKC would affect
the association of Par6 with type I TGF receptors (TRI; Figure 3.5A). TRI and Par6
constructs (WT or K19A) were expressed in the presence of increasing levels of aPKC.
Par6 protein was then immunoprecipitated and immunoblotted for aPKC and TRI to
assess association with these binding partners. We found that increasing aPKC expression
reduced the amount of TRI bound to Par6, accompanied by an increased association of
aPKC with Par6 (Figure 3.5A). However, the Par6 mutant that cannot associate with
aPKC (K19A) continued to associate with TRI despite increasing aPKC levels (Figure
3.5B, right panel). Interestingly, we also observed that the steady state levels of Par6
increased when it was displaced from the TRI (Figure 3.5A; cell lysates, lanes 4-6).
However, this was not observed in cells expressing Par6 K19A (Figure 3.5A; cell lysates,
lanes 8-10).
The ubiquitin ligase Smurf1 is known to regulate the levels of Par6 as well as the
TGF receptors [50-52]. Interestingly, we observed that expression of Par6 with TGF
receptors and Smurf1 decreased the steady state levels of receptors, Par6 and Smurf1
(Figure 3.5B). This effect was reduced when the K19A or S345A mutants were expressed
in place of WT Par6, suggesting that both endogenous aPKC association with Par6 and
phosphorylation on S345 may be involved in Smurf1 mediated degradation of the TGF
receptor-Par6 complex.
These data further substantiate the scaffolding of TRI and aPKC via Par6 and
implicates aPKC in the degradation of receptor associated Par6. Taken together, our
results suggest that aPKC association and S345 phosphorylation of Par6 can regulate
TGF receptor and Par6 levels.
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Figure 3.5
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Figure 3.5. aPKC reduces TRI associated Par6
(A) aPKC displaces Par6 from TGF Receptors. HEK293T cells were transfected with
Flag-TRI, Flag-Par6 (WT or K19A) and increasing amounts of GFP-tagged PKC.
Lysates were immunoprecipitated (IP) with anti-Par6 antibodies. The immunoprecipiates
(IP) were subjected to SDS-PAGE, and immunoblotted anti ()-GFP, or -Flag
antibodies as primary antibodies to visualize proteins that co-precipitated with Par6. Total
lysates are shown in the bottom panel. Par6-associated TRI levels were quantitated and
are shown graphically. Shown are representative immunoblots from 3 independent
replicate experiments. (n=3 ± SEM, Two-way ANOVA, *p<0.05).
(B) Par6 mutants attenuate aPKC-dependent reduction of TGF Receptor steady state
levels. HEK 293T cells expressing HA-tagged TGF type II receptors (TRII), Flagtagged TGF type I receptors (TRI), Flag-tagged Smurf1, and Flag-tagged Par6 (WT,
K19A, or S345A) were lysed, subjected to SDS-PAGE and immunoblotted with anti HA, -Flag, -Actin, or -Phospho-specific S345 Par6 (-P-Par6) antibodies. Shown are
representative immunoblots from at least 3 independent replicate experiments.
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3.4.6 aPKC expression and association increases Par6 levels
After observing that the expression of aPKC displaced Par6 from TRI and
increased steady state Par6 levels, we assessed the protein stability of Par6 when coexpressed with PKC (Figure 3.6A). Using the translation inhibitor, cycloheximide, cells
expressing Par6 were assessed for Par6 levels over a 6 hour time course. We observed
that Par6 levels dropped to approximately 16.2% ± 8.3% within 6 hours (Figure 3.6A,
right panel). When Par6 was co-expressed with aPKC, we observed stabilization of Par6
protein levels. Indeed, when Par6 was expressed with aPKC, Par6 protein levels
remained 88.8% ± 3.9% of the Time 0 control (Figure 3.6A, right panel).
We next assessed the effect of Smurf1 on Par6 levels. We observed that the coexpression of Par6 with Smurf1 led to reduced steady state levels of Par6 (Figure 3.6B).
However, co-expression of aPKC with Par6 blocked this degradation, as observed by an
increase in steady state levels of Par6 (Figure 3.6B). We further wanted to explore
whether S345 phosphorylation of Par6 would alter its steady state levels. We analyzed
this by expressing aPKC in cells expressing Par6 or the K19A and S345A mutants
(Figure 3.6C). Notably, we observed an increase in steady state Par6 levels when aPKC
was introduced to cells expressing WT or S345A Par6 mutant (Figure 3.6C, lanes 2 to 3
and lanes 6 to 7). This effect was not observed in cells expressing Par6-K19A, a mutant
that cannot associate with aPKC (Figure 3.6B, lane 4 vs. 5). These results suggest that
aPKC association and not the phosphorylation of Par6 inhibited Smurf1-mediated
reduction of steady state levels of Par6 (Figure 3.6C).
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Figure 3.6
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Figure 3.6. aPKC expression stabilizes Par6 protein levels
(A) HEK 293T cells were transfected with Flag-Par6 and empty vector or with Flag-Par6
and GFP tagged PKC. These cells were then subjected to a time course with the
translation inhibitor cycloheximide (100 g/mL) and lysed after the indicated time points.
Lysates were subjected to SDS-PAGE, followed by immunoblotting with -GFP, -Flag,
or -GAPDH (loading control). Average Par6 levels over time were quantitated and are
shown graphically in the right panel. Shown are representative immunoblots from 3
independent replicate experiments. (n=3 ± SEM, Two-way ANOVA, **p<0.01).
(B) HEK 293T cells expressing combinations of Flag-Smurf1, GFP-PKC, and FlagPar6, were subjected to SDS-PAGE, followed by immunoblotting with -GFP, -Flag,
or -P-Par6 to assess protein or phosphoprotein levels. Shown are representative
immunoblots from at least 3 independent replicate experiments.
(C) HEK 293T cells expressing combinations of Flag-Smurf1, GFP-PKC, and FlagPar6, Flag-Par6-K19A, or Flag-Par6S345A (phosphorylation site mutated) were lysed
and subjected to SDS-PAGE, followed by immunoblotting with the primary antibodies
indicated on the right of the panels. Par6 protein levels were quantitated and shown
graphically. Shown are representative immunoblots from 6 independent replicate
experiments. (n=6, ± SEM).
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3.4.7 Par6 phosphorylation and aPKC association are important for
Par6 induced migration
Expression and phosphorylation of Par6 have been shown to increase the
migration and metastatic processes of breast cancer cells [12]. We therefore tested
whether Par6 phosphorylation and aPKC association could affect cell migration of a
metastatic NSCLC cell line (H1299) using transwell migration assays (Figure 3.7).
Briefly, H1299 cells were transiently transfected with empty pIRES vector, wild type
Par6 or the two mutant Par6 constructs (K19A, S345A). Relative expression levels are
shown in Figure 3.7A. Our results indicated that overexpression of wild type Par6
increased cell migration (5.3 ± 0.1 fold) towards serum compared to control cells. Cells
expressing the aPKC binding mutant of Par6 (Par6-K19A) also stimulated H1299 cell
migration by 2.4 ± 0.4 fold. This muted, yet significant stimulation of cell migration was
expected, as Par6-K19A can still associate with TGF receptors and be phosphorylated
by TRII on S345. Finally, cells expressing the S345 mutant of Par6 that cannot be
phosphorylated by either TRII or aPKC did not significantly stimulate cell migration
(Figure 3.7B).
Taken together, these results suggest that aPKC isoforms play a role in NSCLC
cell migration both through Par6 association and S345 phosphorylation. We next
explored if siRNA directed towards aPKC would affect TGF-dependent EMT.
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Figure 3.7. Par6 induces cell migration
(A) H1299 cells were transiently transfected with empty vector (pIRES), wild-type Par6
(Par6-WT), Par6-K19A or Par6-S345A constructs. Immunoblots of lysates show relative
expression levels of transfected cells.
(B) Cells transfected as described in Panel A were plated into the top chamber of a
transwell chamber and allowed to migrate towards serum for 18 hours. Representative
images from the migration assay are shown above graphical analysis. Data are presented
as a percentage of control (pIRES) and represent the average of 3 independent
experiments (n=3 ± SEM, One-way ANOVA, **p<0.01). Bar = 100 m.
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3.4.8 aPKC siRNA alters RhoA levels
The TGF-Par6 pathway has been shown to regulate EMT by stimulating
cytoskeletal remodelling and cell plasticity. A critical step in this process is TGF
induced degradation of RhoA by Smurf1 [10]. Interestingly, this was shown to be
Smurf1-dependent, as reduction of Smurf1 expression blocked RhoA degradation and
EMT [10, 25]. Furthermore, both the phosphorylation of Par6 as well as PKC activity,
were shown to be important for the recruitment of Smurf1 and targeting of RhoA for
degradation [10, 25]. Since we observed that aPKC co-operate with TGF receptors to
phosphorylate Par6, we next determined whether aPKC played a role in TGF induced
RhoA degradation. Using siRNA targeting both aPKC isoforms, we monitored RhoA
levels in response to TGF in A549 NSCLC cells (Figure 3.8).
Previous work has shown, that upon TGF stimulation, RhoA levels are reduced
by ~20%, followed by the cell cytoskeletal and morphological changes associated with
EMT [10]. Similarly, we detected a consistent reduction in RhoA levels following TGF
treatment in cells transfected with control siRNA (Figure 3.8). However, siRNA targeting
aPKC resulted in a TGF-dependent increase in RhoA steady state levels (Figure 3.8).
Intriguingly, this result was similar to previous findings that RhoA accumulates with
Smurf1 knockdown [25]. We next monitored activated aPKC levels in response to TGF
treatment.
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Figure 3.8. aPKC silencing attenuates TGF-dependent decreases in RhoA levels
A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota and
zeta (siPKC /) were treated with TGF followed by lysing and processing for SDSPAGE and immunoblotting with anti -RhoA, -PKC, -PKC or -actin antibodies.
Average RhoA levels were quantitated and graphed in the bottom panel. Shown are
representative immunoblots from 5 independent replicate experiments. (n=5 ± SEM,
Two-way ANOVA, *p<0.05).
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3.4.9 TGF treatment activates aPKC
We next examined aPKC activity in response to TGF using a phospho-specific
antibody that detects T410 phosphorylated PKC (or T403 in PKC). Phosphorylation of
aPKC on this site is known to regulate its enzymatic activity [53]. Consistent with studies
carried out using prostate cancer cells and mouse embryonic fibroblasts [24], we
observed that TGF treatment increased the levels of endogenous phospho-PKC/in
A549 cells (Figure 3.9, Cell lysates). Interestingly, expression of Par6 also increased PPKC/ levels to equivalent levels seen with TGF addition, indicating that Par6 may
also scaffold aPKC to endogenous activators. Following immunoprecipitation of Par6
and immunoblotting for activated aPKC, we found that Par6-associated P-PKC/ levels
increased by 22 ± 7% upon TGF treatment compared to control (Figure 3.9, IP and
Graph). These results prompted us to assess whether aPKC played a role in TGF
induced cell morphology and EMT.
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Figure 3.9. TGF increases total and Par6 associated aPKC activity
A549 cells transfected with empty vector or Flag-tagged Par6 were treated with (or
without) TGF for 1 hour. Cell lysates were immunoprecipitated (IP) with anti-Flag
antibodies. The immunoprecipitates (IP) were subjected to SDS-PAGE, and
immunoblotted with anti (-phospho-specific PKC (P-PKC), total PKC, and -Flag
as indicated. The asterisk (*) denotes a non-specific band. Average Par6 associated PPKC levels were quantitated and are shown graphically below immunoblots. Shown are
representative immunoblots from 3 independent replicate experiments. (n=3 ± SEM).
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3.4.10

aPKC siRNA induces changes in cell morphology

TGF-treated A549 cells acquire a spindle–shaped appearance and reduce cellcell contacts [7]. We observed that siRNA-medated aPKC silencing reduced TGF
induced morphological changes of A549 cells, as assessed by DIC microscopy (Figure
3.10A). In cells expressing aPKC isoforms, the cobblestone appearance of A549 cells
became elongated in the presence of TGFafter 48 and 72 hours. In contrast, aPKC
silenced cells retained their cobblestone morphology with TGF treatment at both time
points. We also examined the front-rear polarization of sub-confluent control and aPKC
silenced A549 cells (Figure 3.10B). Interestingly, we found that the proportion of cells
that polarize and form a leading edge is reduced in aPKC silenced cells. Furthermore, we
detected a greater number of cells with a rounded phenotype in aPKC-silenced cells than
in control (Figure 3.10C). This is in agreement with previous work that aPKC plays an
important role in cell polarization [21] and similar to work that cells are less protrusive
with Smurf1 knockdown [25].
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Figure 3.10
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Figure 3.10. aPKC silencing reduces TGF induced changes in cell morphology
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC /) were treated with TGF for 0, 48, or 72 hours and imaged by
brightfield microscopy. Shown are representative images from at least 3 independent
replicate experiments. Bar = 100 m.
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC /) were plated sub-confluently, fixed, permeabilized and
immunostained with anti-PKC (PKC, blue) anti-Rac1 (Rac1, green), and biotin-labelled
TGF (biotin-TGF; red). Shown are representative images from 3 independent replicate
experiments.
(C) The average number of total elongated verses rounded cells was quantitated over 3
experiments and is presented graphically (n=3 ± SEM, Two-way ANOVA, **p<0.01).
Bar = 100 m.
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3.4.11

aPKC siRNA reduces TGF induced EMT

Since we observed that both aPKCs and TGF receptors could phosphorylate
Par6, that TGF increases activated aPKC levels, and that aPKC modulates TGF
induced RhoA degradation, we next determined to what extent aPKC was involved in
TGF induced EMT. TGFβ-dependent EMT involves the loss, in the expression and
organization, of the adhesion protein E-cadherin [1, 2, 7] and leads to decreased cell
adhesion and increased cell motility.
Using siRNA directed at both aPKC isoforms, we assessed changes in TGF
induced E-cadherin protein levels in A549 NSCLC cells (Figure 3.11A). Control, or
aPKC-silenced cells were treated with TGF for 0-72 hours and cell lysates were
immunoblotted for E-cadherin, P-Smad2, PKC, PKC, Smad2 and Actin. We observed
that E-cadherin protein levels were significantly reduced in control cells incubated with
TGF after 48 or 72 hours (Figure 3.11A, lanes 1-3). In addition, we observed Smad2
phosphorylation after 48 and 72 hours of TGFtreatment. In contrast, basal E-cadherin
levels were significantly higher in aPKC-silenced cells and were only moderately
decreased in response to TGF (Figure 3.11A, lanes 4-6). This suggested that aPKC was
important for TGF induced E-cadherin loss despite efficient phosphorylation of Smad2.
Interestingly, the levels of mRNA for the transcriptional repressors of E-cadherin, SNAI1
and SNAI2, both increased to a similar extent in control and aPKC silenced cells (Figure
3.11B). This is consistent with the idea that Smad2 signalling was still occurring in both
control and aPKC silenced cells.
We next assessed E-cadherin expression and stress fibre formation in A549 cells
by immunofluorescence microscopy. We observed that in the absence of TGF
treatment, 88 ± 5% of control cells and 82 ± 4% of siPKC/ cells contained few
spanning stress fibres and maintain a cortical F-actin distribution (Figure 3.11C). In
contrast, upon TGF treatment, the majority of cells transfected with control siRNA (76
± 4%) display elongated, cell spanning stress fibres after 48 and 72 hours. This effect was
significantly reduced in aPKC-silenced cells in which only 15 ± 5% of cells show
elongated stress fibres (Figure 3.11C). Furthermore, TGF induced E-cadherin loss was
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reduced in aPKC silenced cells (Figure 3.11C), consistent with immunoblot analyses
(Figure 3.11A). Taken together, these data suggest that aPKC is necessary for efficient
TGF induced EMT of NSCLC cells.
After observing that aPKC knockdown attenuated TGF induced EMT, we next
assessed cell motility. Our results showed that after 48 hours of TGFstimulation,
siControl cells migrated towards serum to a greater extent than aPKC-silenced cells, as
assessed by transwell migration assays (Figure 3.11D). This indicated that aPKC silenced
cells that did not undergo EMT were also less motile.

3.4.12

aPKC knockdown reduces claudin loss and individual aPKC
siRNA reduces TGF induced EMT

We also examined levels of a second epithelial marker, Claudin 1, in cells
transfected with control siRNA or siRNA targeting both aPKC isoforms. Similar to Ecadherin levels, TGF induced a loss in Claudin1 levels in control cells, but this effect
was abrogated in aPKC knockdown cells (Figure 3.12A). Furthermore, we wanted to
examine whether individual aPKCs were involved in reducing TGF induced E-cadherin
loss. Using siRNA directed at each aPKC isoform individually as well as both aPKC
isoforms together, we assessed changes in TGF induced E-cadherin protein levels in
A549 NSCLC cells. Interestingly, knockdown of individual aPKCs (siPKC, or
siPKC,) could also reduce TGF induced E-cadherin loss, although only cells
transfected with siPKC showed statistically significant results through average
densitometrical analysis (Figure 3.12B). Importantly, the double knockdown (siPKC /)
also significantly reduced TGF induced E-cadherin loss as observed before (Figure
3.12B). Taken together, these results indicated that aPKC knockdown cells were indeed
exhibiting a greater degree of epithelial phenotype when stimulated with TGF. We next
assessed whether re-introduction of exogenous P-Par6 into aPKC silenced cells could
restore TGF induced EMT.
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Figure 3.11
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Figure 3.11. aPKC silencing reduces TGF induced EMT and motility
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC /) were treated with TGF for 0, 48, or 72 hours. Cells were then
lysed and processed for SDS-PAGE and immunoblotting with anti ()-E-cadherin, phospho-specific Smad 2 (-P-Smad2), -Smad2, -PKC, -PKC or -actin
antibodies. The asterisk (*) denotes a non-specific band.

Shown are representative

immunoblots from at 5 independent replicate experiments. Average E-cadherin levels
were quantitated and graphed (bottom panel, n=5 ± SEM, Two-way ANOVA, **p<0.01).
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC /) were treated with or without TGF. After 24 hours, total RNA was
extracted; reverse transcribed, and subjected to quantitative real time PCR analysis
(qPCR) of PRKCI (PKC, PRKCZ (PKC, SNAI1 (Snail) and SNAI2 (Slug). Average
relative gene expression from 3 independent experiments is shown graphically (n=3 ±
SEM, Two-way ANOVA, p<0.05).
(C) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC /) were treated with or without TGF 48 hours followed by processing
for immunofluorescence microscopy and stained for filamentous actin with Phalloidin
(red), E-cadherin (green) and DAPI to image nuclei (blue). Cell morphology changes
over 3 independent experiments were quantified and are displayed graphically below
representative images. "a" indicates a statistically significant change with TGF
treatment. "b" indicates a statistically significant difference between siControl and
siPKC/ cells at the indicated time point. (n=3 ± SEM, Two-way ANOVA, *p<0.05).
Bar = 100 m.
(D) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC /) were untreated, or treated with TGF for 48 hours and assessed for
migration towards serum for 18 hours. Representative images from the migration assay
are shown below the graphical analysis (n=4 ± SEM, Two-way ANOVA, **p<0.01). Bar
= 100 m.
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Figure 3.12. aPKC silencing reduces TGF induced Claudin-1 loss and individual
aPKC knockdown also reduces TGF induced E-cadherin loss
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC/) were treated with or without TGF 48 hours. Cells were then lysed
and processed for SDS-PAGE and immunoblotting with

()-Claudin1, or -Actin

antibodies. Shown are representative immunoblots from 3 independent replicate
experiments (n=3).
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
(siPKC), zeta (siPKC), or both (siPKC/) were treated with or without TGF for 48
hours. Cells were then lysed and processed for SDS-PAGE and immunoblotting with E-cadherin or -actin antibodies. Three experiments were carried out as described in
Panel A, quantitated and are shown graphically below immunoblot (n=3 ± SEM, Twoway ANOVA, *p<0.05)
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3.4.13

Phospho-mimetic Par6 induces TGF-dependent EMT and
RhoA degradation in aPKC silenced cells

We next sought to test whether a reduction in phospho-Par6 was indeed
responsible for the reduced EMT response we were seeing in aPKC-silenced cells. To
carry this out, we generated a serine 345 phospho-mimetic version of Par6 (Par6 S345E).
We first ascertained that the Par6 S345E mutant was phospho-mimetic by immunoblot
analysis using the phospho-Par6 antibody (Figure 3.13A). Indeed, the phospho-S345 Par6
antibody recognized the Par6 S345E mutant.
Next, we introduced Par6 S345E into aPKC-silenced cells, and assessed Ecadherin protein levels following TGF-treatment (Figure 3.13B).

Consistent with

observations in Figure 3.11A, aPKC silencing reduced TGF-dependent loss of Ecadherin levels (Figure 3.13B, lanes 1-4). However, the Par6 S345E mutant restored the
TGF effect (lanes 9 and 10). Furthermore, Par6 S345E reduced the induction of basal
E-cadherin levels observed in aPKC-silenced cells (Figure 3.13B, lane 3 vs. 9).
As observed with the E-cadherin analysis, expression of the phospho-mimetic
Par6 S345E mutant significantly reversed the effect of aPKC silencing on TGFdependent RhoA levels (Figure 3.13C). aPKC silenced cells contained a significant
increase of RhoA protein levels in response to TGF. However, not only did Par6 S345E
reduce this effect, cells expressing this Par6 mutant had lower RhoA levels than cells
transfected with only control siRNA (Figure 3.13C, bottom panel).
Taken together, the data suggest that the phosphorylation of Par6 by both TGF
receptors and aPKC is necessary for efficient EMT of A549 NSCLC cells (summarized
in Figure 3.14).
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Figure 3.13. A S345E phospho-mimetic Par6 mutant restores TGF-dependent Ecadherin and RhoA loss in aPKC silenced cells
(A) HEK293T cells transfected with Flag-Par6 (WT, K19A, S345A, or S345E) were
lysed, processed for SDS-PAGE and immunoblotted with anti ()-Flag, or -PhosphoPar6 antibodies to determine the relative levels of P-Par6. A representative immunoblot
from three independent replicate experiments is shown.
(B) A549 cells transfected with control siRNA (siControl) or siRNA targeting PKC iota
and zeta (siPKC /) and Par6-S345E or empty vector, were incubated in the presence or
absence of TGF for 48 hours. Cells were then lysed and processed for SDS-PAGE and
immunoblotting with anti ()-E-cadherin, -PKC, -PKC or -Actin antibodies.
Average E-cadherin levels from 4 independent replicate experiments were quantitated by
densitometrical analysis and graphed below a representative immunoblot (n=4 ± SEM,
Two-way ANOVA, *p<0.05).
(C) A549 cells were treated as described in panel B. Cells were then lysed and processed
for SDS-PAGE and immunoblotting with anti ()-RhoA, and -Actin antibodies.
Average RhoA levels from 4 independent replicate experiments were quantitated by
densitometrical analysis and graphed below a representative immunoblot (n=4 ± SEM,
Two-Way ANOVA *p<0.05).
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Figure 3.14 Atypical PKC phosphorylates Par6 and facilitates TGF induced EMT
TGF stimulation leads to the activation of aPKC. Both aPKC and TGF receptors can
phosphorylate Par6 on S345 to initiate RhoA degradation, E-cadherin loss and
subsequently EMT.
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3.5 Discussion
Epithelial to mesenchymal transition is a critical event in tumour progression
leading to the disorganization of tissue architecture. The aPKC-Par6 axis is an emerging
pathway shown to be important in the stimulation of EMT and progression of metastatic
tumours. Phosphorylation of Par6 is associated with tumours that are more invasive and
have been correlated with reduced survival in breast cancer patients [12]. Until now, Par6
phosphorylation on Serine 345 has only been reported to occur through TGF receptor
activation.
In this report, we have observed that both atypical PKC isoforms ( and ) also
phosphorylate Par6 on S345 and suggests a role for aPKC in promoting epithelial derived
tumour cells into EMT through the Par6 pathway. Coupled with the observations that
aPKC shows malignant activity in various cancers [32, 33, 54] and oncogenic potential in
lung cancer [28-30, 34], our results suggest that aberrant phosphorylation of Par6 by
aPKC may be a major tumour promoting process.
Interestingly, we discovered that aPKC increases steady state Par6 protein levels,
which we attribute to a decrease in Smurf1 mediated degradation. A recent report has
indicated that protein kinase A (PKA)-dependent phosphorylation of Smurf1 leads to the
protection of Par6 and the simultaneous Smurf1 mediated degradation of RhoA [52].
Given our observations, it would be interesting to explore whether aPKC can also
phosphorylate Smurf1, thus leading to protection of Par6 from Smurf1 mediated
degradation. Furthermore, Smurf1 may target TGF receptors and Par6 for degradation
via aPKC association and Par6 S345 phosphorylation. Since we have previously
described a role for aPKC in TGF receptor trafficking and degradation [35], we believe
the current results suggest a role for aPKC regulation of TGF receptor-Par6 complexes.
Ozdamar et al. have previously shown that Par6 phosphorylation on S345 is
important for TGF mediated RhoA degradation and adherens junction dissolution [10].
Here, we show that basal E-cadherin levels are significantly higher in aPKC-silenced
cells, and furthermore, TGF -induced reductions of both RhoA and E-cadherin are
severely impaired when aPKC is silenced. This effect was seen despite similar PhosphoSmad2 signalling levels between control and aPKC silenced cells, highlighting the
importance of aPKC in the EMT process via the Par6 pathway.
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A similar effect has been reported with respect to the ability of the ErbB2 receptor
to disrupt tissue architecture of polarized epithelia [22]. Inhibiting the interaction of
aPKC and Par6 (with K19A) blocked the ability of ErbB2 to disrupt the acinar
organization of breast epithelial cells [22]. Interestingly, activation of the TGF-Par6
pathway has also been shown to disrupt acini-like structure formation in normal murine
mammary gland (NMuMG) cells [12]. This effect is reduced through expression of the
S345A Par6 mutant indicating that phosphorylation of Par6 on S345 is important for this
disruption. Given the observations that both aPKC association with Par6 and S345
phosphorylation are important for tissue organization, we believe that aPKC
phosphorylation of Par6 may be critical in the disorganization of normal tissue
architecture. Interestingly, introduction of the Phospho-mimetic Par6 (S345E) into aPKC
silenced cells restored full TGF induced E-cadherin loss and RhoA degradation highlighting an important role for aPKC induced P-Par6 in these processes.
Taken together, we propose that multiple tumour promoting pathways (including
TGF and ErbB2) may require aPKC to disrupt cell polarity, and that aPKC may be a
target for blocking oncogenic signalling pathways that induce tissue disruption during
tumour progression. Indeed, we observed that the silencing of aPKC reduces TGF
induced EMT and migration of A549 adenocarcinoma cells. Furthermore, others have
shown that loss of function experiments of PKC in A549 cells showed reduced invasive
activity as well as significantly reduced tumour growth and expansion in vivo in nude
mice [30, 34]. aPKC has recently been implicated in various disease states, and several
studies have highlighted the oncogenic characteristics of PKC in NSCLC [28, 30, 31,
54-56], with an elevated level of PKC expression reported to be correlated with poor
outcome in NSCLC patients. Patients with early stage lung cancer and high
PKCexpression are more than 10 times likely to perish from the disease than those with
low levels of PKC. A similar trend is evident in patients with increased PKC DNA
copy number and ovarian cancer [33]. Increased PKCexpression is also correlated with
increased cyclin E expression in ovarian cancers, and is implicated with increased
proliferation, defects in cell polarity, and decreased survival rates [33]. Furthermore,
aPKC has been shown to be important in the Par6 induced cell proliferation in breast
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epithelial cells, as the K19A Par6 mutant reduces the mitogenic effects of Par6 signalling
[23].
We believe that aPKC is an important component of TGF activated
phosphorylation of Par6, and that silencing of aPKC gene expression blocks TGF
induced EMT and migration of NSCLC cells. It will be interesting to explore whether the
aPKC-Par6 axis is an important pathway in the metastatic progression of NSCLC
tumours in vivo.

3.6 Footnotes
We would like to thank Dr. Jeffrey L. Wrana for generously providing the S345
Phospho-specific Par6 antibody. This work was funded by the Canadian Institutes of
Health Research (MOP-93625).
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Chapter 4

4.1 Chapter Summary
TGFβ signalling regulates many cellular responses including proliferation, EMT,
and apoptosis. This wide array of responses occurs through the intricate control of Smad
activity as well as other non-Smad pathways including Par6 and MAPK. My previous
work demonstrated that aPKCs are important for TGF receptor trafficking, degradation,
and signalling pathways. Here I analyzed gene changes and responses in A549 lung
cancer cells in which aPKC has been silenced using siRNA.
When analyzing the gene responses in aPKC-silenced cells, we observed a
dampening of TGF response, as assessed by microarray and qPCR, which correlated
with a reduction in Smad2 nuclear accumulation in response to TGF. Interestingly, we
also detected an increase in p38 MAPK phosphorylation in aPKC-silenced cells.
Although the enhanced p38 MAPK levels parallelled an increase in apoptotic response,
p38 inhibition did not rescue Smad2 nuclear accumulation. p38 MAPK activation in
aPKC silenced cells was found to occur downstream of TRAF6, as TRAF6 knockdown
abrogated the increased p38 MAPK phosphorylation we observed in aPKC silenced cells.
Interestingly, knockdown of aPKC stabilized TRAF6-TGF receptor complexes,
providing a mechanism for the enhanced p38 activation observed. Finally, in aPKC
silenced cells we observed an increase in the expression of the Smad2 cytoplasmic
retention factor, SARA, and concomitantly a reduction in Smad2 release upon TGF
stimulation. Furthermore, this followed a reduction in Smad2-Smad4 complex formation
in aPKC-silenced cells. We reason this deregulated SARA-Smad2-Smad4 exchange leads
to a reduced nuclear accumulation of R-Smads and reduced transcriptional response.
We conclude that aPKC influences the stability of receptor binding partners (such
as TRAF6 and SARA) which can subsequently affect TGF signalling and cellular
response.
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4.2 Introduction
TGF signalling controls many cellular processes including proliferation,
apoptosis, and EMT. Aberrant TGF signalling is a hallmark of several pathological
conditions including cancer and fibrosis [1-5]. The canonical TGF pathway involves the
cell surface binding of TGF ligand to TRII, which then binds and phosphorylates TRI
[6]. Phosphorylation of TRI leads to its activation, and its ability to transduce
intracellular signalling through the phosphorylation of substrate proteins such as the RSmads, Smad2 and Smad3 [2, 6]. Once phosphorylated, R-Smads accumulate in the
nucleus where they act as transcription factors to regulate subsequent TGF gene
response [2, 6-9]. Entry into the nucleus of R-Smads is facilitated by directly binding the
nucleopore complex, binding to Importins (for Smad3), or facilitated by the binding of
the common Smad, Smad 4 [8, 10]
Proteins that control the membrane trafficking and endocytosis of TGF receptors
play a role in regulating the intensity and duration of TGF signals. For example, the
efficient regulation of Smad signalling can be facilitated by the adaptor protein SARA
(Smad anchor for receptor activation). SARA contains a Smad binding domain, as well as
a TGF receptor complex interacting region, and acts as a bridge, facilitating R-Smad
presentation to the activated receptor complex [11, 12]. SARA also contains a
phosphatidylinositol 3-phosphate (PI3P) binding FYVE domain, which induces its
association with the early endosome, and links receptor endocytosis and trafficking to
Smad signal transduction [12, 13]. Once SARA-bound R-Smads are phosphorylated, they
dissociate from the SARA-receptor complex, bind to Smad4, and subsequently
translocate to and accumulate in the nucleus to regulate transcription [14]. Interestingly,
although receptor endocytosis has been reported to be dispensable for the
phosphorylation of R-Smads, it has been reported that endocytosis is required for the
efficient dissociation of R-Smads from SARA, nuclear accumulation, and subsequent
transcriptional response [15]. The precise regulation of transcriptional activity of Smads
in the nucleus is important for the proper execution of embryonic development by
controlling tissue patterning, normal organ development, and also for controlling cellular
growth and apoptotic response in adult tissues [4, 7, 8, 16, 17].
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Although it is established that Smads are central regulators of gene response to
TGF, multiple Smad independent pathways are also initiated upon TGF receptor
activation [10, 16-19]. TGF can activate the mitogen associated protein kinase family
(MAPK). There are three principle MAPK proteins: ERK, JNK, and p38 - each of which
has a role in the development and progression of cancer [20]. The p38 MAPK pathway
downstream of TGF has gained considerable interest as a pathway that regulates
apoptosis. Briefly, TGF receptor activation leads to the recruitment and Lys-63 linked
auto-ubiquitination and activation of TRAF6, an E3 ubiquitin ligase. This stimulates a
cascade that culminates in the activation of p38 MAPK and ultimately apoptosis in
various cell types [21-23]. Interestingly, aPKC isoforms interact with TRAF6 to mediate
cytokine signalling [24], but less is known about whether aPKC mediates the TGF-p38
MAPK pathway.
We have previously shown that aPKC isoforms can alter TGF signalling patterns
in NSCLC cells by altering receptor trafficking, degrading specific receptor complexes
and by enhancing Par6 dependent phosphorylation [25, 26]. However, we had not
examined gene changes on a large scale. Furthemore, we have not examined whether
aPKCs alter TGF-induced MAPK pathways. The aPKC isoforms, which consist of
PKC and PKC, are a subset of the Protein Kinase C family that are calcium and
diacylglycerol (DAG) independent [27]. Importantly, the aPKCs show altered expression
and activities in various cancers [28], and PKC has been described as an oncogene [29,
30]. Interestingly, aPKC isoforms have been known to play a role in p38 MAPK induced
apoptosis, as inhibition or knockdown of aPKC sensitizes glioblastoma cells to
chemotherapeutic agents via a p38 dependent mechanism [31].
In this report we examined TGFβ-dependent transcriptional response in aPKC
silenced cells by microarray analyses, and also examined how knockdown of aPKC alters
Smad dynamics and MAPK pathways to alter cellular apoptosis.
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4.3 Materials and Methods
4.3.1 Antibodies and Reagents
Primary antibodies were purchased from the following vendors: Anti--Actin
(Sigma-A2668), anti-PKC (BD Transduction-610175), anti-PKC (Cell Signalling
Tech-9372), anti-Phospho-Smad2 (Cell Signalling Tech-3101), anti-Smad2/3 (BD Trans610842), anti-Tubulin (Sigma-T4026),

anti H3-Histone (Millipore-05-499), anti-

phospho-p38 (Cell Signalling-9211), anti p38 (Cell Signalling- 9212), anti phospho-ERK
(Cell Signalling – 4370), anti-phospho-JNK (Cell Signalling Tech-9255s), anti-Smad4
(Abcam-AB40759), anti-SARA (Santa Cruz, sc-9135), anti-Flag (Sigma Aldrich –
F3165), anti-Traf6 (Cell Signalling Tech- 8028s), anti-EEA1 (BD Transduction-610457).
HRP conjugated secondary goat-anti-rabbit (Thermo Scientific -31460) and goat-antimouse (Thermo Scientific -31430) were used for immunoblot analysis. Fluorescently
conjugated donkey -mouse (Life Technologies A21206), donkey -rabbit (Life
Technologies-A31572) were used for immunofluorescence studies. Human siRNA
constructs were purchased from Life Technologies (siPKC, siPKC and siControl
catalogue

numbers:

(10620319-HSS183348,

10620319-HSS183318,

12935112)

respectively. TRAF6 siRNA was purchased from Life Technologies, product number
s14389- 4390824). p38 MAPK inhibitor was purchased from Calbiochem (506126).

4.3.2 Cell Culture and Transfections
A549 and H1299 NSCLC cell lines were maintained in F12K and RPMI-1640
Medium (respectively) supplemented with 10% fetal bovine serum. Cells were kept in a
humidified tissue culture incubator at 37ºC in 5% CO2. siRNA transfections were
conducted using Lipofectamine RNAi max (Life Technologies) according to the
manufacturer’s protocol. TGF treatments (250 pM) were conducted in serum deprived
media (0.2% FBS) for the indicated times after cells were serum deprived overnight.
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4.3.3 Protein Concentrations
Protein concentrations were determined using the Lowry method (Fisher).

4.3.4 Immunoblotting and Immunoprecipitation
Cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and a mixture of protease inhibitors)
and centrifuged at 14,000 rpm at 4 °C for 10 min. Aliquots of supernatants were collected
for analysis of total protein concentration. For immunoprecipitation, equal amounts of
remaining cell lysates were incubated with primary antibody, followed by incubation
with protein G-Sepharose beads. The precipitates were washed three times with lysis
buffer, eluted with sample buffer, and subjected to SDS-PAGE. Proteins were transferred
to nitrocellulose followed by blocking in 5% skim milk, and incubation with primary
antibody in TBST overnight at 4ºC. Following incubation with HRP conjugated
secondary antibody, proteins were visualized using West Dura Super Signal ECL (Fisher)
and imaged on a VersaDoc Imaging system (BioRad).

4.3.5 Cellular Fractionation
Cytoplasmic and Nuclear cellular fractions were isolated using the Thermo
Scientific Kit NE-PER® kit (78833) according to the manufacturer’s protocols.

4.3.6 Immunofluorescence Microscopy
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X100, and incubated with primary antibodies at 4°C overnight. Following incubation with
the appropriate fluorescent probe conjugated secondary antibodies, the probes were
visualized by immunofluorescence microscopy using an inverted IX81 Microscope
(Olympus, Canada).
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4.3.7 RNA Quality Assessment, Probe Preparation and GeneChip
Hybridization
All GeneChips were processed at the London Regional Genomics Centre (Robarts
Research Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA quality was
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA)
and the RNA 6000 Nano kit (Caliper Life Sciences, Mountain View, CA). Single
stranded complimentary DNA (sscDNA) was prepared from 200 ng of total RNA as per
the Ambion WT Expression Kit for Affymetrix GeneChip Whole Transcript WT
Expression Arrays (Applied Biosystems, Carlsbad, CA) and the Affymetrix GeneChip
WT Terminal Labeling kit and Hybridization User Manual (Affymetrix, Santa Clara,
CA). Total RNA was first converted to cDNA, followed by in vitro transcription to make
cRNA. 5.5 ug of single stranded cDNA was synthesized, end labeled and hybridized, for
16 hours at 45°C, to Human Gene 1.0 ST arrays. All liquid handling steps were
performed by a GeneChip Fluidics Station 450 and GeneChips were scanned with the
GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA) using Command Console
v1.1. Probe level (.CEL file) data was generated using Affymetrix Command Console
v1.1. Probes were summarized to gene level data in Partek Genomics Suite v6.5 using the
RMA algorithm adjusted for GC content[32]. Using Partek, any batch affect due to scan
date was removed and an ANOVA (Yijk = μ + Condition * Timeij+ eijk) using Method
of Moments [33] was run to determine gene level p-values. Fold change comparisons are
expressed relative to untreated siControl cells, and represent the average of three separate
experiments (3 separate gene chips per condition). A fold change of ±1.6 was considered
as the cutoff for induction.

4.3.8 Reverse Transcription, Real time PCR and Statistical Analyses
Total RNA was isolated from A549 cells using the RNAeasy Mini kit (Qiagen)
according to the manufacturer’s protocol. For complementary DNA (cDNA) synthesis,
1000 ng of total RNA was reverse transcribed using the Superscript® VILO cDNA
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synthesis kit according to manufacturer’s protocol (Applied Biosystems). A cDNA
equivalent to 10 ng of total RNA was used for all PCR reactions in a total volume of 20
l. Each reaction was carried out in triplicate. Quantitative PCR (qPCR) reactions were
conducted using SsoFast EvaGreen® supermix (BioRad) using a Chromo4 Real-time
Thermal Cycler (Bio-Rad) according to the recommended protocol of the manufacturer.
Primer sequences (5'-3') are as follows: PKC (TACGGCCAGGAGATACAACC and
TCGGAGCTCCCAACAATATC),

PKCATCATTCATGTTTTCCCGAGCA

GTTGGCACGGTACAGCTTCPKCACAACCTTCCAACAACCTTGAC
CCTTCCTGTCGGCAAGCAT)

SNAI-1

and
and

(AATCGGAAGCCTAACTACAGCG

andGTCCCAGATGAGCATTGGCA),SNAI-2 (ATACCACAACCAGAGATCCTCA
andGACTCACTCGCCCCAAAGATG), E-cadherin (CCCACCACGTACAAGGGTC
and CTGGGGTATTGGGGGCATC), MMP9 (CATTTCGACGATGACGAGTTGT and
CGGGTGTAGAGTCTCTCGC),

PAI-1

(CTCTCTCTGCCCTCACCAAC

and

GTGGAGAGGCTCTTGGTCTG), SMURF2 (GTCCAGAGACCGAATAGGCAC and
CCAGAGGCGGTTCTCCTTTC),

TIEG1

(TTCCGGGAACACCTGATTTTC

and

GCAATGTGAGGTTTGGCAGTA), DAPK1 (AGCTTCGGCTCAAATCCCAAT and
TCTCCTTCTCGGTTCTTGATGT),

Beta-Actin

(GGGAAATCGTGCGTGACATTAAG andTGTGTTGGCGTACAGGTCTTTG), and
POLR2A (GGATGACCTGACTCACAAACTG and CGCCCAGACTTCTGCATGG).
Primers were selected using Primer3 [34] as well as PrimerBank [35-37]. Baseline and
threshold for Ct calculation were set manually using the Opticon Monitor 3.1 Software
(Bio-Rad). PCR efficiencies (E) were calculated using cDNA dilution curves and were >
90% for all genes assessed. Calculated PCR efficiencies were used for gene expression
quantification using the Pfaffl formula[38], ratio = (Etarget)Ct target(control-treated)/ (Ereference)Ct
ref(control-treated)

, where control = siControl, no TGF. Final ratios were calculated using

geometric averaging [39] from two reference genes: POLR2A, a gene which was found
to be a suitable reference gene in NSCLC models [40], and -Actin. Gene expression of
each treatment is expressed in relation to the control (siControl, no TGF) and is an
average of 3-6 independent experimental trials. Two-way ANOVA analysis followed by
post-hoc Bonferonnis’s Tests were used to evaluate the significance of the results.
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Statistical analyses were performed using GraphPad Prism® Software 5.0 and p values of
<0.05 were considered statistically significant.

4.3.9 Cell Death Assays
A549 and H1299 cells transfected with the appropriate siRNA constructs were
serum deprived (0.2% FBS), and then incubated with or without TGF in serum deprived
media in the presence or absence of a p38 MAPK inhibitor for 48 hours. After 48 hours,
apoptosis of A549 and H1299 cells was analyzed by examining nuclear morphology after
Hoechst 33342 staining. Hoescht stain (1 ug/mL) was added directly to the medium and
incubated for 30 minutes at 37°C. The cells were then visualized using a fluorescent
microscope (Olympus IX71), and ten random images were acquired per condition.
Normal, and apoptotic nuclei were counted and the apoptotic nuclei (characterized by
condensed chromatin) were scored as a proportion of normal/healthy cells.

4.3.10

Statistical Analysis

One-way or Two-way ANOVA analyses followed by post-hoc Bonferonnis’s Test
were used to evaluate the significance of the results. Statistical analyses were performed
using GraphPad Prism® Software 5.0 and p values of <0.05 were considered statistically
significant.

4.4 Results
4.4.1 Knockdown of Atypical PKC isoforms alters TGF induced gene
expression
We have previously reported that aPKC gene silencing using small interfering
RNA (siRNA) leads to a temporal extension of TGF induced Smad2 phosphorylation
[25], and that aPKC facilitates Par6 signalling [26]. Here we assessed global
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transcriptional changes in aPKC-silenced cells using gene array (microarray) analysis.
Using small interfering RNA (siRNA) targeted to aPKC iota (siPKC) and zeta (siPKC),
we were able to successfully reduce protein levels of both aPKC  and  individually, as
well as together (siPKC/) in A549 lung adenocarcinoma cells (Figure 4.1A). As we
have previously reported in these cells, knockdown of PKC alone results in a
compensatory expression of PKC (Figure 4.1A). Furthermore, as reported previously,
knockdown of aPKC temporally extends P-Smad2 levels 4.5 hours after TGF treatment
(Figure 4.1B) as well as 24 hours following a pulse of TGF stimulation (Figure 4.1C)
[25].
To conduct the microarray analyses, we stimulated siRNA treated cells (siControl
vs. siPKC/ double knockdown) with TGF for 1 hour, followed by washout and further
incubation of cells for 24 hours in serum-deprived media. Total RNA was extracted and
submitted to the London Regional Genomics Centre for microarray analyses. The raw
data were processed and normalized as outlined in the Methods section and a summary
table of selected TGF gene changes is presented in Table 4.1.
We summarized fold change differences between siControl and siPKC/ cells
after TGF induction (Table 4.1). This list was selected from a set of commonly known
genes to be regulated by TGF, modified from [7]. The full microarray data set can be
accessed online at the NCBI Gene Expression Omnibus website (GEO; GSE26241).
Interestingly, there are several classical TGF genes that show similar expression
patterns between control and aPKC silenced cells including BMP4, SNAI1, and SNAI2.
However, there were several genes that had muted TGF-dependent gene changes in
aPKC-silenced cells compared to control cells, including IL1A, SMURF2, MMP2, and
MMP9. We next followed up on these gene changes using real-time PCR.
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Figure 4.1
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Figure 4.1. aPKC knockdown prolongs TGF induced Smad2 phosphorylation
(A) A549 cells transfected with the indicated siRNA were grown for 24 hours and then
lysed. Cell lysates were processed for SDS-PAGE and immunoblotted with anti ()PKC, anti-PKC, or anti-Actin antibodies as indicated to observe protein knockdown
levels.
(B) A549 cells transfected with the indicated siRNA were serum starved and treated with
250 pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours prior to
lysis. Lysates were then processed for SDS-PAGE and immunoblotted with anti ()phospho-specific Smad2 or Smad2/3 antibodies. A representative immunoblot from 3
independent replicate experiments is shown.
(C) A549 cells transfected with the indicated siRNA were serum starved and treated with
250 pM TGF for 1 hour, washed and further incubated for 24 hours in serum deprived
media prior to lysis. Lysates were then processed for SDS-PAGE and immunoblotted
with ()-phospho-specific Smad2 or Smad2/3 antibodies. A representative immunoblot
from 3 independent replicate experiments is shown.
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Table 4.1
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Table 4.1. aPKC knockdown alters TGF gene response by microarray analysis
A549 cells transfected with control (siControl) or siRNA directed at aPKC isoforms
(siPKC/) were serum starved and treated with 250 pM TGF for 1 hour, washed and
further incubated for 24 hours in serum deprived media. Total RNA was then extracted
and subjected to microarray analysis. Shown is a selected list of genes that differed
between control and aPKC silenced cells after 24h for several genes regulated by TGF
(list adapted from Table 1 in [7]) Fold change comparisons are expressed relative to
untreated siControl cells (siControl, -TGF), and represent the average of three separate
experiments (n=3). In bold are some genes that show a muted response in aPKC
knockdown cells.
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4.4.2 Knockdown of Atypical PKC alters TGF induced gene
expression in qPCR analyses
We next re-examined some of the changes we observed in microarray analysis by
qPCR. Control and aPKC-silenced cells were treated as described above in the
microarray analyses. However, in this case, total RNA was extracted, reverse transcribed,
and subjected to qPCR analysis for various TGF induced genes. SNAI-1, SNAI-2, Ecadherin, MMP9, PAI-1, Smurf2, DAPK1, and TIEG 1 were tested for relative gene
expression in TGF induced control or aPKC knockdown cells. We also tested
expression of PKC, PKC, and PKCto confirm aPKC knockdown efficiency. Relative
gene expression was normalized using 2 reference genes (Beta-Actin and POLR2A) as
described in the Methods section. The graphs represent the average gene expression from
at least 3 independent experimental trials.
Figure 4.2A indicates that siRNA targetting aPKC iota and zeta was successful at
reducing gene expression of the atypical PKCs (aPKC and ), but not the classical
isoform PKC. Figure 4.2B shows the gene expression of the various TGF-induced
genes in aPKC knockdown and control cells. SNAI-1 (Snail), SNAI-2 (Slug) and Ecadherin are TGF dependent genes involved in the maintenance of epithelial cell
junctions. In invasive cancers, TGF is known to trigger breakdown of epithelial cell
junctions to promote an invasive phenotype by reducing E-cadherin levels through the
transcriptional repressors SNAI-1 and SNAI-2 [17]. Our results indicate the transcription
factors SNAI-1 and SNAI-2 increase with TGF treatment. Furthermore, E-cadherin
gene expression is reduced with TGF treatment. These results were similar in both
control and aPKC silenced cells indicating that aPKC may not be important for
transcriptional regulation of these genes. However, several other genes were dampened
with aPKC knockdown.
Smurf2 (SMAD ubiquitination regulatory factor 2), is a regulatory factor for the
TGF receptors, typically involved in targeting Smads and receptors for ubiquitin
mediated degradation [8, 13]. Our results indicate that upon TGF stimulation, there is an
increase in SMURF2 gene expression, however, this effect is abrogated in aPKC-silenced
cells.
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TGF signalling is often involved in inducing expression of genes that are
involved in the remodelling of the extracellular matrix and degradation of the basement
membrane. These types of TGF induced gene changes are implicated in the progression
of fibrotic disorders as well as metastatic phenotypes in cancer. Two such genes regulated
by TGF are PAI-1 (plasminogen activator 1) and MMP9 (matrix metalloproteinase 9)[7,
41]. In observing the gene expression of PAI-1, we saw that TGF stimulation induced a
significant increase in PAI-1 expression in siControl cells. However, PAI-1 induction
was significantly reduced in aPKC silenced cells. Similarly, MMP9 gene expression
increases with TGF induction and this effect is also significantly reduced in aPKCsilenced cells.
TGF Smad signalling can also stimulate pro-apoptotic effects in the epithelium
through the positive regulation of genes such as DAPK1 (death-associated protein kinase
1) and TIEG1 (TGF-inducible early response gene 1) [19]. Interestingly, we found that
in A549 cells, TGF actually stimulates a modest decrease in DAPK1 and no change in
TIEG 1 expression. No significant differences were observed in aPKC-silenced cells
compared to control.
Notably, as we observed in the microarray data, the significant differences we
observed in TGF-induced expression in aPKC knockdown cells were actually decreased
gene response. This is despite having temporally extended P-Smad2 levels. We next
sought to determine what might be causing this muted TGF response.
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Figure 4.2
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Figure 4.2. aPKC silencing alters TGF dependent gene induction
Real time PCR analysis of TGF induced mRNA levels in A549 control siRNA cells as
compared to aPKC double silenced cells (siPKC/). RNA extracts were isolated from
cells treated for one hour with TGF followed by 24 hours of incubation in the absence
of ligand. Two-way ANOVA analysis followed by post-hoc Bonferonni‘s tests were used
to determine statistical significance of gene changes (PKC, PKC, PKC, CDH1,
SNAI1, SNAI2, n=3; all other genes n=6, ±SEM, Two-Way Anova *=p<0.05) a=
significant change with TGF; b= significant change with aPKC knockdown (A) aPKC
siRNA is specific. aPKC knockdown was effective in silencing aPKC gene expression,
but not classical PKC expression. (B) TGF effected similar changes in SNAI-1,
SNAI-2, E-cadherin, and DAPK1 in control and aPKC silenced cells. However, aPKC
knockdown results in reduced TGF induced MMP9, PAI-1 and Smurf2 expression.
TIEG1 was unaffected by TGF treatment or aPKC knockdown.
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4.4.3 aPKC knockdown reduces TGF induced Smad2 nuclear
accumulation
Activated TGF receptors phosphorylate receptor regulated Smads (Smad2 and
Smad3) on a C-terminal SSXS motif which facilitates their accumulation in the nucleus
[8]. Since the reduced transcriptional response we were observing in aPKC silenced cells
may be due to a reduced nuclear translocation of Smad2, we examined the cytosolicnuclear translocation of Smad2 in control and aPKC silenced cells using
immunofluorescence microscopy (Fig 4.3A). As expected, in cells tranfected with control
siRNA, TGF induced an increase in Smad2 nuclear staining, indicating a robust nuclear
accumulation of Smad2 (Fig 4.3A). However, aPKC silenced cells showed a reduced
nuclear accumulation of Smad2 in response to TGF. To verify this observation, we also
conducted subcellular fractionation studies and immunoblotting of cellular cytosolic and
nuclear fractions when cells were treated in the presence or absence of TGF. Consistent
with our immunofluorescence microscopy analysis, TGF treatment stimulates an
increase in nuclear Smad2 levels in cells transfected with control siRNA (Figure 4.3B)
This is in contrast to aPKC knockdown cells, which show significantly reduced nuclear
Smad2 levels upon TGF addition. We next assessed whether knockdown of aPKC was
mediating effects specific to the TGF pathway or whether it was affecting general
nuclear import.
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Figure 4.3
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Figure 4.3. aPKC knockdown reduces TGF induced Smad2 nuclear accumulation
(A) A549 cells were transfected with the indicated siRNA, serum starved and treated with
250 pM TGF for 1 hour. The cells were processed for immunofluorescence microscopy
with antibodies against Smad2. DAPI was used to visualize DNA. Representative images
from at least 3 independent replicate experiments are shown. Bar = 10 µm
(B) A549 cells were transfected and treated with TGF as described in panel A. The
cells were then subjected to subcellular fractionation to isolate cytoplasmic and nuclear
fractions. The fractions were subjected to SDS-PAGE and immunoblotted using anti ()Smad2, anti-tubulin, and anti-Histone H3 antibodies to determine the subcellular
distribution of Smad2. Histone H3 and Tubulin antibodies were used as loading controls
for the nuclear and cytoplasmic fractions, respectively Average nuclear Smad2 levels
from 3 independent replicate experiments were quantitated by densitometrical analysis
and graphed below the representative immunoblots. (n=3 ± SEM, Two-way ANOVA,
*p<0.05.)
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4.4.4 siRNA targeting aPKC does not alter TNF induced NF-B
nuclear translocation
After finding that the cytosolic retention of Smad2 was increased in aPKC
silenced cells, we next sought to determine whether aPKC knockdown might be altering
general nuclear import. To test this, we examined the classical NF-B pathway, wherein
subsequent to TNF stimulation, NF-B translocates to the nucleus via a classical
importin dependent mechanism [42]. Using immunofluorescence microscopy we
examined the subcellular localization of NF-kB in cells treated with or without TNF
(Figure 4.4). In cells transfected with either control siRNA or siRNA targeting aPKC,
NF-B showed a robust accumulation in the nucleus following TNF stimulation (Figure
4.4). This suggested that the reduction in Smad2 nuclear localization in aPKC silenced
cells was not likely due to an inhibition of general nuclear import machinery and
therefore was possibly specific to the Smad pathway. We next sought to determine the
cause of cytosolic retention of Smad2 in aPKC silenced cells.
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Figure 4.4. aPKC knockdown does not alter TNF induced NF-B nuclear
accumulation
A549 cells transfected with the indicated siRNA were serum deprived, treated with
10ng/mL TNF for 30 minutes, and then fixed and processed for immunofluorescence
microscopy with antibodies against NF-B to observe NF-B subcellular localization.
DAPI was used to visualize DNA. Representative images from 3 independent replicate
experiments are shown. Bar = 10 µm.
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4.4.5 Knockdown of aPKC enhances P-p38 MAPK levels
R-Smads shuttle to and from the nucleus and their subcellular localization is
primarily controlled through their C-terminal phosphorylation. The protein structure of
Smads has been largely conserved among species and consists of 2 Mad homology
domains (MH1 and MH2) connected by an intermediate, proline rich linker region [8].
Interestingly, this linker region contains multiple phosphorylation sites that have been
shown to alter Smad localization and function [10]. Originally, linker phosphorylation
was discovered to occur through ERK MAPK (via Ras) to exclude Smad from the
nucleus [43]. Given our observation of reduced nuclear accumulation of Smads in aPKC
silenced cells, we next assessed whether MAPK pathways were altered in aPKC depleted
cells. We analyzed the levels of activated MAPK pathways in response to a pulse of
TGF in control and aPKC silenced cells (Figure 4.5). We noted that at 1 and 24 h time
points there did not appear to be a difference between siControl and siPKC/cells with
regards to the levels of phosphorylated ERK 1/2. However, aPKC knockdown increased
basal levels of phosphorylated p38 MAPK and extended the duration of p38
phosphorylation to at least 24 hours (Figure 4.5A). Appreciable levels of P-JNK (the last
MAPK) were not detected in this cell line (Figure 4.5A). We went on to test a shorter
time course of p38 MAPK activation in control and aPKC knockdown cells and
discovered that in aPKC-silenced cells (single, or double knockdown) TGF-induced p38
MAPK phosphorylation was increased and extended in duration compared to control
cells (Figure 4.5B). Because MAPK crosstalk is well known to alter Smad nuclearcytoplasmic shuttling dynamics [10, 44, 45], we hypothesized that increased p38 MAPK
activity may be altering Smad2 nuclear import in aPKC-silenced cells. Thus, after
determining that aPKC knockdown was enhancing p38 MAPK signalling, we next sought
to test whether this enhanced p38 MAPK activity might play a role in Smad2 nuclear
entry.
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Figure 4.5. aPKC knockdown increases and prolongs p38 MAPK phosphorylation
in response to TGF
(A) A549 cells transfected with control siRNA (siControl) or siRNA directed at the
aPKC isoforms (PKC/) were treated with or without 250 pM TGF for 1 or 24 hours
prior to lysis. Samples were then processed for SDS-PAGE and immunoblotted with anti
()-phospho-specific antibodies directed at phosphorylated forms of ERK, p38, and JNK
as indicated on the right of the panels. Shown are representative immunoblots from at
least 3 independent replicate experiments. Immunoblotting for Actin was used as a
loading control.
(B) A549 cells transfected with the indicated siRNA were serum starved and treated with
250 pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours prior to
lysis. Lysates were then processed for SDS-PAGE and immunoblotted with the anti ()phospho-specific p38 and total p38 MAPK antibodies as indicated on the right of the
panels. Average P-p38 MAPK levels from 3 independent replicate experiments were
quantitated by densitometrical analysis and graphed below the representative
immunoblots. (n=3 ± SEM, Two-way ANOVA, *p<0.05, **p<0.01).

190

4.4.6 Inhibition of p38 MAPK does not rescue Smad2 nuclear
translocation
Given that we observed increased levels of P-p38 MAPK, we next wanted to
assess whether p38 MAPK was responsible for the altered Smad2 nuclear translocation
observed in aPKC silenced cells. To carry this out, we phamacologically inhibitted p38
activity in aPKC silenced cells and assayed for Smad2 nuclear translocation by
immunofluorescence microscopy. As we previously observed, in cells transfected with
control siRNA, TGF induced a robust nuclear accumulation of Smad2, whereas in
aPKC knockdown cells Smad2 nuclear accumulation was impaired (Figure 4.6).
Interestingly, we found that the p38 MAPK inhibitor did not rescue Smad2 nuclear
translocation in aPKC silenced cells (Figure 4.6). This result suggested that p38 MAPK
activity was likely not responsible for the reduced Smad2 nuclear accumulation observed
in aPKC silenced cells. Although, we found that inhibiting p38 MAPK did not rescue
Smad2 nuclear accumulation, we wanted to address whether the enhanced p38 MAPK
levels we observed might be altering TGF induced apoptosis.
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Figure 4.6. p38 MAPK inhibition of aPKC knockdown cells does not rescue Smad2
nuclear accumulation
A549 cells transfected with the indicated siRNA, were serum deprived in the presence or
absence of a p38 MAPK inhibitor, and then treated with 250 pM TGF for 1 hour. Cells
were then fixed and processed for immunofluorescence microscopy with antibodies
against Smad2 to observe Smad2 subcellular localization. DAPI was used to visualize
DNA. Representative images from at least 3 independent replicate images are shown. Bar
= 10 µm.
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4.4.7 Knockdown of aPKC increases TGF induced apoptotic
response via p38 MAPK
TGF receptors can activate the p38 MAPK pathway to stimulate apoptosis [18,
46]. We next examined whether the increased p38 MAPK signalling observed in aPKC
silenced cells could sensitize cells to TGF induced apoptotic response. To measure
apoptosis, control and aPKC silenced cells were treated with or without TGF for 48
hours, and the percentage of apoptotic cells was measured through the assessment of
nuclear morphology after Hoescht staining. Cells treated with control SiRNA showed a
modest apoptotic response to TGF, which is in contrast to aPKC-silenced cells, which
exhibited a significant increase in cell death when treated with TGF (Figure 4.7A).
Importantly, treatment of aPKC silenced cells with a p38 MAPK inhibitor reduced the
number of apoptotic nuclei, indicating the apoptotic response observed was downstream
of p38 MAPK. Furthermore, cleaved-Parp levels (a marker of apoptosis) induced by
TGF were significantly higher in aPKC silenced cells than in control cells (Figure
4.7B). Similar to the above results, p38 MAPK inhibition reduced cleaved-Parp levels in
aPKC silenced cells indicating that the apoptotic response observed in aPKC silenced
cells likely involved the p38 MAPK pathway (Figure 4.7B). We next tested another
NSCLC cell line, H1299 cells, for apoptotic response and Smad2 nuclear accumulation to
assess whether the results we were observing were cell type specific.

4.4.8 Knockdown of aPKC also mediates TGF effects in H1299
NSCLC cells
We next examined whether the results we observed in A549 cells could be
recapitulated in H1229 cells, a second NSCLC cell line. We tested whether aPKC
knockdown in H1299 cells altered Smad2 nuclear accumulation upon TGF stimulation.
Using an immunofluorescence approach as we have done above (Figure 4.3A), we
examined the localization of Smad2 after TGF treatment in control, and aPKC
knockdown cells. Similar to our findings with A549 cells, TGF treatment increased the
nuclear localization of Smad2 in H1299 cells transfected with control siRNA (Figure
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4.8A). Furthermore, siRNA targeting aPKC reduced TGF induced nuclear accumulation
of Smad2 (Figure 4.8A). We also tested whether aPKC knockdown cells showed
enhanced p38 MAPK phosphorylation by treating cells with TGF in a timecourse as we
have done before for A549 cells. As we had seen in A549 cells, aPKC-silenced H1299
cells also showed an enhanced p38 MAPK response compared to control cells (Figure
4.8B). Furthermore, we also observed that this increased p38 MAPK signalling correlated
with an increased apoptotic response in aPKC knockdown cells (Figure 4.8C), and that
this effect was abrogated with a p38 MAPK inhibitor. Importantly, these results are in
agreement with our A549 cell data. After seeing that the results we had observed did not
seem to be cell type specific, we next wanted to investigate the mechanisms for these
altered responses in aPKC knockdown cells. The TGF signalling pathway to p38
MAPK involves the recruitment and activation of the ubiquitin ligase TRAF6 [21, 22].
To gain mechanistic insight into why aPKC silenced cells showed enhanced p38 MAPK
levels, we next examined the role of TRAF6 in this pathway.
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Figure 4.7
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Figure 4.7. aPKC knockdown enhances TGF induced apoptotic response
(A) A549 cells transfected with control siRNA (siControl) or siRNA directed at the
aPKC isoforms (PKC/) were serum deprived and treated with or without 250pM TGF
for 48 hours in the presence or absence of a p38 MAPK inhibitor. Hoescht 33342 was
used to stain the nuclei of cells prior to image acquisition and cell counting.
Quantification of apoptotic nuclei (yellow arrowheads) from four independent
experiments are expressed graphically to the right of the representative images.
(n=4±SEM, Two-way ANOVA, *=p<0.05)
(B) A549 cells were treated as in (A) and then lysed. Cell lysates were processed for
SDS-PAGE and immunoblotted with anti ()-cleaved PARP and anti-Actin antibodies.
Average densitometrical analysis from 4 independent replicate experiments is shown
graphically below the representative immunoblot. (n=4±SEM, Two-way ANOVA,
*=p<0.05.)
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Figure 4.8
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Figure 4.8. aPKC knockdown in H1299 cells also reduces Smad2 nuclear
accumulation, increases p38 MAPK levels, and enhances apoptosis, similar to A549
cells
(A) H1299 NSCLC cells were transfected with the indicated siRNA, serum starved and
treated with 250 pM TGF for 1 hour. The cells were processed for immunofluorescence
microscopy with antibodies against Smad2. DAPI was used to visualize DNA.
Representative images from at least 3 independent replicate experiments are shown. Bar
= 10 µm
(B) H1299 NSCLC cells transfected with the indicated siRNA were serum starved and
treated with 250 pM TGF for 30 minutes, washed, and further incubated for 1 or 4 hours
prior to lysis. Lysates were then processed for SDS-PAGE and immunoblotted with anti
()-phospho-specific p38 and total p38 MAPK antibodies as well as anti-PKC and antiPKC antibodies as indicated on the right of the panels. Representative immunoblots
from at least 3 independent replicate experiments is shown.
(C) H1299 NSCLC cells transfected with control siRNA (siControl) or siRNA directed at
the aPKC isoforms (PKC/) were serum deprived and treated with or without 250pM
TGF for 48 hours in the presence or absence of a p38 MAPK inhibitor. Hoescht 33342
was used to stain the nuclei of cells prior to image acquisition and cell counting.
Quantification of apoptotic nuclei (yellow arrowheads) from four independent replicate
experiments are expressed graphically to the right of the representative images.
(n=4±SEM, Two-way ANOVA, **= p<0.01)
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4.4.9 Knockdown of aPKC increases TRI-TRAF6 complexes
TGF-stimulated apoptosis mediated via p38 MAPK has been previously
reported to occur through the recruitment and activation of the E3 ubiquitin ligase
TRAF6 [21, 22]. Briefly, upon TGF activation, TRAF6 is recruited to TRI of the
TGF receptor complex. This causes TRAF6 to become auto-ubiquitinated, which
activates TAK1 (a MAP3K), which in turn triggers the MAPK cascade to p38 activation
[21, 22]. We have previously shown that aPKC expression can alter binding patterns of
TRI substrates [26]. We hypothesized that the increased TGF-p38 MAPK signals we
observed in aPKC silenced cells, may have beeen due to an increased association of
TRAF6 with TGF receptors when aPKC was depleted. Indeed we have also previously
shown that overexpressed aPKC can negatively regulate steady-state TGF receptor
levels and that knockdown of aPKC reduces the rate of activated TGF receptor complex
degradation [25]. We tested this idea by immunoprecipitating endogenous TRAF6 from
control, and aPKC silenced cells, followed by immunoblotting for exogenously expressed
TRI (Figure 4.9). Interestingly, TRI associated to a greater degree with TRAF6 in the
absence of aPKC expression (Figure 4.9). This finding suggested that TRI-TRAF6
complexes were more stable in aPKC knockdown cells. We reasoned that this increase in
TRI-TRAF6 complexes may have led to increased TGF-induced p38 MAPK signals in
aPKC silenced cells. To test this idea, we next examined whether TRAF6 knockdown
could abrogate the p38 MAPK signalling seen in aPKC silenced cells.
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Figure 4.9. aPKC knockdown increases levels of TRI-TRAF6 complexes
HEK 293T cells transfected with control siRNA (siControl) or siRNA targeting aPKC
isoforms (PKC/) were co-transfected with cDNA encoding Flag-tagged TGF type 1
receptor (FlagTRI) as indicated. Cells were then lysed and endogenous TRAF6 was
immunoprecipitated (IP) using anti-TRAF6 antibodies. The immunoprecipitates were
processed for SDS-PAGE and immunoblotted with anti ()-Flag and anti-TRAF6
antibodies to visualize immunoprecipitated Flag-tagged TRI and TRAF6 (top panel).
Cell lysates were immunoblotted with anti- PKC, anti-PKC, anti-Flag and anti-TRAF6
antibodies to visualize endogenous aPKC and TRAF6 levels as well as expressed Flagtagged TRI (bottom panel). Representative immunoblots from at least from 3
independent replicate experiments are shown.
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4.4.10

Knockdown of TRAF6 in aPKC silenced cells reduces
activated p38 MAPK and apoptosis

Because aPKC knockdown was enhancing P-p38 MAPK levels in response to
TGF, we inferred that knockdown of TRAF6 may reduce this effect. We used siRNA to
knockdown the aPKCs alone, TRAF6 alone, or aPKC and TRAF6 together. As we had
seen before, aPKC silencing increased P-p38 MAPK levels in response to TGF (Figure
4.10A). Interestingly, in cells where we depleted protein levels of aPKC and TRAF6
simultaneously by siRNA knockdown, TGF-induced p38 MAPK phosphorylation was
abrogated (Figure 4.10 A). Furthermore, as we had observed before, aPKC knockdown
cells exhibited an increased TGF-induced apoptotic response as measured by Hoescht
staining and quantitation of pyknotic nucleic (Figure 4.10B). In contrast, simultaneous
knockdown of TRAF6 and aPKC reduced the TGF-induced apoptotic effect (Figure
4.10B), which corresponds to the reduced p38 MAPK phosphorylation seen in these cells
(Figure 4.10A). These results suggested that the enhanced p38 MAPK signalling and
apoptosis we had observed in aPKC silenced cells were TRAF6 dependent. Although, we
found that p38 MAPK was enhancing apoptosis via a TRAF6 dependent mechanism in
aPKC depleted cells, we still did not resolve why Smad2 nuclear translocation was
reduced. We therefore next assessed Smad2-Smad4 complex formation in aPKC
knockdown cells.
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Figure 4.10
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Figure 4.10. Knockdown of TRAF6 abrogates TGF-p38 MAPK effects observed in
aPKC depleted cells
(A) A549 cells transfected with control siRNA, or siRNA directed at aPKC (siPKC/),
TRAF6 (siTRAF6), or both aPKC and TRAF6 (siPKC/ + TRAF6) were serum starved
and treated with 250 pM TGF for 1 hour prior to lysis. Lysates were then processed for
SDS-PAGE and immunoblotted with the anti ()-phospho-specific p38 and total p38
MAPK antibodies as indicated on the right of the panels. Immunoblotting using antiTRAF6, anti-PKC, and anti-PKC antibodies were used to determine knockdown levels.
Average P-p38 MAPK levels from 3 independent replicate experiments were quantitated
by densitometrical analysis and graphed below the representative immunoblots
(n=3±SEM, Two-way ANOVA, **= p<0.01).
(B) A549 cells transfected as in (A) were serum deprived and treated with or without 250
pM TGF for 48 hours. Hoescht 33342 was then used to stain the nuclei of cells prior to
image acquisition and cell counting. Quantification of apoptotic nuclei (yellow
arrowheads) from three independent experiments are expressed graphically below the
representative images. (n=3±SEM, Two-way ANOVA, *=p<0.05).
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4.4.11

Knockdown of aPKC reduces Smad2-Smad4 complex
formation

In the basal state, Smad2 is predominantly localized to the cytoplasm, however, in
response to phosphorylation, Smad2 associates with Smad4, and accumulates in the
nucleus [2, 8]. Although phosphorylated R-Smads can activate transcription alone, a full
TGF response requires complex formation of Smad2 and Smad4 [47].

We next

examined whether aPKC silencing was altering TGF-induced Smad2-Smad4 interaction
by immunoprecipitating Smad2 and immunoblotting for Smad4 in Control and aPKC
silenced cells (Figure 4.11). As expected, in cells transfected with control siRNA, the
addition of TGF increased the amount of Smad4 co-immunoprecipitating with Smad2
indicating that TGF treatment induced Smad2-Smad4 complex formation (Figure 4.11).
In contrast, aPKC silenced cells exhibited a signficantly reduced level of Smad2
associated Smad4 with TGF addition (Figure 4.11). This indicated that the reduction in
gene response we observed in aPKC silenced cells may be due to reduced Smad2-Smad4
interaction. We next examined whether SARA could be playing a role in this process.
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Figure 4.11
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Figure 4.11. aPKC knockdown reduces TGF-induced Smad2-Smad4 complex
formation
A549 cells transfected with control siRNA (siControl) or siRNA directed at the aPKC
isoforms (PKC/) were serum starved and treated with or without 250 pM TGF for 1
hour prior to lysis. Cell lysates were then immunoprecipitated (IP) using anti ()-Smad2
antibodies, followed by immunoblotting for Smad4 to determine the level of induction of
Smad2-Smad4 complex formation. Cell lysates were included to show relative
endogenous protein expression. Average densitometrical analysis from three independent
replicate experiments is shown below the representative immunoblots. (n=3 ±SEM, Twoway ANOVA, **=p<0.01).
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4.4.12

Knockdown of aPKC increases SARA expression

The subcellular localization of R-Smads can be controlled by a balance between
binding factors that retain them in the cytoplasm vs. transcription factors that retain them
in the nucleus. One such cytoplasmic retention factor is the Smad anchor for receptor
activation (SARA), an early endosome anchored FYVE domain containing protein.
Under normal conditions, Smad2 can be anchored to the early endosome by SARA [12,
15, 48]. Originally the function of SARA was described to recruit non-phosphorylated
Smad2 to the activated receptor complex [12, 15, 48]. However, a more complex role for
SARA is emerging, as recent reports have indicated that SARA may be dispensable for
TGF signalling [49], and also that SARA may be involved in more general endocytic
trafficking mechanisms [50]. Because we have previously reported alterations in
membrane trafficking of TGF receptors upon PKC inhibition ([25]; Chapter 2), we next
examined whether SARA levels were altered in aPKC silenced cells. Interestingly, aPKC
silenced cells showed an increased total protein expression of SARA compared to control
cells (Figure 4.12A), although no appreciable alterations were observed in early
endosome localization with aPKC knockdown by immunofluorescence microscopy
(Figure 4.12B). We next analyzed whether the increased SARA levels could be retaining
Smad2 in the cytoplasm.

4.4.13

Knockdown of aPKC increases cytosolic rentention of
Smad2 by SARA

SARA preferentially binds unphosphorylated forms of Smad2, and it is thought
that the activated receptor complex formed at the plasma membrane is captured by SARA
in the early endosome, which then presents the bound R-Smad to the receptor for
phosphorylation [2]. Smad2 then dissociates from SARA and associates with Smad4
prior to nuclear translocation and the initiation of transcription [2]. We examined whether
the increased SARA levels in aPKC silenced cells correlated with enhanced cytoplasmic
retention. We immunoprecipitated Smad2 from control and aPKC silenced cells treated
with TGF to examine whether SARA was dissociating from Smad2 upon TGF
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addition. As expected, TGF addition causes a dissociation of SARA from Smad2
(Figure 4.13). Smad2 dissociation from SARA is followed by a concomitant increase in
the binding of Smad4, similar to what we observed in Figure 4.11. Interestingly, in aPKC
silenced cells TGF addition reduced SARA-Smad2 dissociation, and also reduced the
binding of Smad2 to Smad4 (Figure 4.13). This implied that SARA was retaining Smad2
in the cytoplasm to a greater degree in aPKC silenced cells, and was likely responsible
for the observed reduced nuclear translocation of Smad2 that we had observed. Thus, in
summary, we found that aPKC silenced cells showed reduced Smad2 nuclear
accumulation in response to TGF probably due to an increased cytoplasmic retention by
SARA, and furthermore, aPKC silenced cells showed increased TRI-TRAF6 complex
levels, and enhanced TGF-induced p38 MAPK phosphorylation and apoptotic response
(summarized in Figure 4.14).
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Figure 4.12
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Figure 4.12. Knockdown of aPKC increases steady state SARA protein levels
(A) A549 cells transfected with control siRNA (siControl) or siRNA targeting aPKC
isoforms (PKC/) were lysed and immunoblotted using antibodies for SARA and Actin
as indicated on the right of the panels. Average densitometrical analysis of steady state
SARA levels from three independent experiments is shown graphically to the right of the
representative immunoblots. (n=3±SEM, Two way ANOVA, *=p<0.05).
(B) aPKC knockdown does not inhibit the localization of SARA in the early endosome.
A549 cells were transfected as described in Panel A and processed for
immunofluorescence microscopy to visualize EEA1 (green) and SARA (red). DAPI was
used to visualize DNA (blue). Representative images from at least 3 independent
experiments are shown.Bar = 10m.
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Figure 4.13
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Figure 4.13. Knockdown of aPKC reduces TGF induced Smad2 release from
SARA
A549 cells transfected with control siRNA (siControl) or siRNA directed at the aPKC
isoforms (PKC/) were serum starved and treated with or without 250 pM TGF for 1
hour prior to lysis. Cell lysates were then immunoprecipitated (IP) using anti ()-Smad2
antibodies, and subjected to SDS-PAGE and immunoblotting using -SARA, -Smad4
and -Smad2 antibodies. IgG heavy chain is indicated. Cell lysates were included to
show relative endogenous protein expression. Average densitometrical analysis of Smad2
associated SARA levels from three independent replicate experiments is shown
graphically below the representative immunoblots. (n=3 ±SEM, Two Way Anova,
*=p<0.05).
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Figure 4.14. aPKC knockdown alters TGF induces Smad-dependent and Smadindependent pathways
Knockdown of aPKC increased steady state levels of SARA. aPKC knockdown cells also
exhibit reduced Smad2 nuclear accumulation in response to TGF due to increased
SARA mediated Smad2 cytosolic retention, and reduced Smad2-Smad4 complex
formation. Knockdown of aPKC also increased levels of TRI-TRAF6 complexes, and
enhanced TGF-induced, TRAF6-dependent p38 MAPK phosphorylation to stimulate
apoptotic response.
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4.5 Discussion
The TGFβ pathway controls an array of developmental and homeostatic processes
and alterations in the pathway are associated with various pathologies such as fibrosis
and cancer. Given the varied responses associated with a TGF signal, it is clear that the
context dependent execution of signalling may be regulated at multiple levels. We have
recently demonstrated an important role for aPKC in regulating TGF signals. More
specifically, we have previously reported that aPKC alters TGF receptor trafficking, as
well as the execution of a full EMT response through Par6 signalling. Here we have
found that aPKC knockdown alters both Smad-dependent and the Smad-independent p38
MAPK signalling pathways.
In this report we examine the transcriptional changes associated with TGF
signalling in an aPKC silenced background. In this context, we found that several TGF
stimulated genes showed reduced transcriptional activity. We discovered that aPKC
silencing played an important role in allowing a full Smad2 nuclear translocation.
Interestingly, we found aPKC expression was also required for a full Smad2-Smad4
interaction following TGF stimulation. How aPKC controls Smad2-Smad4 dynamics is
an area that requires further examination.
One possibility is an alteration in the access of Smad4 for Smad2. The correct
subcellular localization of Smad2 is controlled by trafficking of Smads and their
association with SARA. In this report we find that the knockdown of aPKC increased the
basal protein levels of SARA. This finding is important, because increased SARA levels
have been reported to reduce TGF receptor degradation, and also to correlate with the
maintenance of epithelial phenotype [13, 51]. Given our previous finding that aPKC
alters the membrane trafficking of the TGF receptors [25], it would be interesting to
explore whether aPKC alters the function or localization of SARA to control the context
under which Smads are signalling. Although we did not detect appreciable changes in
early endosome localized SARA levels, it is possible that in aPKC-silenced cells, the
normal trafficking of SARA (and its binding partners) to other subcellular compartments
could be altered. Indeed, a very recent report has implicated SARA in general endocytic
processes via classical ESCRT complex machinery [50]. More specifically, the correct
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subcellular trafficking of the EGFR from the early endosome to late endosomes to
regulate EGFR degradation was dependent on SARA, implicating SARA with a more
general role in endocytic trafficking than was previously appreciated [50]. This may have
important implications with respect to our findings that aPKC knockdown reduces TGF
receptor degradation and stabilizes particular TGF receptor-protein complexes [25, 26].
One possibility is that aPKC controls the normal degradative trafficking of the TGF
receptors, and depletion of aPKC leads to an accumulation of SARA and TGF receptor
complexes. Indeed, aPKCs has previously been reported to be involved in the trafficking
of membrane proteins, as well as being involved in the passage of EGFR to lysosome
targeted endosomes through the anchoring protein p62 [52]. Whether the knockdown of
aPKC in our model is causing a reduced passage of receptors to lysosomes is an
important area for future study. Furthermore, if this is the case, it would be important to
examine whether altered SARA trafficking changes the subcellular availability of Smad4
for Smad2. Interestingly, although TGF receptors can phosphorylate Smad2 in the
absence of SARA, it has been reported that SARA is required for proper Smad2 nuclear
translocation [15]. Furthermore, although inhibiting TGF receptor internalization from
the membrane only slightly altered phosphorylated Smad2 levels, it did significantly
impact the ability of Smad2 to dissociate from SARA [15].

This suggests that the

coordinated function and subcellular localization of SARA and associated Smads are
important for mediating TGF dependent transcription properly.
Interestingly, our transcriptional analyses revealed that in aPKC silenced cells,
some genes showed a muted response to TGF (e.g. PAI-1, Smurf2, MMP9) but others
responded to the same degree (e.g. SNAI1, SNAI2, E-Cadherin). Surprisingly, this is
consistent with a report that TGF can stimulate two classes of genes: genes which are
Smad4 dependent and genes which are Smad4 independent [53]. Using genetic
knockdown and microarray analyses, the authours identify PAI-1 and Smurf1 as Smad4
dependent genes, and SNAI-2 as a Smad4 independent gene [53]. This suggests that
possibly some of the reduced transcripts we observe in aPKC silenced cells are due to
Smad4 not accessing the nucleus in response to TGF. This is consistent with our
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findings that the SARA-Smad2-Smad4 exchange and Smad nuclear translocation is
altered in aPKC silenced cells.
Interestingly, a recent analysis of Smad mutations in colorectal cancer indicates
that a great proportion of mutations in Smad4 map to the conserved R-Smad binding
surface [54]. Furthermore, the authors report several other R-Smad mutations that reduce
Smad4 binding [54] – indicating that loss of Smad complex formation is an important
event during colorectal tumor formation. This opens the possibility that a posttranslational modification of Smad4 may inhibit Smad2 interaction in aPKC silenced
cells. Certainly, this has been shown before, as Smad4 ubiquitination and
deubiquitination play pivotal roles in Smad complex formation and disassembly [47, 55].
Interestingly, previous reports have described Smad4 dependent and Smad4 independent
gene changes with respect to TGF. Whether ubiquitination status of Smad4 alters
Smad2 binding in aPKC silenced cells remains to be elucidated.
Here, we also made a novel finding that the knockdown of aPKC increased and
prolonged TGF-induced p38 MAPK activation, and this sensitized NSCLC cells to
apoptosis. We found that knockdown of aPKC stabilized TRI-TRAF6 complexes, and
that knockdown of TRAF6 in aPKC silenced cells returned p38 MAPK activation levels
back to control levels. This result is important, because it suggests that the variability
seen in p38 MAPK activation by TGF in various cell models may be due to factors that
destabilize TRAF6-receptor complexes, such as the expression of aPKC.
In line with our results, increases in p38 MAPK activity have been reported
before upon aPKC silencing [31] indicating that aPKC may attenuate p38 MAPK
signalling in multiple cancer cell types. Interestingly, when aPKC is knocked down, p38
MAPK is able to signal an apoptotic response indicating that in some situations aPKC
may be a viable therapeutic target. However, the role of p38 MAPK in cancer is also
complex, and context dependent – and in addition to sensitizing cells to a death response,
p38 activity is also associated with cancer cell survival and both the stimulation and
suppression of EMT [20, 56, 57]. The role of Smad2 linker phosphorylation by MAPK
members in TGF signalling has also yielded mixed results. The original reports show
that linker phosphorylation by MAPK blocked Smad2 nuclear accumulation [43, 58],
however, nuclear stabilization of Smad2 by linker phosphorylation has also been reported
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[44, 59] suggesting that Smad linker phosphorylation is more complex than originally
thought, and thus requires further examination. We report here that the enhanced p38
MAPK activation in aPKC silenced cells was not responsible for the reduction in Smad2
nuclear accumulation. It would be interesting to see whether linker phosphorylation alters
Smad2-Smad4 complex formation. In any case, the role of Smad linker phosphorylation
is complex and requires further detailed examination.
In conclusion, we have found aPKC plays multiple roles in TGF signalling and
the localization and expression patterns of aPKC may dictate how a cell responds to
TGF. This is especially important since aPKCs have recently been implicated cancer
progression [28, 60] and aPKC has been classified as a human oncogene [29, 61].
Although many interesting questions still remain to be answered, our work suggests that
aPKCs may alter the way cells respond to TGF signals.

4.6 Footnotes
The work carried out in this study was supported by the Canadian Institutes of Health
Research (GMDG, grant: MOP-93625).
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Chapter 5

5.1 General Summary
TGF regulates pleiotropic signalling pathways that execute key signalling
programs, which have important roles in development, tissue homeostasis and disease. It
is now clear that the complex and versatile responses to TGF signalling are substantially
defined by regulatory mechanisms that control the intensity and duration of TGF
signals, but also by interacting protein partners that can define which particular signal
will be propagated. It is also clear that this complex regulation of TGF signals is
inherently linked to trafficking, as the internalization and subcellular itinerary of the
TGF receptors can control signalling outcome.
It has been shown that TGF signalling through the Smad family of proteins is
propagated when the receptors internalize via clathrin-coated pits into the early
endosome, whereas TGF receptors are more likely to be degraded when they internalize
via membrane rafts. Thus, receptor trafficking is an important aspect of whether a Smad
signal is propagated or degraded [1]. Furthermore, upon TGF stimulation, non-Smad
pathways are also initiated. These include the TGF-Par6 pathway which stimulates cells
to undergo EMT [2, 3], as well as various MAPK pathways including p38 MAPK
signalling which can stimulate epithelial cells to undergo apoptosis [4-6]. Understanding
the factors that contribute to the regulation of the trafficking and signalling of the TGF
pathway are an important area of research.
In this thesis I examined the role of the aPKC class of proteins in regulating
TGF signalling processes and outcomes. aPKC has known roles in endocytic
trafficking, thereby linking it to classical TGF-Smad signal transduction. Furthermore,
aPKC is a direct binding partner of both Par6 and TRAF6 thereby linking it to both the
TGF-Par6 pathway as well as the TGF-p38 MAPK pathway (respectively); however,
the role of aPKC in these pathways was not fully understood. The overall purpose of this
study was to examine whether aPKC modulates various TGF pathways, while
characterizing mechanisms and outcomes contributing to these effects. I evaluated
whether broad pharmacological PKC inhibition altered membrane trafficking patterns of
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the TGF receptors, and subsequently whether siRNA knockdown of aPKC isoforms
altered TGF receptor dynamics and signalling patterns. Furthermore, I examined the
role of aPKC in the TGF-Par6 pathway, and discovered that both aPKC isoforms could
phosphorylate Par6 to facilitate the EMT of NSCLC cells. Finally, I examined the role of
aPKC in the initiation of TGF genetic program and discovered that aPKC knockdown
reduces Smad2 nuclear accumulation through an increased level of SARA mediated
retention. Furthermore, I also showed that knockdown of aPKC increases TRI-TRAF6
complexes and enhances p38 MAPK activation upon TGF stimulation leading to
increased apoptosis. Thus, I have shown that aPKC is intricately linked to TGF
signalling, and its expression can modulate TGF signalling outcomes. A brief summary
of the major findings from this thesis is described in Figure 5.1.
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Figure 5.1. aPKC affects TGF signalling pathways
In this thesis I have found that aPKC isoforms affect both Smad-dependent and Smadindependent TGF signalling pathways. aPKC plays a role in TGF receptor early
endosome transit, as well as SARA-Smad2-Smad4 binding dynamics. aPKC also
phosphorylates Par6 to facilitate TGF induced EMT. Finally, aPKC expression regulates
TRI-TRAF6 complexes to control the ability of TGF to signal to p38 MAPK.
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5.2 General Discussion and Future Directions
5.2.1 Regulation of TGF receptor trafficking and signalling by
atypical protein kinase C
Although it is now well established that the endocytic itinerary of the TGF
receptors can influence TGF signalling patterns, the proteins that control these processes
are less understood. PKC family members are known regulators of intracellular traffic [7]
but their potential role in TGF signalling was not explored. In chapter 2 of my thesis I
examined the role of PKC in TGF signalling by examining the trafficking and
degradation patterns of the TGF receptors with pharmacological inhibition of PKC. We
discovered that broad inhibition of PKC isoforms shifted the TGF receptors into the
early endosome, and reduced TGF receptor degradation. Interestingly, we also
pinpointed that the atypical class of PKCs (aPKCs) was responsible for enhancing
phospho-Smad2 levels. This is an important finding, because specifying PKC isoforms
relevant to particular pathways will aid in the development of selective therapeutic
approaches. Interestingly, when we knocked down aPKC using siRNA, we were able to
extend TGF induced P-Smad2 levels, which corresponded to a reduced TGF receptor
degradation. However, in chapter 4, when we examined the transcriptional output of this
enhanced Smad2 phosphorylation we determined that aPKC knockdown actually reduced
TGF mediated transcription of several genes. Interestingly, we then found that TGFinduced Smad2 nuclear accumulation was reduced in aPKC depleted cells, and we
showed this was due to an enhanced capacity of SARA to retain Smad2 in the
cytosplasm. This is an interesting finding for a number of reasons. Firstly, it suggests that
the proper exchange of SARA-Smad2 complexes to Smad2-Smad4 complexes is a
regulated process that may require more than just phosphorylation of the R-Smad.
Certainly, it is in line with a previous report that the proper subcellular localization
through internalization of the receptors is required for SARA to dissociate from Smad2
upon phosphorylation [8]. This is particularly important, as there has been some
controversy with respect to SARA, as some reports indicate SARA as being dispensable
for the phosphorylation of R-Smads [9, 10]. Consistent with the above reports, we show
that Smad2 still becomes phosphorylated in aPKC knockdown cells, however,
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dissociation of Smad2 from SARA is severely impaired, which in turn impairs Smad2
nuclear translocation and transcriptional response. However, many questions still need to
be answered. For example, how aPKC knockdown impair SARA-Smad2 dissociation still
needs to be identified. One possibility is a change in trafficking dynamics of the TGF
receptors and SARA. We have shown that the knockdown of aPKC increases the total
protein levels of SARA (in chapter 4) and also slows TGF receptor degradation (in
chapter 2). One possibility is that TGF receptor-SARA complexes are being internalized
slower in aPKC knockdown cells, and thus are accessing intracellular degradatory
machinery (such as Smurf1, Smurf2 or other ubiquitin ligases) at a slower rate. This
could effectively explain why we see increased receptor levels, SARA levels, and
reduced SARA-Smad2 dissociation, as internalization is required for the degradation of
these proteins as well as proper Smad2 dissociation and nuclear translocation [1, 8].
Furthermore, if this is the case, understanding the mechanisms that control the reduced
degradation patterns and altered subcellular itinerary of the TGF receptors is also
needed. Certainly, a recent report implicates SARA in controlling the trafficking patterns
of the EGFR through the recruitment of the ubiquitination factor RNF11 [11].
Importantly, aPKC is a known binding partner of the TGF pathway ubiquitin ligsase
Smurf1, and has been shown to recruit Smurf1 to degrade substrate proteins such as
RhoA [12]. It would be interesting to test whether aPKC was facilitating the recruitment
of Smurf1 to the TGF receptor-SARA complex to control their correct trafficking and
degradation. If this was the case, presumably in aPKC knockdown cells a lack of Smurf1
recruitment could lead to an accumulation of both TGF receptors and SARA, as well as
mislocalized intracellular targeting of the activated complex. Thus, whether the
ubiquitination status of TGF receptor complexes is altered to change subcellular
trafficking is an area that requires further investigation. Also, we have not examined
whether aPKC controls these dynamics through phosphorylation of the TGF receptors.
Interestingly, aPKC can phosphorylate the EGFR to change its trafficking itinerary from
degradation to recycling [13]. Whether aPKC can phosphorylate TGF receptor
complexes is an area that needs to be addressed. Another finding we made in chapter 4
was that aPKC knockdown increased TGF-receptor-TRAF6 complexes which enhanced
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p38 MAPK signalling and subsequent apoptotic response. Interestingly, although it is
well accepted that TGF can activate MAPK pathways, there has been skepticism about
the physiological importance of TGF-p38 MAPK signalling, particularly because the
activation does not occur in all cell lines, and many times the activation is much lower
than classical activators of the p38 MAPK pathway. My data certainly suggests that
enhanced TGF-TRAF6 receptor complex formation stimulates TGF-p38 MAPK
signalling; and importantly, this can be controlled by the expression of other proteins,
such as aPKC. This suggests that the variability seen in TGF-p38 MAPK activation in
various cell lines and models may be due to differences in the endogenous levels of
TGF receptor-TRAF6 complexes. How aPKC knockdown is stabilizing TRI-TRAF6 is
a question that still remains to be answered. Interestingly, some of the ideas mentioned
above for the SARA-Smad2 pathway, may also hold here. aPKC may be involved in
recruiting a ubiquitin ligase (such as Smurf1) for the degradation of TRI-TRAF6
complexes upon internalization. Thus, in aPKC knockdown cells, TRI-TRAF6 is
degraded less, and thus can activate p38 MAPK to a greater degree. Again, understanding
whether ubiquitination, or aPKC phosphorylation is involved in this process would be
interesting areas of study.
Although I have identified aPKC as an important player in signalling patterns of
the TGF receptors, clearly, a more thorough analysis of the internalization patterns of
the TGF receptors, and the mechanisms that control them is warranted for
understanding both Smad and non-Smad signalling pathways.

5.2.2 Atypical Protein kinase C phosphorylates Par6 to facilitate EMT
EMT is an important step in tumour progression, as it signifies that the once
immobile mass of growing carcinoma cells have escaped the physical constraints of the
epithelium and are gaining the capacity for independent movement. The TGF-Par6 axis
was previously shown to be an important pathway in EMT through TRII mediated
phosphorylation of Par6 [2, 3]. In chapter 3, I showed that both aPKC isoforms ( and )
phosphorylate Par6 on S345 to stimulate EMT [14]. Importantly, this was the first time
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another protein other than TRII was shown to phosphorylate Par6 on this critical
residue. Interestingly, I found that aPKC co-localizes with TGF receptors at the leading
edge of migrating cells, and that aPKC associates with TGF receptors through Par6.
Furthermore, upon TGF stimulation, which triggers EMT in A549 adenocarcinoma
cells, aPKC becomes activated as indicated by an increase in its phosphorylation status.
We found that both aPKC isoforms are able to phosphorylate Par6, and that both the
association with Par6 and kinase activity of aPKC were important for this
phosphorylation event. When we silenced aPKC using siRNA we significantly reduced
the ability of TGF to target RhoA and E-cadherin for degradation and subsequently
actin stress fibre formation, EMT and migration were reduced (Figure 5.2A). When we
re-introduced a phospho-mimetic Par6 into aPKC silenced cells, we rescued EMT as
measured by a restored loss in RhoA and E-cadherin [14].
Given the recent important roles reported for both Par6 and aPKC in the
generation and progression of various cancers, we believe that Par6 phosphorylation by
aPKC may be central to various extrinsic cues that can lead to the EMT. In addition to
TGF stimulation, EMT has been shown to occur in response to ErbB2 receptor tyrosine
kinase activation [15]. Indeed, Aranda and colleagues have shown that activation of
ErbB2 leads to a complex formation between the ErbB2 receptor and Par6/aPKC and
disrupts apical-basal polarity and tissue architecture. They further showed that inhibiting
the interaction of Par6 and aPKC (using a Par6 mutant that does not bind aPKC) was
required for this ErbB2 induced disruption of acinar formation in mammary epithelial
cells [15]. Although Par6 S345 phosphorylation was not examined in this report, Par6
phosphorylation was later shown to be an important event in acinar disruption in murine
mammary gland cells downstream of TGF[3]. Given the observations that both
phosphorylation, and aPKC-Par6 interaction are important for acinar disruption and
tissue organization in mammary gland epithelial cells, it would be interesting to
investigate whether aPKC induced Par6 phosphorylation is a common theme in other
tumour promoting pathways.
It is becoming increasingly clear that aPKC can execute its functions through
phosphorylation events of interacting partners. Another interesting substrate of aPKC is
Lgl, a member of the Scribble complex. First identified in D. Melanogaster, Scribble
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complex proteins (which also include Scrib and Dlg) are localized to the basolateral
regions of the cell and they help maintain normal junctional complexes and cell polarity
[16-18]. Loss of Scribble complex proteins through genetic deletion results in a loss of
cell polarity and growth control [16-18]. Interestingly, expression or mislocalization of
these proteins is often observed in various carcinomas and all three members of the
Scribble complex are considered tumour suppressor genes [18-20]. Importantly, active
aPKC can phosphorylate Lgl to regulate its displacement from the apical domain, and in
turn, Lgl inhibits aPKC function at the basolateral domain [21-25].

This mutual

exclusion of aPKC and Lgl is important for tissue homeostasis, as cells overexpressing
aPKC or depleted of Lgl leads to loss in cell polarity and hyperproliferation [23].
Strikingly, Lgl levels are reduced in various human solid tumours including human
prostate, breast, ovary and lung [26] and reduced Lgl function correlates with reduced
cell-cell adhesion [27]. Given the roles of both Lgl and Par6 phosphorylation by aPKC in
cell-cell adhesions, it would be interesting to examine whether aPKC-Par6
phosphorylation plays a role in Lgl localization and activity during cancer progression –
as it is likely that there is interplay between polarity complexes during the dissolution of
tissue structure and tumour development.
A recent report has highlighted a role for another member of the polarity complex,
Par3, in protecting against cancer progression [28]. Par3 which is an interacting partner
of both Par6 and aPKC, as well as an inhibitor of aPKC kinase activity, has been reported
to be a suppressor of breast cancer metastasis [28]. The authors report a down-regulation
of Par3 in human breast cancer and that the loss in expression of Par3 inhibits E-cadherin
junction stability, disrupts actin dynamics, and decreases cell-cell cohesion via a Tiam1Rac-GTP pathway in mammary epithelial cells. Interestingly, knockdown of Par3 induces
metastasis without an overt loss in E-cadherin or an increase in classical EMT phenotype
(as measured by classical markers of EMT, snail and fibronectin). Instead, the loss of
Par3 was observed to increase E-cadherin recycling from the membrane, thereby
reducing the levels of stable and immobile E-cadherin at cell junctions which ultimately
leads to a decreased cell-cell cohesion [28]. Our own results suggest that knockdown of
aPKC increases basal E-cadherin levels in lung adenocarcinoma cells (chapter 3), and it
would be interesting to explore E-cadherin recycling and junctional stability.
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Interestingly, another report outlines a role for E-cadherin translocation during EMT
through the endocytic adaptor protein Numb [29]. In epithelial cells, Numb was described
to stabilize junctional complexes by binding to E-Cadherin and Par3 at adherens
junctions [29]. However, upon stimulation with the EMT inducing growth factor HGF
(hepatocyte growth factor), Numb dissociated from E-cadherin, and then sequestered the
aPKC-Par6 complex to the plasma membrane and the cytosol. Both Par3 and E-cadherin
were re-localized from the junction, leading to reduced cell-cell adhesion and the
facilitation of EMT [29, 30]. Interestingly, aPKC has been shown to phosphorylate Numb
to control integrin endocytosis at the leading edge of migrating cells, outlining an
important role for aPKC in the normal endocytic function of Numb [31]. Given the
recently described role for Numb in E-cadherin and Par complex subcellular localization
and subsequently cell-cell adhesion and EMT, it would be interesting to examine whether
Par6 phosphorylation directs the function of the endocytic adaptor Numb to control Ecadherin trafficking and recycling during EMT. Studying E-cadherin trafficking and
recycling is particularly interesting since as mentioned earlier, aPKC can alter the
trafficking, recycling and degradation patterns of membrane receptors [32, 33] and
furthermore, Par complex proteins have already been implicated in membrane
endocytosis and vesicular trafficking [34, 35]. Whether other polarity complex proteins
regulate normal and/or oncogenic cellular processes through vesicular trafficking is a
promising future area of study.
Thus, the Par polarity complex is considered to be involved in various cellular
polarization processes that facilitate directional cell migration, apico-basal polarity and
embryonic development. However, recent advances in our understanding of this complex
reveal that these proteins can have different functions depending on the interacting
partners, extracellular stimuli, and the cellular context in which the signalling occurs.
We have described above how the phosphorylation of Par6 leads to EMT, but
Par6 phosphorylation has also been reported to regulate axon specification in naïve
neurites [36], and invasive potential of epicardial cells [37]. Thus, the cellular outcomes
of Par6 phosphorylation may depend on the cell type, subcellular localization, availability
of binding partners and the combination of various extracellular and intracellular cues.
How aPKC phosphorylation of Par6 plays a role in these multiple contexts is an area that
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will require further investigation (Figure 5.2B). Specifically, we will likely require a
better understanding of the signalling patterns of the Par interactome, and whether aPKCPar6 phosphorylation alters the function and activation patterns of downstream effectors
(and vice versa). Both Par6 and Par3 act as scaffolding nodes for various binding partners
and effectors that allows this complex to elicit variable signals for multiple pathways.
The factors that determine the binding and/or activation of specific GTPases, as well as
the factors that control aPKC activity will likely be important in understanding how Par
proteins regulate growth, organization, and the maintenance of cellular homeostasis, but
also on cellular transformation and tumour progression.
Much work suggests that aPKC may be an attractive clinical target for protecting
against tumour progression in certain contexts. In support of this idea, the loss of function
experiments of aPKC in lung cancer cells reduces invasive activity and reduces tumour
growth and expansion in vivo [38, 39] and a targeted small molecule inhibitor of aPKCPar6 signalling is currently in early stage clinical trials for lung cancer [40-42]. Future
work will uncover the intricacies of Par signalling pathways in normal and oncogenic
circumstances. These new discoveries will undoubtedly help us further understand how
polarity proteins control basic biological processes, as well as identify targets to block
oncogenesis.
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Figure 5.2
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Figure 5.2. Roles for Par6 phosphorylation in EMT and Migration
(A) Proposed model for aPKC-Par6 induced plasticity.

TGF-dependent Par6

phosphorylation in epithelial cells leads to junctional complex disassembly through
Smurf1 mediated ubiquitination and degradation of RhoA. Degradation of RhoA leads to
the depolymerization of filamentous actin (F-Actin) and loss of structural integrity of the
cortical actin cytoskeleton, dissolution of junctional complexes, and subsequent reduction
in cell-cell adhesion. Par6 phosphorylation may also regulate Rho-GTPases at the leading
edge during cell migration. The aPKC-Par6 complex recruits Smurf1 to degrade RhoA at
the leading edge to promote protrusive activity. Par6 phosphorylation has also been
reported to specify axon differentiation, although the role of aPKC isoforms has not been
defined.
(B) Major questions surrounding aPKC-Par6 phosphorylation. Understanding Par
signalling will involve the investigation of the stimuli that control aPKC activation with
respect to Par6 phosphorylation, how the Par interactome modifies and is modified by
Par6 phosphorylation, and whether these factors contribute to homeostatic and oncogenic
processes.
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5.3 Limitations and Future Directions
The work carried out in this thesis was carried out in established cell lines using
human recombinant TGF protein, and the majority of it was conducted to gain a
mechanistic understanding of TGF signalling processes. Using cell lines provides a well
characterized simplified platform that can be easily evaluated to understand the
mechanistic biology of the TGF system. However, cell lines may not be fully
representative of the results one might gather in an in vivo system. It would be interesting
to test whether aPKC affects TGF induced EMT and apoptotic response using animal
tumour models. Indeed, in line with our data, others have examined the roles of aPKC
and Par6 in oncogenesis using mouse models [3, 38, 39] and have reported both aPKC
and Par6 expression and activity are involved in tumour progression and EMT. However,
how aPKC drives Par6 and or TGF mediated EMT in an in vivo setting is an area that
deserves further exploration. Along with this, it would be interesting to examine human
patient tumour samples and examine whether elevated P-Par6 levels correlate with aPKC
expression levels. Furthermore, another limitation of our studies is that we have been
studying these signalling pathways in 2-dimensional cell culture. Although this approach
is widely used, analysis of EMT and tumour progression in 3D culture would also be a
natural progression to understand the contributions of components of the ECM in our
signalling system. It would be extremely interesting to look at epithelial cell acini
formation and EMT in 3D cultures. Doing this while manipulating levels of aPKC and
Par6 in the context of TGF signalling would further our understanding of the role of
polarity protein dynamics in cell-cell junctional dynamics. Important contributions of the
ECM and integrin signalling have been reported before with respect to aPKC and Par6
polarization processes [43] and thus it would be exciting to study whether Par6
phosphorylation by aPKC plays a role in acini formation and or disruption by TGF.
Another limitation of my studies is that I have not been assigning isoform specific
functions between PKC and PKC. However, whenever I could, I examined PKC and
PKC individually to assess their contributions to TGF effects. For example, in chapter
2, I knocked down each aPKC individually and examine P-Smad2 levels as well as
receptor degradation, in chapter 3 I overexpressed each aPKC individually and examined
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Par6 phosphorylation, and in chapter 4 I knocked down each aPKC individually and
assessed P-p38 MAPK levels. Importantly however, knockdown of PKC alone, resulted
in compensatory expression of PKC, necessitating the need for a double knockdown. In
any case, for the most part, knockdown of each aPKC individually yielded similar
responses in our analyses, and the double knockdown had the most robust effect. For
example, in chapter 4, knock down of each aPKC individually increased p38 MAPK
phosphorylation – but the double knockdown enhances p38 phosphorylation to the
greatest degree. A similar trend was evident for the loss of E-cadherin. Thus, for the
readouts that we examined, it seemed that both aPKC  and  function redundantly.
However, this does not mean that each of these PKCs is functionally redundant in a
normally physiological setting. Although in our cell culture models we find they can
execute some similar functions, possibly their tissue expression patterns and substrate
availability may dictate their true individual function in vivo.
Another limitation of my studies is that I often use overexpression to study
protein-protein interactions. The reason I do this is primarily due to a lack of quality
antibodies for immunoprecipitation of endogenous proteins, this is particularly true for
the TGF receptors and Par6. In any case, most of the interactions we have studied have
been reported before. For example, in chapter 3, I showed that the interaction of aPKC
with the TGF receptors occurs through Par6. A similar interaction has been reported
before for aPKC[2]. The interaction between aPKC and the TRI scaffolded by Par6
has been difficult to observe using endogenous proteins partly due to the lack of quality
reagents, but also possibly related to my finding that aPKC reduces TGF receptor
complexes. I showed in chapter 2 and 3 that aPKC expression can reduce TGF receptor
expression, as well as displace Par6 from the complex. This suggests that aPKC binding
may be involved in the controlled regulation of TRI-Par6 complexes, making the
detection of endogenous interactions challenging. Thus, future studies might include
detecting the endogenous interaction of aPKC with TGF receptors in the presence of a
proteasome and/or lysosome inhibitor to test if that theory holds true. Furthermore, the
utilization of I125 TGF crosslinked to the receptors (as I utilized in chapter 2 for
degradation studies) may also increase the sensitivity of the TGF receptor signal
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following immunoprecipitation of aPKC. Importantly, whenever possible I attempted to
immunoprecipitate endogenous proteins (for e.g in chapter 4, I precipitated endogenous
Smad2 to assess endogenous Smad4 or SARA association).
Another area in which I was limited was in the ability to assess TGF receptor
trafficking in human cells. Our lab used HAT cells (which are mink lung cells stably
expressing HA tagged TRII) to study TGF receptor trafficking. This is primarily due to
a lack of antibodies for the TGF receptors sensitive enough to study using
immunofluorescence microscopy. Because the mink genome has not been sequenced, we
did not have the resources to knockdown aPKCs as we did in human cells. In the future,
it would be extremely interesting to conduct a detailed analysis of TGF receptor
internalization dynamics in aPKC knockdown cells. This may require the generation of
human cells stably expressing TRII. Another approach would be to use biotinylatedTGF which would allow for the study of the internalization of activated TGF
receptors from the cell surface. Coupled with higher resolution confocal microscopy, one
could analyze receptor dynamics and study the residence time of activated receptors in
various intracellular compartments in aPKC knockdown cells (caveolae, early and late
endosome, and lysosomes) (Figure 5.3). This may shed light onto whether Smad2
dissociation from SARA occurs more efficiently at specific points in the endocytic
pathway, or whether TRI-TRAF6 complexes are more likely to persist due to an
increased residence time in one particular intracellular compartment. Interestingly, the
shuttling ubiquitin binding protein p62 is known to bind both TRAF6 and aPKC to
control the intracellular trafficking dynamics and signalling potential of various receptors
[33, 44, 45]. Recent reports indicate that p62 acts as a signalling hub an can recruit and
oligomerize various signalling molecules to control cell survival, apoptosis, and protein
degradation and has important roles in cancer progression (reviewed in [46]). Using
overexpression models, in preliminary analysis I have found that p62 immunoprecipitates
with the TGF receptors (data not shown). It would be interesting to examine whether
p62 plays a role in the shuttling dynamics and intracellular itinerary of the TGF
receptors to control the pathways I have described in this thesis. This remains a
possibility as p62 is involved in the function of TRAF6 [44], as well as in lysosome
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targeting of aPKC [33]. Examining whether p62 functions in the TGF pathway deserves
further exploration.
All in all, a thorough and detailed analysis of TGF receptor intracellular
trafficking dynamics in aPKC knockdown cells would shed light on how aPKC may be
controlling signalling patterns. Furthermore, it is important to explore some of the
mechanisms we have identified in an in vivo setting to confirm these findings in a more
physiologically relevant model.
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Figure 5.3. aPKC may control the subcellular itinerary of activated TGF receptor
complexes to control specific TGF signalling outcomes
TGF receptors internalize into two distinct endocytic pathways. Clathrin-dependent
internalization into the early endosome is important for propagating signals, whereas the
caveolin-1-positive membrane raft compartment is involved in receptor degradation.
aPKC plays roles in regulating the levels of TGF receptor complexes. This may be
occurring through a co-ordinated signalling effort between aPKC and binding partners
such as the late endosome sequestering protein p62, and the polarity protein adaptor Par6.
Detailed understanding of how aPKC controls the intracellular itinerary of TGF
receptors is not known (indicated by question marks). An analysis of how/whether aPKC
controls these dynamic trafficking patterns through these intracellular compartments is
warranted.
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5.4 Conclusions
In conclusion, I have demonstrated that aPKC expression and activity are
intricately linked to the control of multiple TGF pathways, including Smad2, Par6 and
p38 MAPK. I have made the novel finding that the modulation of aPKC activity or
expression alters the way non-small cell lung cancer (NSCLC) cells respond to TGF
signalling by altering specific TGF-dependent pathways. I have provided mechanistic
insight into how aPKC is involved in each of the mentioned pathways, as well as
generated future avenues of research that deserve further exploration.

Given the

important roles of TGF signalling in developmental processes, cellular homeostasis, as
well as the progression of cancer, continued understanding of the mechanisms which
control how cells read TGF signals will further our appreciation of animal physiology in
both the normal and diseased state.

242

5.5 References
1.

Di Guglielmo, G.M., et al., Distinct endocytic pathways regulate TGF-beta
receptor signalling and turnover. Nat Cell Biol, 2003. 5(5): p. 410-21.

2.

Ozdamar, B., et al., Regulation of the polarity protein Par6 by TGFbeta receptors
controls epithelial cell plasticity. Science, 2005. 307(5715): p. 1603-9.

3.

Viloria-Petit, A.M., et al., A role for the TGFbeta-Par6 polarity pathway in breast
cancer progression. Proc Natl Acad Sci U S A, 2009. 106(33): p. 14028-33.

4.

Yamashita, M., et al., TRAF6 mediates Smad-independent activation of JNK and
p38 by TGF-beta. Mol Cell, 2008. 31(6): p. 918-24.

5.

Sorrentino, A., et al., The type I TGF-beta receptor engages TRAF6 to activate
TAK1 in a receptor kinase-independent manner. Nat Cell Biol, 2008. 10(10): p.
1199-207.

6.

Edlund, S., et al., Transforming growth factor-beta1 (TGF-beta)-induced
apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by
TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol
Biol Cell, 2003. 14(2): p. 529-44.

7.

Alvi, F., et al., Regulation of membrane trafficking and endocytosis by protein
kinase C: emerging role of the pericentrion, a novel protein kinase C-dependent
subset of recycling endosomes. Cell Mol Life Sci, 2007. 64(3): p. 263-70.

8.

Runyan, C.E., H.W. Schnaper, and A.C. Poncelet, The role of internalization in
transforming growth factor beta1-induced Smad2 association with Smad anchor
for receptor activation (SARA) and Smad2-dependent signalling in human
mesangial cells. J Biol Chem, 2005. 280(9): p. 8300-8.

9.

Lu, Z., et al., Transforming growth factor beta activates Smad2 in the absence of
receptor endocytosis. J Biol Chem, 2002. 277(33): p. 29363-8.

10.

Bakkebo, M., et al., SARA is dispensable for functional TGF-beta signalling.
FEBS Lett, 2012. 586(19): p. 3367-72.

11.

Kostaras, E., et al., SARA and RNF11 interact with each other and ESCRT-0 core
proteins and regulate degradative EGFR trafficking. Oncogene, 2013. 32(44): p.
5220-32.

12.

Wang, H.R., et al., Regulation of cell polarity and protrusion formation by
targeting RhoA for degradation. Science, 2003. 302(5651): p. 1775-9.

13.

Bao, J., et al., Threonine phosphorylation diverts internalized epidermal growth
factor receptors from a degradative pathway to the recycling endosome. J Biol
Chem, 2000. 275(34): p. 26178-86.

243

14.

Gunaratne, A., B.L. Thai, and G.M. Di Guglielmo, Atypical Protein Kinase C
Phosphorylates Par6 and Facilitates Transforming Growth Factor beta-Induced
Epithelial-to-Mesenchymal Transition. Mol Cell Biol, 2013. 33(5): p. 874-86.

15.

Aranda, V., et al., Par6-aPKC uncouples ErbB2 induced disruption of polarized
epithelial organization from proliferation control. Nat Cell Biol, 2006. 8(11): p.
1235-45.

16.

Opper, M., G. Schuler, and B.M. Mechler, Hereditary suppression of lethal (2)
giant larvae malignant tumor development in Drosophila by gene transfer.
Oncogene, 1987. 1(2): p. 91-6.

17.

Woods, D.F. and P.J. Bryant, The discs-large tumor suppressor gene of
Drosophila encodes a guanylate kinase homolog localized at septate junctions.
Cell, 1991. 66(3): p. 451-64.

18.

Bilder, D., M. Li, and N. Perrimon, Cooperative regulation of cell polarity and
growth by Drosophila tumor suppressors. Science, 2000. 289(5476): p. 113-6.

19.

Iden, S. and J.G. Collard, Crosstalk between small GTPases and polarity proteins
in cell polarization. Nat Rev Mol Cell Biol, 2008. 9(11): p. 846-59.

20.

Huang, L. and S.K. Muthuswamy, Polarity protein alterations in carcinoma: a
focus on emerging roles for polarity regulators. Curr Opin Genet Dev, 2010.
20(1): p. 41-50.

21.

Yamanaka, T., et al., Mammalian Lgl forms a protein complex with PAR-6 and
aPKC independently of PAR-3 to regulate epithelial cell polarity. Curr Biol,
2003. 13(9): p. 734-43.

22.

Plant, P.J., et al., A polarity complex of mPar-6 and atypical PKC binds,
phosphorylates and regulates mammalian Lgl. Nat Cell Biol, 2003. 5(4): p. 301-8.

23.

Rolls, M.M., et al., Drosophila aPKC regulates cell polarity and cell proliferation
in neuroblasts and epithelia. J Cell Biol, 2003. 163(5): p. 1089-98.

24.

Chalmers, A.D., et al., aPKC, Crumbs3 and Lgl2 control apicobasal polarity in
early vertebrate development. Development, 2005. 132(5): p. 977-86.

25.

Betschinger, J., F. Eisenhaber, and J.A. Knoblich, Phosphorylation-induced
autoinhibition regulates the cytoskeletal protein Lethal (2) giant larvae. Curr
Biol, 2005. 15(3): p. 276-82.

26.

Grifoni, D., et al., The human protein Hugl-1 substitutes for Drosophila lethal
giant larvae tumour suppressor function in vivo. Oncogene, 2004. 23(53): p.
8688-94.

244

27.

Schimanski, C.C., et al., Reduced expression of Hugl-1, the human homologue of
Drosophila tumour suppressor gene lgl, contributes to progression of colorectal
cancer. Oncogene, 2005. 24(19): p. 3100-9.

28.

Xue, B., et al., Loss of Par3 promotes breast cancer metastasis by compromising
cell-cell cohesion. Nat Cell Biol, 2012. 15(2): p. 189-200.

29.

Wang, Z., et al., Numb regulates cell-cell adhesion and polarity in response to
tyrosine kinase signalling. EMBO J, 2009. 28(16): p. 2360-73.

30.

Wang, Z. and S.S. Li, Numb: A new player in EMT. Cell Adh Migr, 2010. 4(2): p.
176-9.

31.

Nishimura, T. and K. Kaibuchi, Numb controls integrin endocytosis for
directional cell migration with aPKC and PAR-3. Dev Cell, 2007. 13(1): p. 15-28.

32.

Gunaratne, A., H. Benchabane, and G.M. Di Guglielmo, Regulation of TGFbeta
receptor trafficking and signalling by atypical protein kinase C. Cell Signal,
2012. 24(1): p. 119-30.

33.

Sanchez, P., et al., Localization of atypical protein kinase C isoforms into
lysosome-targeted endosomes through interaction with p62. Mol Cell Biol, 1998.
18(5): p. 3069-80.

34.

Balklava, Z., et al., Genome-wide analysis identifies a general requirement for
polarity proteins in endocytic traffic. Nat Cell Biol, 2007. 9(9): p. 1066-73.

35.

Wissler, F. and M. Labouesse, PARtners for endocytosis. Nat Cell Biol, 2007.
9(9): p. 1027-9.

36.

Yi, J.J., et al., TGF-beta signalling specifies axons during brain development.
Cell, 2010. 142(1): p. 144-57.

37.

Sanchez, N.S. and J.V. Barnett, TGFbeta and BMP-2 regulate epicardial cell
invasion via TGFbetaR3 activation of the Par6/Smurf1/RhoA pathway. Cell
Signal, 2011.

38.

Frederick, L.A., et al., Matrix metalloproteinase-10 is a critical effector of protein
kinase Ciota-Par6alpha-mediated lung cancer. Oncogene, 2008. 27(35): p. 484153.

39.

Regala, R.P., et al., Atypical protein kinase Ciota plays a critical role in human
lung cancer cell growth and tumorigenicity. J Biol Chem, 2005. 280(35): p.
31109-15.

40.

Stallings-Mann, M., et al., A novel small-molecule inhibitor of protein kinase
Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res,
2006. 66(3): p. 1767-74.

245

41.

Murray, N.R., K.R. Kalari, and A.P. Fields, Protein kinase Ciota expression and
oncogenic signalling mechanisms in cancer. J Cell Physiol, 2011. 226(4): p. 87987.

42.

Mansfield, A.S., et al., Phase I dose escalation study of the PKCiota inhibitor
aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and
pancreatic cancer. Anticancer Drugs, 2013. 24(10): p. 1079-83.

43.

Etienne-Manneville, S. and A. Hall, Integrin-mediated activation of Cdc42
controls cell polarity in migrating astrocytes through PKCzeta. Cell, 2001.
106(4): p. 489-98.

44.

Sanz, L., et al., The atypical PKC-interacting protein p62 channels NF-kappaB
activation by the IL-1-TRAF6 pathway. EMBO J, 2000. 19(7): p. 1576-86.

45.

Moscat, J., et al., Cell signalling and function organized by PB1 domain
interactions. Mol Cell, 2006. 23(5): p. 631-40.

46.

Moscat, J. and M.T. Diaz-Meco, p62 at the crossroads of autophagy, apoptosis,
and cancer. Cell, 2009. 137(6): p. 1001-4.

246

247

Appendix
List of Inhibitors Used

Reported Target and IC50 M

Inhibitor
GF 109203X (GFX)
Gö6976

PKC(IC50):
PKC(IC50):

(0.008)
(0.0023)

I(0.018)

Reference

(0.132)

II(0.006)

(5.8)

(0.02)

[1]
[1]

p38 MAPK Inhibitor

p38 MAPK (0.035)

[2]

MG132

Proteasome (0.1)

[3]

Cycloheximide

Ribosome/translation (0.532)

[4]

Shown is a list of inhibitors used in these studies alongside some reported IC50
values.

1.

Martiny-Baron, G., et al., Selective inhibition of protein kinase C isozymes by
the indolocarbazole Go 6976. J Biol Chem, 1993. 268(13): p. 9194-7.

2.

de Laszlo, S.E., et al., Pyrroles and other heterocycles as inhibitors of p38
kinase. Bioorg Med Chem Lett, 1998. 8(19): p. 2689-94.

3.

Tsubuki, S., et al., Differential inhibition of calpain and proteasome activities
by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem, 1996. 119(3): p.
572-6.

4.

Schneider-Poetsch, T., et al., Inhibition of eukaryotic translation elongation by
cycloheximide and lactimidomycin. Nat Chem Biol, 2010. 6(3): p. 209-217.

248

Curriculum Vitae
Name:

Adrian Gunaratne

Post-secondary
Education and
Degrees:
.

University of Toronto at Mississauga
Mississauga, Ontario, Canada
2003-2007 H.BSc.
The University of Western Ontario
London, Ontario, Canada
2008-2014 Ph.D.

Honours and
Awards:

Ontario Graduate Scholarship in Science and Technology
2010
Ontario Graduate Scholarship
2011
Canadian Institute of Health Research Canada Graduate
Scholarship, Doctoral (CIHR-CGS-D)
2011-2014
Hari and Gudrun Sharma Award for Research Excellence
2011

Related Work
Experience

Teaching Assistant
The University of Western Ontario
2009-2013

Publications:
Gunaratne A, and Di Guglielmo GM. Par6 is phosphorylated by aPKC to induce cell
plasticity. Cell Adhesion and Migration. (2013) Jul-Aug;7(4):357-61.
Gunaratne A, Thai BL, and Di Guglielmo GM. Atypical PKC phosphorylates Par6 to
facilitate TGF-induced EMT. Molecular and Cellular Biology. (2013) Mar;33(5):87486.
Gunaratne A, Benchabane H, and Di Guglielmo GM. Regulation of TGF receptor
trafficking and signalling by atypical Protein Kinase C. Cellular Signalling. (2012)
Jan;24(1):119-30.

